**Clinical Trial Protocol: HGT-HIT-094**

**Study Title:** A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment

**Study Number:** HGT-HIT-094

**Study Phase:** Phase II/III

**Investigational Product and Device:**
- Idursulfase for intrathecal use (idursulfase-IT [HGT-2310]),

**IND Number:** 100,610

**Indication:** Long-term treatment of Hunter syndrome in patients with cognitive impairment to slow progression of cognitive and functional impairment

**Study Center(s):** Multicenter

**Lead Investigator:** Joseph Muenzer, MD, PhD

**Sponsor:** Shire Human Genetic Therapies, Inc.

**Sponsor Contact:**
- 300 Shire Way
- Lexington, MA 02421 USA

**Medical Monitor:**
- , MD, PhD

---

<table>
<thead>
<tr>
<th>Date</th>
<th>Original Protocol: 04 April 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment 1</td>
<td>14 August 2013</td>
</tr>
</tbody>
</table>

---

**Confidentiality Statement**

This document is the proprietary and confidential property of Shire Human Genetic Therapies, Inc.
TABLE OF CONTENTS

SYNOPSIS ...........................................................................................................................................9

LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..................................................................20

1 INTRODUCTION ..............................................................................................................................24
  1.1 Mucopolysaccharidosis II (Hunter syndrome) ....................................................................24
  1.2 Unmet Medical Need ........................................................................................................25
  1.3 Overview of Results of Phase I/II Studies ............................................................................25
    1.3.1 Rationale for Current Phase II/III Study .....................................................................26

2 STUDY OBJECTIVES .........................................................................................................................28
  2.1 Primary Objective .................................................................................................................28
  2.2 Secondary Objectives .........................................................................................................28
  2.3 Safety Objectives ................................................................................................................28
  2.4 SOPH-A-PORT Mini S Device Objectives ............................................................................28
  2.5 Pharmacokinetic and Pharmacodynamic Objectives ..........................................................29
  2.6 Health Status Objective ......................................................................................................29
  2.7 Substudy Objective ..............................................................................................................29

3 STUDY ENDPOINTS .........................................................................................................................30
  3.1 Primary Efficacy Endpoint ..................................................................................................30
  3.2 Secondary Efficacy Endpoints ..........................................................................................30
  3.3 Pharmacokinetic and Pharmacodynamic Endpoints ........................................................30
  3.4 Safety Assessments ............................................................................................................31
  3.5 SOPH-A-PORT Mini S Device Assessments .....................................................................31
  3.6 Health Status Assessment ..................................................................................................31

4 INVESTIGATIONAL PLAN .................................................................................................................32
  4.1 Overall Study Design and Plan ..........................................................................................32
    4.1.1 Intrathecal Drug Delivery ..........................................................................................32
  4.2 Rationale for Study Design and Comparator Group .............................................................33
    4.2.1 Rationale for Dose Selection .......................................................................................35
  4.3 Study Duration .....................................................................................................................35

5 STUDY POPULATION SELECTION ..................................................................................................36
  5.1 Study Population ..................................................................................................................36
  5.2 Inclusion Criteria ................................................................................................................36
    5.2.1 Inclusion Criteria for the Pivotal Study .......................................................................36
    5.2.2 Inclusion Criteria for the Substudy .............................................................................37
  5.3 Exclusion Criteria ................................................................................................................38

6 STUDY TREATMENT .........................................................................................................................40
6.1 Description of Treatments..........................................................................................40
   6.1.1 Investigational Product..................................................................................40
   6.1.2 Intrathecal Drug Delivery Device...............................................................40
   6.1.3 Comparator.................................................................................................40
6.2 Treatments Administered.........................................................................................41
6.3 Selection and Timing of Dose for Each Patient......................................................41
6.4 Method of Assigning Patients to Treatment Groups..............................................42
6.5 Blinding..................................................................................................................42
6.6 Concomitant Medications, Therapies, and Medical/Surgical Interventions...........42
   6.6.1 Infusion Reactions and Management...........................................................43
6.7 Restrictions.............................................................................................................43
   6.7.1 Prior Therapies.............................................................................................43
   6.7.2 Fluid and Food Intake..................................................................................44
   6.7.3 Patient Activity Restrictions........................................................................44
6.8 Treatment Compliance............................................................................................44
6.9 Packaging and Labeling..........................................................................................44
   6.9.1 Investigational Product................................................................................44
   6.9.2 Intrathecal Drug Delivery Device...............................................................44
6.10 Storage and Accountability.....................................................................................45
   6.10.1 Investigational Product................................................................................45
   6.10.2 Intrathecal Drug Delivery Device...............................................................45
   6.10.3 Comparator Product.....................................................................................46
7 STUDY PROCEDURES.................................................................................................47
   7.1 Informed Consent..............................................................................................48
   7.2 Study Entrance Criteria.....................................................................................48
   7.3 Medical History................................................................................................48
       7.3.1 Genotype..................................................................................................49
   7.4 Echocardiogram..................................................................................................50
   7.5 Device Related Procedures...............................................................................50
       7.5.1 IDDD Implantation and Revision...............................................................50
       7.5.2 X-ray Verification of Intrathecal Drug Delivery Device Placement...........50
       7.5.3 CSF Sampling Procedure..........................................................................50
       7.5.4 Device Removal.......................................................................................50
   7.6 Investigational Product Administration.............................................................51
   7.7 Pharmacokinetic Assessments..........................................................................52
   7.8 Pharmacodynamic/Biomarker Assessments....................................................52
       7.8.1 CSF Glycosaminoglycan..........................................................................52
       7.8.2 CSF and Serum Albumin...........................................................................52
7.9 Efficacy Assessments ................................................................. 52
  7.9.1 Neurodevelopmental Assessment Tools .............................. 53
7.10 Health Status Assessment ........................................................ 53
7.11 Safety Assessments ............................................................... 53
  7.11.1 Physical and Neurological Examination ......................... 54
  7.11.2 Height and Weight ............................................................ 54
  7.11.3 Head Circumference ....................................................... 54
  7.11.4 Hearing Assessment ........................................................ 54
  7.11.5 Vital Signs ...................................................................... 55
  7.11.6 Electrocardiogram ............................................................ 55
  7.11.7 Intracranial Pressure Measurement .................................. 55
  7.11.8 Brain Magnetic Resonance Imaging ................................ 55
  7.11.9 Clinical and Other Laboratory Tests ................................ 55
  7.11.10 Cerebrospinal Fluid Assessments ................................... 56
  7.11.11 Antibody Assessments .................................................. 56
  7.11.12 Device Assessments ....................................................... 57
  7.11.13 Pregnancy Testing ......................................................... 57
7.12 Sample Collection, Storage, and Shipping ................................. 57
7.13 Concomitant Medications, Therapies/Interventions, and Medical/Surgical Procedures Assessments ................................................................. 57
7.14 Adverse Events Assessments .................................................. 57
  7.14.1 Definitions of Adverse Events and Serious Adverse Events ........ 57
  7.14.1.1 Adverse Events ............................................................ 57
  7.14.1.2 Elaprase-related Adverse Events ................................... 58
  7.14.1.3 IDDD-related Adverse Events ....................................... 58
  7.14.1.4 Device Surgical Procedure-related Adverse Events ........... 59
  7.14.1.5 Intrathecal Administration Process Adverse Events ........... 59
  7.14.1.6 Serious Adverse Events ................................................ 59
  7.14.1.7 Unanticipated Adverse Device Effect ......................... 60
  7.14.2 Device-associated Definitions ......................................... 60
  7.14.2.1 Device Revision (Partial and Full) ............................... 60
  7.14.2.2 Device Malfunction ..................................................... 60
  7.14.2.3 Device Failure ............................................................ 60
  7.14.3 Classification of Adverse Events and Serious Adverse Events .... 60
  7.14.3.1 Clarification between Serious and Severe ...................... 61
  7.14.4 Relatedness of Adverse Events and Serious Adverse Events ... 61
  7.14.5 Procedures for Recording and Reporting Adverse Events ....... 62
  7.14.5.1 Adverse Event Monitoring and Period of Observation ....... 62
7.14.5.2 Reporting Serious Adverse Events .................................................................62
7.15 Pregnancy ................................................................................................................63
7.16 Abuse, Misuse, Overdose, and Medication Error ..................................................63
7.17 Removal of Patients from the Trial or Investigational Product ..........................64
7.18 Other Study Procedures .........................................................................................64
7.18.1 Safety-related Study Stopping Rules ...............................................................64
7.19 Appropriateness of Measurements.........................................................................65
8 STUDY ACTIVITIES .......................................................................................................67
8.1 Screening (Month -1, Week -4 to -1) ....................................................................67
8.1.1 All Patients in the Pivotal Study and Substudy ..................................................67
8.2 Randomization/Enrollment: Clinic Admission (Month 0, Week 0, Day 0) ..........68
8.2.1 All Patients (IT Treatment and No IT Treatment Groups) in the Pivotal Study ......................................................................................................................68
8.2.2 All Patients in the Substudy ...............................................................................68
8.3 Treatment Period (Months 1 to 12) .........................................................................68
8.3.1 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the Substudy: Pre-surgery, Surgery, Follow-up, and Post-op Recovery (Week 2 [+7 days]) ..............................................................................................................68
8.3.1.1 Pre-surgery ....................................................................................................69
8.3.1.2 Surgery ........................................................................................................69
8.3.1.3 Follow-up .....................................................................................................69
8.3.1.4 Post-op Recovery ..........................................................................................69
8.3.2 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the Substudy: IT Dosing (Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 [+7 days]) ..............................................................................................................70
8.3.2.1 Pre-treatment ................................................................................................70
8.3.2.2 IT Injection ..................................................................................................70
8.3.2.3 Follow-up (Post IT Injection) ......................................................................71
8.3.3 Patients in the No IT Treatment Group of the Pivotal Study (Months 1 to 12) ..................................................................................................................................................71
8.3.3.1 Week 2 (+7 days) .........................................................................................71
8.3.3.2 Weeks 4, 16, 28, 40 (+7 days) ....................................................................72
8.3.3.3 Weeks 8, 12, 20, 24, 32, 36, 44, 48 (+7 days) .............................................72
8.4 End of Study: Month 13 (Week 52±7 days) .............................................................72
8.4.1 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the Substudy ..................................................................................................................72
8.4.2 Patients in the No IT Treatment Group of the Pivotal Study .............................73
8.5 Follow-up (Day 7 [+2 Days] Post EOS) ..................................................................74
8.5.1 All Patients in the Pivotal Study and Substudy ..................................................74
9 QUALITY CONTROL AND ASSURANCE .................................................................75
10 STATISTICAL ANALYSIS ...............................................................................76
  10.1 General Methodology ...............................................................................76
  10.2 Determination of Sample Size ....................................................................76
  10.3 Method of Assigning Study Patients to Treatment Groups .......................77
  10.4 Population Description and Exposure ......................................................77
     10.4.1 Analysis Populations ............................................................................77
     10.4.2 Patient Disposition ..............................................................................78
     10.4.3 Protocol Deviations .............................................................................78
     10.4.4 Demographics and Baseline Characteristics ........................................78
     10.4.5 Treatment Compliance .......................................................................79
     10.4.6 Extent of Exposure ..............................................................................79
  10.5 Analysis of Efficacy ....................................................................................79
     10.5.1 Primary Efficacy Endpoint Analysis ...................................................79
     10.5.2 Key Secondary Efficacy Endpoint Analysis .........................................80
     10.5.3 Other Secondary Efficacy Endpoints Analyses ....................................80
     10.5.4 Exploratory Analyses ..........................................................................81
  10.6 Pharmacokinetic, Pharmacodynamic and Health Status Outcomes ............81
     10.6.1 Pharmacokinetic Measurements and Parameters ..................................81
     10.6.2 Pharmacodynamic Outcome ................................................................82
     10.6.3 Health Status Outcome .......................................................................82
  10.7 Safety Assessments ....................................................................................82
     10.7.1 Adverse Events ....................................................................................82
     10.7.2 IDDD and Procedure Related Adverse Events .......................................82
     10.7.3 Clinical Laboratory Evaluations ...........................................................83
     10.7.4 Electrocardiogram Evaluations .............................................................83
     10.7.5 Vital Signs and Physical Measurements .................................................83
     10.7.6 Physical Findings ................................................................................83
     10.7.7 Other Observations Related to Safety ..................................................83
          10.7.7.1 Hearing Assessments ....................................................................83
          10.7.7.2 Immunogenicity ..........................................................................83
          10.7.7.3 Device Performance .....................................................................84
     10.7.8 Concomitant Medications/Therapies ......................................................84
  10.8 Statistical/Analytical Issues .......................................................................84
     10.8.1 Handling of Drop-outs and Missing Data .............................................84
     10.8.2 Adjustment for Covariates ...................................................................85
     10.8.3 Interim Analysis ...................................................................................85
     10.8.4 Multicenter Studies ..............................................................................85
10.8.5 Multiple Comparisons/Multiplicity .............................................................85
10.8.6 Sensitivity Analyses.....................................................................................86

11 ADMINISTRATIVE CONSIDERATIONS ....................................................................88
11.1 Investigators and Study Administrative Structure .................................................88
11.2 Institutional Review Board or Independent Ethics Committee Approval .............88
11.3 Ethical Conduct of the Study .................................................................................88
11.4 Patient Information and Consent ...........................................................................89
11.5 Patient Confidentiality ...........................................................................................89
11.6 Study Monitoring ...................................................................................................90
11.7 Case Report Forms and Study Records .................................................................90
11.7.1 Critical Documents ............................................................................................90
11.8 Data Monitoring Committee ..................................................................................91
11.9 Device Failure Adjudication Process .....................................................................91
11.10 Protocol Violations/Deviations ...........................................................................91
11.11 Premature Closure of the Study ............................................................................92
11.12 Access to Source Documentation ........................................................................92
11.13 Data Generation and Analysis ............................................................................93
11.14 Retention of Data ................................................................................................93
11.15 Financial Disclosure ............................................................................................93
11.16 Publication and Disclosure Policy ........................................................................93

12 LIST OF REFERENCES ................................................................................................95

13 APPENDICES .............................................................................................................97

LIST OF IN-TEXT TABLES

Table 7-1 Assessments for Physical and Neurological Examinations..........................54
Table 7-2 List of Laboratory Tests ...............................................................................55
Table 7-3 Adverse Event Severity .................................................................................60
Table 7-4 Adverse Event Relatedness ..........................................................................61
Table 7-5 Endpoint Model............................................................................................66

LIST OF APPENDICES

Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study .................................................................................................................97
Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study ........................................................................................................100
Appendix 3 Schedule of Events for Patients Enrolled in the Substudy .................102
Appendix 4  Expected Adverse Device Effects .........................................................105
Appendix 5  Protocol Amendment Summary of Changes .......................................107
Appendix 6  Protocol Signature Page ........................................................................131
SYNOPSIS

Sponsor:
Shire Human Genetic Therapies, Inc.

Names of Investigational Product and Device:
idursulfase for intrathecal use (idursulfase-IT [HGT-2310])
SOPH-A-PORT® Mini S, Implantable Access Port, Spinal, Mini Unattached, with
Guidewire (SOPH-A-PORT Mini S)

Study Title:
A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of
Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric
Patients with Hunter Syndrome and Early Cognitive Impairment

Study Number:
HGT-HIT-094

Study Phase:
Phase II/III

Investigational Product Dose, Mode of Administration:

Investigational Product Dose:
Pivotal study - idursulfase-IT 10 mg
Substudy - Dose adjustment for patients below 3 years of age based on reference brain
weight: up to 8 months of age at dosing, idursulfase-IT 5 mg; >8 months to 30 months of
age at dosing, idursulfase-IT 7.5 mg; >30 months to 3 years of age at dosing, idursulfase-
IT 10 mg

Mode of Administration:
intrathecal (IT) injection

Device, Intended Use:
The SOPH-A-PORT® Mini S is a system intended for implantation by physicians. The
SOPH-A-PORT Mini S, once implanted, allows healthcare personnel to administer
idursulfase-IT (HGT-2310) indicated for IT delivery intermittently over a long period of
time.

Comparator, Dose, and Mode of Administration:
No treatment

Treatment Regimen:
Once monthly (ie, every 28 days) IT administration of idursulfase-IT for 12 months via a
surgically implanted intrathecal drug delivery device (IDDD), or lumbar puncture
Primary Objective:
- To determine the effect of the treatment regimen in pediatric patients with Hunter syndrome and early cognitive impairment on the General Conceptual Ability (GCA) score as measured by the DAS-II, in conjunction with Elaprase therapy

Key Secondary Objective:
- To determine the effect of the treatment regimen in pediatric patients with Hunter syndrome and early cognitive impairment on the Adaptive Behavior Composite (ABC) score as measured by the VABS-II, in conjunction with Elaprase therapy

Secondary Objectives:
- To determine the effect of the treatment regimen in pediatric patients with Hunter syndrome and early cognitive impairment, in conjunction with Elaprase therapy, on:
  - Cognitive function as measured by the cluster areas and subtests of the DAS-II
  - Adaptive behavior as measured by the domains of the VABS-II

Safety Objectives:
- To determine the effect of the treatment regimen on safety as assessed by adverse events, clinical laboratory testing, physical and neurological examination findings, vital signs, and electrocardiogram (ECG) results
- To evaluate the anti-idursulfase antibody response in serum and cerebrospinal fluid (CSF) during the treatment regimen

SOPH-A-PORT Mini S Device Objectives:
- To determine the safety and performance of the SOPH-A-PORT Mini S device

Pharmacokinetic and Pharmacodynamic Objectives:
- To evaluate the concentration of idursulfase and determine pharmacokinetic (PK) parameters in serum after IT administration
- To evaluate the concentration of idursulfase in CSF prior to each monthly administration of idursulfase-IT
- To determine the effect of the treatment regimen on the concentration of glycosaminoglycan (GAG) in CSF

Health Status Objective:
- To evaluate health status as measured by the EQ-5D instrument

Substudy Objective:
- To examine the effect of the treatment regimen on safety and efficacy measures in pediatric patients with Hunter syndrome and early cognitive impairment who are below 3 years of age
Study Efficacy Endpoints:
The primary efficacy endpoint of this study is:
- Change from baseline in the GCA score after 12 months of treatment, at Visit Week 52, as obtained by DAS-II testing

The key secondary efficacy endpoint of this study is:
- Change from baseline in the ABC score after 12 months of treatment at Visit Week 52, as obtained by VABS-II testing

The secondary efficacy endpoints of this study are:
- Change from baseline to Visit Weeks 16, 28, and 40 in the GCA score as obtained by DAS-II testing
- Change from baseline to Visit Weeks 16, 28, and 40 in the ABC score as obtained by VABS-II testing
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores in cluster areas of the DAS-II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC)
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores of the VABS-II domains: Communication, Daily Living Skills, Socialization, and Motor Skills
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in age equivalents, developmental quotients, and T-scores for the subtests of the DAS-II: Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II/Early Years and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II/School Years
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in age equivalents, developmental quotients, and V-scale scores of the VABS-II subdomains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine)
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in the V-scale scores and the observed maladaptive levels of the VABS-II Maladaptive Behavior Index and its subscales (Internalizing, Externalizing)

Study Population:
Pivotal study - 42 male patients (14 untreated, 28 treated) are planned.

Substudy - enrollment of patients below 3 years of age into the separate substudy will be considered additional to the 42 patients planned for the pivotal study, and will conclude when enrollment of patients in the pivotal study closes.

Study Design:
This is a controlled, randomized, two-arm, open-label, assessor-blinded, multicenter study to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT for 12 months in pediatric patients with Hunter syndrome and early cognitive impairment who have previously received and tolerated a minimum of 4 months of therapy with Elaprase.
All patients will continue to receive Elaprase therapy as standard of care throughout the study. Elaprase will not be provided by the Sponsor, but rather will be prescribed by the patient’s physician in accordance with local prescribing information.

The pivotal study design is “no IT treatment-controlled” in that 28 patients are assigned randomly to receive IT treatment and 14 patients are assigned randomly to participate without receiving IT treatment.

The pivotal study will consist of a Screening period of up to 28 days prior to randomization (Day 0). Those patients randomized to IT treatment will undergo surgical implantation of the SOPH-A-PORT Mini S IDDD followed by a post-operative recovery period of at least 14 days prior to the first IT administration of idursulfase-IT. Treated patients will then receive 12 monthly IT injections of 10 mg idursulfase-IT corresponding to a treatment and assessment interval of 13 (28-day) months from randomization to the end-of-study (EOS) evaluations. Likewise, patients randomized to no IT treatment will be assessed over 13 (28-day) months after randomization.

Patients in the IT treatment arm of the pivotal study will be assessed according to the following schedule:

- Screening (Weeks -4 to -1 [Day -28 to Day -1])
- Randomization (Week 0 [Day 0])
- Pre-surgery, Surgery, Follow-up, and Post-operative Recovery (Week 2 [+7 days])
- Treatment and Assessments (Week 4 through Week 48 [+7 days])
- End of Study (EOS, Week 52 [+7 days])
- Follow-up (telephone contact) 7 (+2) days from the Week 52 (or EOS)

Patients in the no IT treatment arm of the pivotal study will be assessed according to the following schedule:

- Screening (Weeks -4 to -1 [Day -28 to Day -1])
- Randomization (Week 0 [Day 0])
- Telephone Contact (Week 2 [+7 days])
- Assessments (Week 4 through Week 48 [+7 days])
- End of Study (EOS, Week 52 [+7 days])
- Follow-up (telephone contact) 7 (+2) days from the Week 52 (or EOS)

The separate substudy is open-label and single arm. Patients who meet all entry criteria for participation in the substudy will be considered enrolled on Day 0. Thereafter, patients in the separate substudy will follow the same schedule of study visits as idursulfase-IT-treated patients in the pivotal study.

Patients in the substudy will be assessed according to the following schedule:

- Screening (Weeks -4 to -1 [Day -28 to Day -1])
- Enrollment (Week 0 [Day 0])
- Pre-surgery, Surgery, Follow-up, and Post-operative Recovery (Week 2 [+7 days])
- Treatments and Assessments (Week 4 through Week 48 [+7 days])
- End of Study (EOS, Week 52 [+7 days])
- Follow-up (telephone contact) 7 (+2) days from the Week 52 (or EOS)
All patients will complete EOS assessments at Week 52 (Visit Month 13) and will participate in a follow-up contact (by telephone) approximately 7 days after the EOS visit. A patient who discontinues or is withdrawn prior to study completion will be asked to participate in an EOS visit within approximately 30 days after withdrawal or discontinuation (EOS assessments for such patients will be the same as Week 52 assessments), and also to complete a follow-up contact approximately 7 days after the patient’s EOS visit. There is no replacement of patients who do not complete the study.

It is planned that the SOPH-A-PORT Mini S IDDD will be used to obtain cerebrospinal fluid (CSF) samples and to deliver IT injections of idursulfase-IT. If the IDDD appears to be non-functional, or if its use is precluded on a scheduled day of dosing, site personnel will refer to the IDDD Manual, which provides details on the investigation and management of any IDDD-related issues. If the IT space is not accessible via the IDDD, lumbar puncture may be utilized under defined circumstances for administration of idursulfase-IT or to obtain a CSF sample.

General anesthesia/sedation may be required for injections of study drug and some evaluations, and can be used at the discretion of the Investigator.

A Data Monitoring Committee (DMC) will oversee both idursulfase-IT and device safety. The DMC will be notified of IDDD failures and related complications on a periodic basis according to the DMC charter.

Patients will have the IDDD removed when they discontinue from the study, unless the patient is continuing to receive treatment through another mechanism (eg, extension study, expanded access program).

**Study Duration:**

The planned overall duration of each patient’s participation in the study is approximately 14 to 15 months from Screening to the last scheduled contact.

An extension study is planned during which patients who complete HGT-HIT-094 and are eligible according to the inclusion/exclusion criteria for the extension study may continue, or begin, to receive IT treatment with idursulfase-IT via the SOPH-A-PORT Mini S device.

**Study Inclusion and Exclusion Criteria:**

**Inclusion Criteria**

Patients must meet the following criteria to be considered eligible for randomization in the pivotal study:

1. The patient is male and is \( \geq 3 \) and \(< 18 \) years of age at the time of informed consent. Spanish-speaking patients who are to be assessed using the Spanish version of the DAS-II Early Years must be \(< 7 \) years 8 months of age at the time of informed consent.

   *Note that patients who are younger than 3 years of age may be enrolled in a separate substudy provided that they meet other inclusion criteria, provided below.*

2. The patient must have a documented diagnosis of MPS II. Of the three criteria below,
the combinations (2a AND 2b) or (2a AND 2c) will be accepted as diagnostic of MPS II:

a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).

AND

b. The patient has a documented mutation in the iduronate-2-sulfatase gene that leaves the FMR1 and FMR2 genes intact.

OR

c. The patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory).

3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment, defined as follows:

Note that separate inclusion criteria with respect to patient cognitive status at Screening apply to patients ≥3 and <13 years of age and patients ≥13 and <18 years of age.

A patient who is ≥3 and <13 years of age must have one of the following criteria (3a OR 3b):

a. A GCA score ≥55 and ≤85.

OR

b. If the patient has a GCA score at Screening >85, there must be evidence of a decrease in GCA score of ≥10 points over 12 months from a previously documented test result in observational study HGT-HIT-090.

A patient who is ≥13 and <18 years of age must have both of the following criteria (3c AND 3d):

a. A GCA score of ≥55 and ≤85

AND

b. There must be evidence of a decrease in GCA score of ≥10 points over 12 months from a previously documented test result in observational study HGT-HIT-090.

4. The patient has received and tolerated a minimum of 4 months of therapy with Elaprase during the period immediately prior to Screening.

5. The patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator’s judgment to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days.

6. The patient’s parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient’s parent(s) or legally authorized guardian(s) and the patient’s assent, if applicable, must be obtained prior to the start of any study procedures.
Patients must meet all of the following criteria to be considered eligible for enrollment in the separate substudy:

1. The patient is male and is <3 years of age at the time of informed consent.
2. The patient must have a documented diagnosis of MPS II. Of the three criteria below, the combinations (2a AND 2b) or (2a AND 2c) will be accepted as diagnostic of MPS II:
   a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).
      AND
   b. The patient has a documented mutation in the iduronate-2-sulfatase gene that leaves the FMR1 and FMR2 genes intact.
   OR
   c. The patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory).
3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment as assessed using the BSID-III and defined as a composite score on the cognitive scale ≥55 and ≤85.
4. The patient has received and tolerated a minimum of 4 months of therapy with Elaprase during the period immediately prior to Screening.
5. The patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator’s judgment, to complete the required protocol testing, and must be compliant with wearing the hearing aid(s) on scheduled testing days.
6. The patient’s parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient’s parent(s) or legally authorized guardian(s) and the patient’s assent must be obtained prior to the start of any study procedures.

Exclusion Criteria
Patients who meet any of the following criteria are not eligible to be randomized into the pivotal study or enrolled in the separate substudy:

1. The patient has clinically significant non-Hunter syndrome-related CNS involvement (such as Fragile-X syndrome) which is judged by the Investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments.
2. The patient has a large chromosomal deletion or complex rearrangement that includes a deletion of the FMR1 and/or FMR2 genes.
3. The patient has a significant medical or psychiatric comorbidity(ies) that might affect study data or confound the integrity of study results.
4. The patient has contra-indications for performance of lumbar puncture such as musculoskeletal/spinal abnormalities or risk of abnormal bleeding.
5. The patient has a history of complications from previous lumbar punctures or technical challenges in conducting lumbar punctures such that the potential risks
would exceed possible benefits for the patient.
6. The patient has an opening CSF pressure upon lumbar puncture that exceeds 30.0 cm H₂O.
7. The patient has experienced infusion-related anaphylactoid event(s) or has evidence of consistent severe adverse events related to treatment with Elaprase which, in the Investigator’s opinion, may pose an unnecessary risk to the patient.
8. The patient has received a cord blood or bone marrow transplant at any time or has received blood product transfusions within 90 days prior to Screening.
9. The patient has a history of poorly controlled seizure disorder.
10. The patient is unable to comply with the protocol (eg, has significant hearing or vision impairment, a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, known clinically significant psychiatric/behavioral instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator.
11. The patient is enrolled in another clinical study that involves clinical investigation or use of any investigational product (drug or [intrathecal/spinal] device) within 30 days prior to study enrollment or at any time during the study.
12. The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions.
13. The patient has a condition that is contraindicated as described in the SOPH-A-PORT Mini S IDDD Instructions for Use (IFU), including:
   a. The patient has had, or may have, an allergic reaction to the materials of construction of the SOPH-A-PORT Mini S device
   b. The patient’s body size is too small to support the size of the SOPH-A-PORT Mini S Access Port, as judged by the Investigator
   c. The patient’s drug therapy requires substances known to be incompatible with the materials of construction
   d. The patient has a known or suspected local or general infection
   e. The patient is at risk of abnormal bleeding due to a medical condition or therapy
   f. The patient has one or more spinal abnormalities that could complicate safe implantation or fixation
   g. The patient has a functioning CSF shunt device
   h. The patient has shown an intolerance to an implanted device

**Pharmacokinetic Assessments:**
Determination of idursulfase serum concentration-time profiles and serum pharmacokinetic parameters after IT administration.
Measurement of idursulfase concentration in CSF samples obtained immediately prior to each IT administration (and at the EOS Visit) to determine the degree of accumulation of monthly idursulfase-IT administrations in the CSF.

**Pharmacodynamic Assessments:**
Determination of the concentration of GAG in CSF samples.
Efficacy Assessments:
Neurodevelopmental status will be assessed over time by measuring cognitive and adaptive functions as follows:
Cognition: the Differential Ability Scales, Second Edition (DAS-II) will be used to assess all patients randomized in the pivotal study. Only the DAS-II Early Years (Spanish version) will be used for assessment of eligible Spanish-speaking patients. For patients participating in the separate substudy only (ie, patients who are below the age of 3 years and who have early cognitive impairment) cognition will be assessed initially using the Bayley Scales of Infant Development, Third Edition (BSID-III). When these patients reach at least 42 months of age, if considered evaluable using the DAS-II instrument, they will transition to use of the DAS-II for continued assessment of cognition.
Adaptive Behaviors: the Vineland Adaptive Behavioral Scales, Second Edition (VABS-II) will be used to assess all patients. The Expanded Interview Form will be utilized.

Safety Assessments:
Safety will be assessed by adverse events (by type, severity, and relationship to treatment [idursulfase-IT, IDDD, device surgical procedure, IT administration process] and IV Elaprase infusion), changes in clinical laboratory testing (serum chemistry, hematology, urinalysis), physical and neurological examination, vital signs, 12-lead ECG, CSF laboratory parameters (chemistries, cell counts), anti-idursulfase antibodies in CSF and serum, and determination of antibodies having enzyme neutralizing activity.

SOPH-A-PORT Mini S Device Assessments:
SOPH-A-PORT Mini S assessments will include measures of device implantation, device function, device longevity, record of revisions, removals, and replacements of the implanted IDDD, and adverse events associated with the device. This data will be collected on the patient’s case report form (CRF) from the time of implantation and continue throughout the study as long as the SOPH-A-PORT Mini S remains implanted.

Statistical Methods:
General Methods
Continuous variables will be summarized using descriptive statistics (N, mean, standard deviation, minimum, median, and maximum). Categorical variables will be summarized using the number and percentage of patients in each category. Data will be summarized with respect to patient disposition, demographic and baseline characteristics and concomitant medication use. The efficacy endpoints, safety assessments and other outcome results for each treatment group will be summarized descriptively unless otherwise indicated. Statistical model estimates of least squares means, p-values and 95% confidence intervals (CIs) for least squares mean treatment differences will also be provided where relevant for efficacy endpoints. All statistical tests will be two-sided and will be performed at the 0.05 level of significance unless stated otherwise.
Safety and efficacy data from the single-arm substudy will be summarized separately or listed separately.
Analysis Populations
For the pivotal trial, all efficacy data analyses will be performed using the Intent-to-Treat
(ITT) Population, which is defined as all randomized patients.

All safety data analyses will be performed according to treatment received using the Safety Population, which is defined as all randomized patients with any post-randomization safety assessments. Device related analyses will be conducted in the set of patients in the Safety Population who had the device implant procedure performed.

All PK data analyses will be performed using the PK population. The PK population will be defined as all patients who received study drug and had sufficient serum samples collected to derive pharmacokinetic parameters.

For the substudy, all analyses will be performed on the Substudy Population, defined as all patients enrolled and treated with study drug in the substudy.

**Analysis of Efficacy**

For the pivotal trial, the primary efficacy endpoint is the change from study baseline (Screening Visit) to Visit Week 52 in the General Conceptual Ability (GCA) score as measured by the DAS-II. The primary analysis will compare the treatment groups using a linear mixed model repeated measures (MMRM) analysis. The repeated measures are the change from baseline GCA scores obtained at the scheduled Visit Weeks 16, 28, 40, and 52, respectively. The model will include fixed categorical effects for treatment, visit week, treatment by visit week interaction, baseline GCA classification factor (either ≤70 or >70), and the baseline GCA score as a continuous covariate. From this model, least squares means, standard errors, treatment differences in least squares means, and 95% CIs will be estimated for each time point. Primary inference is based on the treatment comparison of least squares means at Visit Week 52 from this model, and a p-value will be presented for this time point only.

The key secondary efficacy endpoint is the change from study baseline (Screening Visit) to Visit Week 52 in the Adaptive Behavior Composite (ABC) score as measured by the VABS-II. This endpoint will be analyzed using an MMRM analysis with effects of treatment, visit week, treatment by visit week interaction, baseline GCA classification factor (either ≤70 or >70), and the baseline ABC score as a continuous covariate. The significance test will be based on the difference in least squares means at Visit Week 52 and a p-value will be presented for this time point only.

The following secondary efficacy endpoints will be analyzed using an MMRM analysis in the same manner as described above for the key secondary endpoint with the continuous covariate corresponding to the baseline score for each measure:

1. The change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores in cluster areas of the DAS-II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC)
2. The change from baseline to Visit Weeks 16, 28, 40, and 52 in the standard domain scores of the VABS-II: Communication, Daily Living Skills, Socialization, and Motor Skills

All other secondary efficacy endpoints will be summarized descriptively by treatment group.

The familywise type-I error rate (FWER) for the statistical tests of the primary, key secondary and other selected secondary efficacy endpoints from the MMRM analyses will
be controlled at 0.05. To strongly control the FWER at this level, a Gatekeeping approach will be utilized in which each family of statistical tests will be conducted in a sequential manner. The test for the primary endpoint will be conducted first at the 5% significance level and, if significant, the key secondary endpoint will be similarly tested at the 5% significance level. If these two tests are both significant, tests of the additional secondary efficacy endpoints specified below will be conducted using the Hommel closed testing procedure\textsuperscript{1} to control the FWER.

Analysis of Safety

All safety analyses will be descriptive. Adverse events will be summarized by treatment group, both overall and within system organ class by preferred term. Adverse events will also be tabulated by severity (mild, moderate, severe) and by relationship to study drug (not related, related) for treated patients. Separate tabulations will be provided for adverse events related to study drug, IV Elaprase infusion, the IDDD, device surgical procedure, and the IT-administration process.

SOPH-A-PORT safety and performance will be summarized for implanted patients. The proportion of patients with at least one IDDD failure and the proportion with malfunction only, as well as the number of and reasons for IDDD failures and malfunctions will be summarized. The annual event rate of IDDD failures and the time to first failure will be summarized.

Laboratory values in serum and CSF components, vital signs, ECG parameters, and other safety assessments will be summarized descriptively by treatment group. The number and percentage of patients testing anti-idursulfase antibody positive and negative at each time point will be summarized.

All safety data from the separate substudy will be similarly summarized in a descriptive manner or listed, as appropriate.

Date: 14 August 2013
# LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC</td>
<td>adaptive behavior composite</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>ALB</td>
<td>albumin</td>
</tr>
<tr>
<td>ALK</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase (SGPT)</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>analysis of covariance</td>
</tr>
<tr>
<td>AP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>aPTT</td>
<td>activated partial thromboplastin time</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AR(1)</td>
<td>autoregressive</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>cc</td>
<td>cubic centimeter(s)</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>cGMP</td>
<td>Current Good Manufacturing Practices</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>maximal concentration</td>
</tr>
<tr>
<td>cm</td>
<td>centimeter(s)</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>total carbon dioxide</td>
</tr>
<tr>
<td>CRF</td>
<td>case report form (paper or electronic)</td>
</tr>
<tr>
<td>CRO</td>
<td>contract research organization</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CV</td>
<td>coefficient of variation</td>
</tr>
<tr>
<td>DAS-II</td>
<td>Differential Ability Scales, Second Edition</td>
</tr>
<tr>
<td>DQ</td>
<td>developmental quotient</td>
</tr>
<tr>
<td>DS</td>
<td>dermatan sulfate</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EOS</td>
<td>end of study</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>EuroQol-5D instrument for use as a measure of health outcome</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ERT</td>
<td>enzyme replacement therapy</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>F</td>
<td>Fahrenheit</td>
</tr>
<tr>
<td>FDA</td>
<td>United States Food and Drug Administration</td>
</tr>
<tr>
<td>FWER</td>
<td>familywise type-I error rate</td>
</tr>
<tr>
<td>g</td>
<td>gram(s)</td>
</tr>
<tr>
<td>GAG</td>
<td>glycosaminoglycans</td>
</tr>
<tr>
<td>GCA</td>
<td>general conceptual ability</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma glutamyl transferase</td>
</tr>
<tr>
<td>Hct</td>
<td>hematocrit</td>
</tr>
<tr>
<td>Hgb</td>
<td>hemoglobin</td>
</tr>
<tr>
<td>HGT-2310</td>
<td>drug code name for formulation of recombinant iduronate-2-sulfatase (idursulfase) for intrathecal administration</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>ICP</td>
<td>intracranial pressure</td>
</tr>
<tr>
<td>IDS</td>
<td>iduronate-2-sulfatase gene</td>
</tr>
<tr>
<td>IDDD</td>
<td>intrathecal drug delivery device</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent Ethics Committee</td>
</tr>
<tr>
<td>IFU</td>
<td>Instructions for Use</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug application</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>IT</td>
<td>intrathecal</td>
</tr>
<tr>
<td>ITT</td>
<td>intent-to-treat</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous(ly)</td>
</tr>
<tr>
<td>IVR</td>
<td>interactive voice response</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram(s)</td>
</tr>
<tr>
<td>KM</td>
<td>Kaplan Meier</td>
</tr>
<tr>
<td>L</td>
<td>liter(s)</td>
</tr>
<tr>
<td>LDH</td>
<td>lactic dehydrogenase</td>
</tr>
<tr>
<td>m</td>
<td>meter(s)</td>
</tr>
<tr>
<td>M6P</td>
<td>mannose-6-phosphate</td>
</tr>
<tr>
<td>MCH</td>
<td>mean corpuscular hemoglobin</td>
</tr>
<tr>
<td>MCV</td>
<td>mean corpuscular volume</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>min</td>
<td>minute(s)</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter(s)</td>
</tr>
<tr>
<td>mm</td>
<td>millimeters</td>
</tr>
<tr>
<td>mM</td>
<td>millimolar</td>
</tr>
<tr>
<td>MMRM</td>
<td>mixed model repeated measures</td>
</tr>
<tr>
<td>MPS II</td>
<td>Mucopolysaccharidosis II (Hunter syndrome)</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>n</td>
<td>number</td>
</tr>
<tr>
<td>N or n</td>
<td>number of observations</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram(s)</td>
</tr>
<tr>
<td>PD</td>
<td>pharmacodynamic</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic(s)</td>
</tr>
<tr>
<td>PRO</td>
<td>patient reported outcome</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>partial thromboplastin time</td>
</tr>
<tr>
<td>QTc</td>
<td>corrected QT interval</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell(s)</td>
</tr>
<tr>
<td>REML</td>
<td>restricted maximum likelihood estimation</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SAS</td>
<td>Statistical Analysis System©</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SE</td>
<td>standard error</td>
</tr>
<tr>
<td>SGOT</td>
<td>serum glutamic oxaloacetic transaminase (ast)</td>
</tr>
<tr>
<td>SGPT</td>
<td>serum glutamic pyruvic transaminase (alt)</td>
</tr>
<tr>
<td>Shire HGT</td>
<td>Shire Human Genetic Therapies, Inc. (Shire)</td>
</tr>
<tr>
<td>SmPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>SNC</td>
<td>special nonverbal composite</td>
</tr>
<tr>
<td>SOC</td>
<td>system organ class</td>
</tr>
<tr>
<td>SOE</td>
<td>schedule of events</td>
</tr>
<tr>
<td>T4</td>
<td>thyroxine</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid-stimulating hormone</td>
</tr>
<tr>
<td>U</td>
<td>unit(s)</td>
</tr>
<tr>
<td>Term</td>
<td>Definition</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>UADE</td>
<td>unanticipated adverse device effect</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
<tr>
<td>V&lt;sub&gt;ss&lt;/sub&gt;</td>
<td>apparent volume of distribution at steady state</td>
</tr>
<tr>
<td>VAS</td>
<td>visual analog scale</td>
</tr>
<tr>
<td>VABS-II</td>
<td>Vineland Adaptive Behavior Scales, Second Edition</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell count</td>
</tr>
<tr>
<td>WHO-DD</td>
<td>World Health Organization Drug Dictionary</td>
</tr>
<tr>
<td>WOCF</td>
<td>worst observation carried forward</td>
</tr>
<tr>
<td>WRS</td>
<td>Wilcoxon rank-sum test</td>
</tr>
</tbody>
</table>
1 INTRODUCTION

1.1 Mucopolysaccharidosis II (Hunter syndrome)

Mucopolysaccharidosis II (MPS II) is a rare, X-linked, inherited disease that affects males nearly exclusively. Its estimated incidence is 1 in approximately 162,000 live births. Though typically appearing normal at birth, all MPS II patients suffer from a progressive, serious, life-limiting disease.

The disease is caused by the absence of, or deficiency in, the activity of the lysosomal enzyme, iduronate-2-sulfatase which acts to cleave O-linked sulfate moieties from the glycosaminoglycan (GAG) molecules dermatan sulfate (DS) and heparan sulfate (HS). Insufficient activity of iduronate-2-sulfatase leads to progressive accumulation of GAG in nearly all organs and body tissues.

The central underlying pathophysiological process leading to the clinical manifestations of MPS II is the chronic accumulation of dermatan sulfate and heparan sulfate inside cellular lysosomes, resulting in cellular engorgement, organomegaly, tissue destruction, and organ system dysfunction. Accumulation of GAG affects nearly all cell types, tissues, and organs of the body including the respiratory tract, heart, liver, spleen, leptomeninges, bones, joints, oropharynx, head, neck, and central nervous system (CNS). Clinical manifestations include severe airway obstruction, skeletal deformities, cardiomyopathy and, in most patients, neurological decline. Death may occur in the first or second decade of life. Patients with attenuated disease may survive into adulthood, with airway obstruction and cardiac causes often contributing to death.

Phenotypic expression of the disease spans a wide spectrum of clinical severity. However, two extremes at either end of the continuum of MPS II have been identified based on cognitive status. The first is broadly characterized as an “attenuated” or milder form in which intellectual and neurodevelopmental faculties are largely intact, although somatic pathology is present. The term “severe” has been adopted to describe a second broad phenotype of MPS II patients who suffer from neurodevelopmental impairment in addition to somatic manifestations of the disease. It has been estimated that approximately three-quarters of MPS II patients will develop CNS involvement and be characterized as “severe.” Despite these characterizations, patients with predominantly somatic involvement may nevertheless have a life-limiting disease course.

Although there is heterogeneity with respect to disease progression, the onset of signs and symptoms typically occurs at about 2 to 4 years of age. An earlier appearance of clinical symptoms generally, but not always, predicts a more severe clinical course. Knowledge of the genotype is of limited value in predicting a patient’s clinical course with respect to CNS involvement. An exception is represented by children with complete absence of functional enzyme due to deletion/rearrangement of the iduronate-2-sulfatase gene (IDS), who manifest severe neurodevelopmental impairment.
1.2 Unmet Medical Need

The currently approved therapy for Hunter syndrome is Elaprase® (idursulfase), recombinant human iduronate-2-sulfatase for intravenous (IV) administration. Elaprase has provided clinical benefit with respect to somatic pathologies in patients with Hunter syndrome, and has a well characterized safety profile. Although many of the physical symptoms of the disease can be reduced or eradicated by IV enzyme replacement, Elaprase has not been evaluated specifically regarding its independent quantifiable impact on CNS pathology, due to the acknowledged impermeability of the blood-brain barrier to macromolecules such as idursulfase. In addition, Elaprase is formulated for IV use only and is contraindicated for direct injection into the CNS. Thus, no specific therapy exists for the CNS pathologies of Hunter syndrome.

A distinct formulation, designated idursulfase-IT (HGT-2310), was developed specifically for delivery into the cerebrospinal fluid (CSF) via intrathecal (IT) administration to access CNS tissues. The active ingredient of the idursulfase-IT product [recombinant human iduronate-2-sulfatase] is the same active ingredient as in commercially available Elaprase. In contrast to Elaprase, however, idursulfase-IT is specially formulated for, and compatible with, direct introduction into CSF since it is isotonic and contains excipients suitable for IT use.

In order to traverse the blood-brain barrier, Shire HGT is evaluating delivery of idursulfase-IT directly into the CNS using an intrathecal drug delivery device (IDDD), the SOPH-A-PORT® Mini S, Implantable Access Port, Spinal, Mini Unattached, with Guidewire (SOPH-A-PORT Mini S). The advantage of using an IDDD is the potential to obviate the need for multiple lumbar punctures for drug delivery.

1.3 Overview of Results of Phase I/II Studies

The safety and tolerability of ascending doses (1, 10, or 30 mg) of intrathecally administered idursulfase-IT were investigated in the first-in-human study HGT-HIT-045, a randomized, open-label, no-treatment controlled Phase I/II study in which idursulfase-IT was administered once monthly to pediatric MPS II patients via a surgically implanted IDDD (PORT-A-CATH® II Low Profile™ Intrathecal Implantable Access System [PORT-A-CATH]) for 6 months in conjunction with once weekly IV infusion of Elaprase. Eligible patients who completed HGT-HIT-045 are receiving monthly IT injections of idursulfase-IT, in conjunction with Elaprase therapy, in extension study HGT-HIT-046. Across the HGT-HIT-045 and HGT-HIT-046 studies, long-term safety, pharmacokinetics (PK), and pharmacodynamics (PD) (effect on GAG concentration in CSF) have been evaluated. Effects of IT administration of idursulfase-IT on neurodevelopmental health have been evaluated using standardized tests of cognitive and adaptive functions.

Based on the data available from HGT-HIT-045 and HGT-HIT-046, idursulfase-IT has been found to be well tolerated at all doses administered without safety concerns related to the study drug. There have been no deaths or discontinuations due to adverse events in either study, and no serious adverse events related to idursulfase-IT. The majority of serious adverse events in both studies have been associated with the PORT-A-CATH device, and designated as serious because of the requirement for overnight hospitalization for surgical revision/removal of the
IDDD. The events related to the use of the IDDD included surgical removal and replacement of the device because of mechanical failures, primarily connector pin breaks and catheter slippage, to overnight admissions to the clinical site for a suspected device infection, and device removal because of wound issues.

As a result of the device-related concerns in the Phase I/II program, additional guidelines and training materials were developed for implanting neurosurgeons concerning the surgical implantation of the IDDD, and repeated lumbar punctures were permitted per protocol amendment as a means of IT delivery of study drug in the event of device malfunction. To address the frequent occurrence of device failures observed with use of the PORT-A-CATH IDDD in the Phase I/II studies, the SOPH-A-PORT Mini S will be used in this Phase II/III study. The SOPH-A-PORT Mini S device is intended to address the frequent occurrence of device failures observed with use of the PORT-A-CATH IDDD in the Phase I/II studies.

Intrathecal administration of idursulfase-IT to MPS II patients in HGT-HIT-045 and HGT-HIT-046 at the 10 and 30 mg dose regimens resulted in a pronounced pharmacodynamic reduction from baseline in the concentration of GAG in CSF; the 1 mg dose regimen induced a slower and less pronounced reduction in GAG concentration in CSF. Available results of neurodevelopmental assessments performed across HGT-HIT-045 and HGT-HIT-046 suggest the potential of intrathecal delivery of idursulfase-IT to halt or slow the progressive decline in neurodevelopmental status in this patient population. Several patients at earlier stages of cognitive decline who received treatment with idursulfase-IT at the 10 mg and 30 mg doses showed evidence of stabilization or improvement of cognitive and adaptive functions.

1.3.1 Rationale for Current Phase II/III Study

Because intravenously administered idursulfase has not been shown to traverse the blood-brain barrier due to its impermeability to large macromolecules such as proteins, there is an unmet medical need in the population of MPS II patients with CNS disease to support clinical development of idursulfase-IT for intrathecal use.

The SOPH-A-PORT Mini S delivery device will be used for IT administration of idursulfase-IT to MPS II patients in this study. In contrast to IT administration via lumbar puncture, the use of an IDDD does not always require full anesthesia; in many cases, sedation may be appropriate. Multiple drug administrations, therefore, may require only a single episode of general anesthesia (for device implantation), in contrast to the multiple episodes of general anesthesia that would be required for repeated lumbar punctures in this patient population.

Nonclinical experience with IT administration of idursulfase-IT has demonstrated wide distribution of idursulfase to the CNS tissues. Idursulfase-IT has been shown to be well tolerated in several species and to be active in a murine disease model of idursulfase deficiency.

In Phase I/II clinical studies in MPS II patients, idursulfase-IT has been generally well tolerated. Stabilization or improvement in cognitive and adaptive functions has been noted in some of the children enrolled in the trials. The available data support the Sponsor’s hypothesis that a therapeutic benefit may be expected in MPS II children with cognitive impairment.
The therapeutic strategy consisting of idursulfase-IT administered intrathecally via the SOPH-A-PORT Mini S device and concomitant IV Elaprase therapy is intended to address both the CNS and somatic manifestations of Hunter syndrome. Idursulfase-IT is intended for long-term treatment of Hunter syndrome in patients with cognitive impairment to slow progression of cognitive and functional impairment.

The design of the proposed study, including the neurodevelopmental assessment tools and endpoints, and the selection of idursulfase-IT 10 mg dose, have been informed by the results of Phase I/II studies HGT-HIT-045 and HGT-HIT-046 (See Section 1.3). Please refer to the current edition of the Investigator’s Brochure for additional information concerning the safety and clinical development of idursulfase-IT and for information concerning the SOPH-A-PORT Mini S delivery device.
2 STUDY OBJECTIVES

The treatment regimen is defined as once monthly (ie, every 28 days) intrathecal administration of idursulfase-IT for 12 months via a surgically implanted IDDD (or lumbar puncture).

2.1 Primary Objective

The primary objective of this study is:

- To determine the effect of the treatment regimen in pediatric patients with Hunter syndrome and early cognitive impairment on the General Conceptual Ability (GCA) score as measured by the Differential Ability Scale, Second Edition (DAS-II), in conjunction with Elaprase therapy

2.2 Secondary Objectives

The key secondary objective of this study is:

- To determine the effect of the treatment regimen in pediatric patients with Hunter syndrome and early cognitive impairment on the Adaptive Behavior Composite (ABC) score as measured by the Vineland Adaptive Behavior Scales, Second Edition (VABS-II), in conjunction with Elaprase therapy

The secondary objectives of this study are:

- To determine the effect of the treatment regimen in pediatric patients with Hunter syndrome and early cognitive impairment, in conjunction with Elaprase therapy, on:
  - Cognitive function as measured by the cluster areas and subtests of the DAS-II
  - Adaptive behavior as measured by the domains of the VABS-II

2.3 Safety Objectives

- To determine the effect of the treatment regimen on safety as assessed by adverse events, clinical laboratory testing, physical and neurological examination findings, vital signs, and electrocardiogram (ECG) results
- To evaluate the anti-idursulfase antibody response in serum and CSF during the treatment regimen

2.4 SOPH-A-PORT Mini S Device Objectives:

- To determine the safety and performance of the SOPH-A-PORT Mini S device
2.5 Pharmacokinetic and Pharmacodynamic Objectives

The PK and PD objectives of this study are:

- To evaluate the concentration of idursulfase and determine PK parameters in serum after IT administration
- To evaluate the concentration of idursulfase in CSF prior to each monthly administration of idursulfase-IT
- To determine the effect of the treatment regimen on the concentration of GAG in CSF

2.6 Health Status Objective

- To evaluate health status as measured by the EQ-5D instrument

2.7 Substudy Objective

The objective of the substudy is:

- To examine the effect of the treatment regimen on safety and efficacy measures in pediatric patients with Hunter syndrome and early cognitive impairment who are below 3 years of age
3 STUDY ENDPOINTS

3.1 Primary Efficacy Endpoint

The primary efficacy endpoint of this study is:

- Change from baseline in the GCA score after 12 months of treatment, at Visit Week 52, as obtained by DAS-II testing

3.2 Secondary Efficacy Endpoints

The key secondary efficacy endpoint of this study is:

- Change from baseline in the adaptive behavior composite (ABC) score after 12 months of treatment at Visit Week 52, as obtained by VABS-II testing

The secondary efficacy endpoints of this study are:

- Change from baseline to Visit Weeks 16, 28, and 40 in the GCA score as obtained by DAS-II testing
- Change from baseline to Visit Weeks 16, 28, and 40 in the ABC score as obtained by VABS-II testing
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores in cluster areas of the DAS-II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC)
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores of the VABS-II domains: Communication, Daily Living Skills, Socialization, and Motor Skills
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in age equivalents, developmental quotients, and T-scores for the subtests of the DAS-II: Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II/Early Years and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II/School Years
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in age equivalents, developmental quotients, and V-scale scores of the VABS-II subdomains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine)
- Change from baseline to Visit Weeks 16, 28, 40, and 52 in the V-scale scores and observed maladaptive levels of the VABS-II Maladaptive Behavior Index and its subscales (Internalizing, Externalizing)

3.3 Pharmacokinetic and Pharmacodynamic Endpoints

The PK and PD endpoints of this study are:
- Serum concentration of idursulfase and serum PK parameters after IT administration
- CSF concentration of idursulfase prior to each monthly IT administration
- Change from baseline in the concentration of GAG in CSF

### 3.4 Safety Assessments

Safety will be assessed during the study by collection of adverse events (by type, severity, and relationship to treatment [idursulfase-IT, the IDDD, device surgical procedure, or IT administration process] and IV Elaprase infusion), changes in clinical laboratory testing (serum chemistry, hematology, urinalysis), physical and neurological examination, vital signs, 12-lead ECG recordings, CSF laboratory parameters (chemistries, cell counts), anti-idursulfase antibodies in CSF and serum, and determination of antibodies having enzyme neutralizing activity.

### 3.5 SOPH-A-PORT Mini S Device Assessments

SOPH-A-PORT Mini S assessments will include measures of device implantation, device function, device longevity, record of revisions, removals, and replacements of the implanted IDDD, and adverse events associated with the device. This data will be collected on the patient’s case report form (CRF) from the time of implantation and continue throughout the study as long as the SOPH-A-PORT Mini S remains implanted.

### 3.6 Health Status Assessment

Health status dimensions as obtained by the EQ-5D questionnaire.
4 INVESTIGATIONAL PLAN

4.1 Overall Study Design and Plan

This is a controlled, randomized, two-arm, open-label, assessor-blinded, multicenter study to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT for 12 months in pediatric patients with Hunter syndrome and early cognitive impairment who have previously received and tolerated a minimum of 4 months of therapy with Elaprase.

All patients will continue to receive Elaprase therapy as standard of care throughout the study.

The pivotal study design is “no IT treatment-controlled” in that 28 patients are assigned randomly to receive IT treatment and 14 patients are assigned randomly to participate without receiving IT treatment.

Those patients randomized to the IT treatment arm will undergo surgical implantation of the SOPH-A-PORT Mini S IDDD followed by a post-operative recovery period of at least 14 days prior to the first IT administration of idursulfase-IT. Treated patients will then receive 12 monthly IT injections of 10 mg idursulfase-IT corresponding to a treatment and assessment interval of 13 (28-day) months from randomization to the end-of-study (EOS) evaluations. Likewise, patients randomized to the no IT treatment arm will be assessed over 13 (28-day) months after randomization.

The separate substudy is open label and single arm. Patients who are enrolled in the substudy will follow the same schedule of study visits as idursulfase-IT-treated patients in the pivotal study.

4.1.1 Intrathecal Drug Delivery

The study drug, idursulfase-IT (HGT-2310) will be administered to patients via the SOPH-A-PORT® Mini S, Implantable Access Port, Spinal, Mini Unattached, with Guidewire (SOPH-A-PORT Mini S), manufactured by Sophysa SA (Orsay, France) or, alternatively, via lumbar puncture in the event of device malfunction. This IDDD will be used to obtain CSF samples and to deliver IT injections of idursulfase-IT.

If the IDDD appears to be non-functional, or if its use is precluded on a scheduled day of dosing, site personnel will refer to the IDDD Manual, which provides details on the investigation and management of any IDDD-related issues. This includes possible partial revision or complete replacement of the IDDD as indicated. If the intrathecal space is not accessible via the IDDD, study drug may be administered to a patient by lumbar puncture up to 12 times. Should the IDDD become clogged, undergo mechanical complications, or otherwise not be accessible, the CSF sample may also be obtained from a patient by lumbar puncture up to 12 times during the treatment phase of the study.

General anesthesia/sedation may be required for injections of study drug and some evaluations, and may be used at the discretion of the Investigator.
A Data Monitoring Committee (DMC) will oversee both idursulfase-IT and device safety. The DMC will be notified of IDDD failures and related complications on a periodic basis according to the DMC charter (See Section 11.8).

Patients will have the IDDD removed when they discontinue from the study, unless the patient is continuing to receive treatment through another mechanism (eg, extension study, expanded access program).

See Section 13 for the Schedule of Events (SOE) for the pivotal study (Appendix 1 and Appendix 2) and separate substudy (Appendix 3).

4.2 Rationale for Study Design and Comparator Group

Hunter syndrome (MPS II) is an X-linked genetic disease that occurs predominantly in males; affected females are exceedingly rare. The primary analysis of efficacy in the pivotal study will focus on pediatric MPS II patients ([male] ≥3 and <18 years of age) with evidence of cognitive impairment. Note that for the purpose of this study, cognitive impairment is defined as a DAS-II GCA standard score at Screening between 85 and 55. Patients with a GCA score at Screening >85 who are ≥3 to ≤13 years of age may still be eligible to participate if there is demonstrated evidence of a decrease in GCA score of ≥10 points within a 12-month period in observational study HGT-HIT-090.

Eligible patients will be assigned randomly to either the monthly IT injection of 10 mg idursulfase-IT group or to the no treatment group in a 2:1 allocation ratio. The randomization scheme will be stratified by the baseline GCA score (≤70 or >70). The duration of treatment will be 12 months, based on 12 consecutive monthly IT injections in the treated group. The treated patients will be implanted with a SOPH-A-PORT Mini S IDDD with the intent that idursulfase-IT will be administered via this IDDD. However, in case of IDDD malfunction, the drug may also be administered via lumbar puncture (refer to Section 4.1.1).

The intrathecally administered dose of idursulfase-IT (10 mg) to be used in this study and the treatment regimen were based on findings from studies HGT-HIT-045 and HGT-HIT-046 (See Section 4.2.1).

The comparator group in this study is randomized to “no IT treatment.” Surgical implantation of a device, performance of sham injections, and use of a placebo control were not considered appropriate for this group for ethical reasons.

All patients will receive standard-of-care treatment with Elaprase during the study. Elaprase will not be provided by the Sponsor, but rather will be prescribed by the patient’s physician in accordance with local prescribing information.

The endpoints will be clinical in nature, namely, changes in cognitive and adaptive functioning over time. The proposed primary efficacy endpoint is the change from baseline in the GCA score after 12 months of treatment at Visit Week 52 as obtained by DAS-II testing and a comparison of treated versus untreated patients will be performed. This primary endpoint was chosen because of its clinical relevance. Data from the scientific literature concerning the rate of
cognitive decline in children with MPS II\textsuperscript{10,18} and the Sponsor’s clinical trial experience with cognitively impaired MPS II patients suggest that an annual 11 to 14 point drop in GCA may be expected in the absence of an effective treatment. The change from baseline in GCA score after 12 months of treatment is a suitable endpoint for the development of idursulfase-IT in the proposed indication, and a 10 to 11 point difference compared with control in mean GCA change over that time frame represents a clinically meaningful benefit to patients. Secondary efficacy measures proposed include tests for activities of daily living using the VABS-II.\textsuperscript{19} The proposed key secondary efficacy endpoint is the change from baseline in the ABC score after 12 months of treatment at Visit Week 52 as obtained by VABS-II testing and a comparison of treated versus untreated patients will be performed.

Given that the pivotal study will enroll only those patients with early cognitive impairment, it is expected, based on the Sponsor’s Phase I/II experience, that such children will be able to complete serial neurodevelopmental assessments using the DAS-II and VABS-II assessment tools.

As discussed in Section 1.1, the age distribution of cognitive and functional impairment in MPS II indicates that cognitive deficit begins to become quantifiable at around the age of 2 to 4 years.\textsuperscript{10,11} By the time a child with MPS II is 12 years old, he is typically either at the final stages of the neurodegenerative process or has largely escaped cognitive impairment. This was confirmed by the data from Phase I/II study HGT-HIT-045, where the patients with the mildest and earliest forms of cognitive impairment were in the age range of 3 to 7 years. There are two exceptions to this general pattern. In rare cases, cognitive and functional impairment may be noticeable prior to the age of 3 years. This is, for instance, observed in children with a complex rearrangement/large deletion of the iduronate-2-sulfatase gene who are at the severe end of the spectrum both for physical and CNS disease. Even more rarely, children may exhibit a slow progression of CNS disease.\textsuperscript{10,13} Such children may have measurable cognitive and functional abilities into their mid teens. MPS II patients within these two subcategories, ie, those <3 years of age and those ≥13 to <18 years of age, may be eligible for participation in HGT-HIT-094 and are discussed in further detail below.

Patients in whom cognitive impairment can be identified below 3 years of age are ineligible to be part of the pivotal study and will not be randomized, but rather, will be enrolled into a separate substudy to receive IT treatment with idursulfase-IT. Because the primary assessment tool of the pivotal study, the DAS-II, is not suitable for the evaluation of these younger children, a more suitable tool, the Bayley Scales of Infant Development (BSID-III),\textsuperscript{20} will be used. As these children will be identified infrequently, no enrollment target will be implemented. The analysis of substudy data will be descriptive only and will not be part of the efficacy analysis of the pivotal study. Like patients in the pivotal study, patients in the substudy will continue to receive the standard of care, Elaprase, under the supervision of their treating physician.

Children ≥13 years of age with slowly progressing CNS disease were not identified in study HGT-HIT-045 or in conversations with MPS II experts, but have been described sporadically in the literature.\textsuperscript{10,13} It is a reasonable hypothesis that the clinical course in these children with an attenuated disease subtype may be different from the typical course of neurodevelopmental decline. To mitigate this risk, children ≥13 years of age with cognitive impairment, should they
be identified during the enrollment period of this trial, will be required to have shown a decrease in GCA of at least 10 points over a 12-month period in the observational study HGT-HIT-090 and to have a DAS-II GCA standard score at Phase II/III study entry between 85 and 55. These criteria will be implemented to ensure that the clinical course of cognitive decline in these children is similar in rate to that in children for whom the cognitive decline manifested earlier, thereby ensuring a more homogeneous target population for the trial. If these and other eligibility criteria are met, such patients will be randomized (2:1) to receive IT treatment with idursulfase-IT or no IT treatment in the pivotal study.

4.2.1 Rationale for Dose Selection

Extrapolation to humans from data in non-human primates suggests that a dose from 5 to 35 mg delivered intrathecally would result in sufficient exposure to potentially elicit a clinical treatment response in MPS II patients. The selection of the 10 mg dose of idursulfase-IT to be given in this study was further informed by the PK and PD data of Phase I/II studies, HGT-HIT-045 and HGT-HIT-046.

The serum PK profiles of idursulfase-IT were dose proportional with respect to $C_{\text{max}}$ between the 1 mg and 10 mg idursulfase-IT dose groups. However, the 10 and 30 mg idursulfase-IT groups exhibited overlapping serum concentration-time profiles indicative of saturation of the transport processes from the CSF to the serum and CNS tissue compartments.

The PD properties of idursulfase IT were evaluated in HGT-HIT-045 and HGT-HIT-046 by measuring GAG concentration in CSF at 1 month after each idursulfase-IT administration. Compared with the 1 mg idursulfase-IT dose, the 10 mg and 30 mg doses produced equivalent, sustained reductions of CSF GAG concentrations. No appreciable change in CSF GAG concentration was observed in the untreated group (note that patients in this group, as well as the treated group, received weekly Elaprase infusions throughout the study). Thus, the PD profiles associated with monthly idursulfase-IT administration indicated that the 1 mg dose was suboptimal, with the 10 mg dose achieving maximal PD response and the 30 mg dose demonstrating no appreciable added benefit. This response correlates with the therapeutic dose range (5 to 35 mg) estimated from evaluation of HGT-2310 in non-human primates.

The doses (1, 10, 30 mg) of idursulfase-IT evaluated in the Phase I/II studies demonstrated equivalent safety profiles. The clinical PK and PD profiles of idursulfase-IT in MPS II patients indicated that the 10 mg dose provides a maximum pharmacologic response. Therefore, the 10 mg dose of idursulfase-IT was selected for Phase II/III investigation in this study.

4.3 Study Duration

The planned overall duration of each patient’s participation in the study is approximately 14 to 15 months from Screening to the last scheduled contact.

An extension study is planned during which patients who complete HGT-HIT-094 and are eligible according to the inclusion/exclusion criteria for the extension study may continue, or begin, to receive IT treatment with idursulfase-IT via the SOPH-A-PORT Mini S device.


5 STUDY POPULATION SELECTION

5.1 Study Population

For the pivotal study, it is planned that 42 patients (28 treated, 14 untreated) with early cognitive impairment who are ≥3 to <18 years of age at the time of informed consent and meet all study entrance criteria will be randomized. Note that, to meet study entry criteria, patients who are ≥13 to <18 years of age at the time of informed consent must have documented evidence of cognitive decline over 12 months in observational study HGT-HIT-090 in order to participate in this study.

A separate substudy will enroll patients who have early cognitive impairment and are below the age of 3 years at the time of informed consent. Such patients are ineligible for the pivotal study and will not be randomized, but may receive treatment with idursulfase-IT in the substudy. In view of the rarity of such patients, no enrollment target will be proposed. The enrollment of patients below 3 years of age into this separate substudy will be considered additional to the 42 patients planned for the pivotal study, and will conclude when enrollment of patients in the pivotal study closes.

5.2 Inclusion Criteria

5.2.1 Inclusion Criteria for the Pivotal Study

Patients must meet all of the following criteria to be considered eligible for randomization in the pivotal study:

1. The patient is male and is ≥3 and <18 years of age at the time of informed consent. Spanish-speaking patients who are to be assessed using the Spanish version of the DAS-II Early Years must be <7 years 8 months of age at the time of informed consent.

   Note that patients who are younger than 3 years of age may be enrolled in a separate substudy provided that they meet other inclusion criteria, provided below.

2. The patient must have a documented diagnosis of MPS II. Of the three criteria below, the combinations (2a AND 2b) or (2a AND 2c) will be accepted as diagnostic of MPS II:
   a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).

   AND

   b. The patient has a documented mutation in the iduronate-2-sulfatase gene that leaves the FMR1 and FMR2 genes intact.

   OR

   c. The patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory).
3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment, defined as follows:

*Note that separate inclusion criteria with respect to patient cognitive status at Screening apply to patients ≥3 and <13 years of age and to patients ≥13 and <18 years of age.*

A patient who is **≥3 and <13 years** of age must have one of the following criteria (3a OR 3b):

a. A GCA score ≥55 and ≤85

OR

b. If the patient has a GCA score at Screening >85, there must be evidence of a decrease in GCA score of ≥10 points over 12 months from a previously documented test result in observational study HGT-HIT-090.

A patient who is **≥13 and <18 years** of age must have both of the following criteria (3c AND 3d):

a. A GCA score of ≥55 and ≤85.

AND

b. There must be evidence of a decrease in GCA score of ≥10 points over 12 months from a previously documented test result in observational study HGT-HIT-090.

4. The patient has received and tolerated a minimum of 4 months of therapy with Elaprase during the period immediately prior to Screening.

5. The patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator’s judgment to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days.

6. The patient’s parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient’s parent(s) or legally authorized guardian(s) and the patient’s assent, if applicable, must be obtained prior to the start of any study procedures.

### 5.2.2 Inclusion Criteria for the Substudy

Patients must meet all of the following criteria to be considered eligible for enrollment in the separate substudy:

1. The patient is male and is **<3 years** of age at the time of informed consent.
2. The patient must have a documented diagnosis of MPS II. Of the three criteria below, the combinations (2a AND 2b) or (2a AND 2c) will be accepted as diagnostic of MPS II:
   a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).

   AND
b. The patient has a documented mutation in the iduronate-2-sulfatase gene that leaves the FMR1 and FMR2 genes intact.

OR

c. The patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory).

3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment as assessed using the BSID-III and defined as a composite score on the cognitive scale ≥55 and ≤85.

4. The patient has received and tolerated a minimum of 4 months of therapy with Elaprase during the period immediately prior to Screening.

5. The patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator’s judgment to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days.

6. The patient’s parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient’s parent(s) or legally authorized guardian(s) must be obtained prior to the start of any study procedures.

5.3 Exclusion Criteria

Patients who meet any of the following criteria are not eligible to be randomized into the pivotal study or enrolled in the separate substudy:

1. The patient has clinically significant non-Hunter syndrome-related CNS involvement (such as Fragile-X syndrome) which is judged by the Investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments.

2. The patient has a large chromosomal deletion or complex rearrangement that includes a deletion of the FMR1 and/or FMR2 genes.

3. The patient has a significant medical or psychiatric comorbidity(ies) that might affect study data or confound the integrity of study results.

4. The patient has contra-indications for performance of lumbar puncture such as musculoskeletal/spinal abnormalities or risk of abnormal bleeding.

5. The patient has a history of complications from previous lumbar punctures or technical challenges in conducting lumbar punctures such that the potential risks would exceed possible benefits for the patient.

6. The patient has an opening CSF pressure upon lumbar puncture that exceeds 30.0 cm H2O.

7. The patient has experienced infusion-related anaphylactoid event(s) or has evidence of consistent severe adverse events related to treatment with Elaprase which, in the Investigator’s opinion, may pose an unnecessary risk to the patient.

8. The patient has received a cord blood or bone marrow transplant at any time or has received blood product transfusions within 90 days prior to Screening.

9. The patient has a history of poorly controlled seizure disorder.

10. The patient is unable to comply with the protocol (eg, has significant hearing or vision impairment, a clinically relevant medical condition making implementation of the protocol
difficult, unstable social situation, known clinically significant psychiatric/behavioral instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator.

11. The patient is enrolled in another clinical study that involves clinical investigation or use of any investigational product (drug or [intrathecal/spinal] device) within 30 days prior to study enrollment or at any time during the study.

12. The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to compromised airways or other conditions.

13. The patient has a condition that is contraindicated as described in the SOPH-A-PORT Mini S IDDD Instructions for Use (IFU), including:
   a. The patient has had, or may have, an allergic reaction to the materials of construction of the SOPH-A-PORT Mini S device
   b. The patient’s body size is too small to support the size of the SOPH-A-PORT Mini S Access Port, as judged by the Investigator
   c. The patient’s drug therapy requires substances known to be incompatible with the materials of construction
   d. The patient has a known or suspected local or general infection
   e. The patient is at risk of abnormal bleeding due to a medical condition or therapy
   f. The patient has one or more spinal abnormalities that could complicate safe implantation or fixation
   g. The patient has a functioning CSF shunt device
   h. The patient has shown an intolerance to an implanted device
6 STUDY TREATMENT

6.1 Description of Treatments

6.1.1 Investigational Product

The investigational product to be used in this study is idursulfase-IT for intrathecal use.

The idursulfase-IT drug product is an isotonic, sterile solution intended for IT administration. It is formulated as a 10 mg/mL protein concentration in 154 mM NaCl, pH 6.0, 0.005% polysorbate 20. It does not contain any preservatives and is intended for single use.

The active ingredient of the idursulfase-IT drug product is idursulfase (recombinant human iduronate-2-sulfatase) the same active ingredient in the commercially available drug Elaprase. However, Elaprase and idursulfase-IT are specifically formulated for the IV and IT compartments respectively; they cannot be interchanged.

In contrast to Elaprase, idursulfase-IT is specially formulated for, and compatible with, direct introduction into the IT space, because it is isotonic and contains excipients suitable for IT administration.

6.1.2 Intrathecal Drug Delivery Device

The investigational product will be administered via the SOPH-A-PORT Mini S Implantable Access Port. The SOPH-A-PORT Mini S is intended for long-term, intermittent access to the IT space for delivery of investigational product. The device is CE marked in the European Union (EU).

The SOPH-A-PORT Mini S device comprises the following seven components:

- One SOPH-A-PORT Mini S Access Port
- One intrathecal port closed-tip catheter
- One guidewire
- Two suture wings
- One 14-gauge Tuohy needle
- One 22-gauge non-coring Huber needle
- One Luer lock Connector

Further details are provided in the IFU.

6.1.3 Comparator

The comparator group receives no study treatment.
6.2 Treatments Administered

After informed consent is signed, all patients who meet the eligibility requirements for the pivotal study will be randomized on a 2:1 allocation to one of the following pivotal study arms:

- IT Treatment Arm: treatment with idursulfase-IT 10 mg administered intrathecally via the surgically implanted IDDD (or lumbar puncture) once every 28 days
- No IT Treatment Arm: no study treatment

All patients will continue to receive standard-of-care therapy with Elaprase during the study. Elaprase will not be provided by the Sponsor, but rather will be prescribed by the patient’s physician in accordance with local prescribing information.

Patients who are randomized to receive treatment with idursulfase-IT will be scheduled to undergo surgical placement of the SOPH-A-PORT Mini S device. At least 14 days will be allowed for recovery following the placement of the IDDD before the administration of the first intrathecal idursulfase-IT dose. During this time, the patient will receive standard perioperative care. Thereafter, these patients will be administered idursulfase-IT 10 mg as an IT injection once monthly for 12 months.

Patients who are randomized to no treatment will not undergo surgical placement of an IDDD and will not be administered idursulfase-IT during the study.

The separate substudy is an open-label, single arm study. Patients who are enrolled in the separate substudy will undergo surgical placement of the SOPH-A-PORT Mini S device and receive treatment with idursulfase-IT administered intrathecally via IDDD (or lumbar puncture) once monthly for 12 months in addition to standard-of-care therapy with Elaprase prescribed by their physician.

6.3 Selection and Timing of Dose for Each Patient

The dosing schedule for the study is described above in Section 6.2.

Those patients randomized to treatment in the pivotal study will undergo surgical implantation of the IDDD. Treated patients will then receive 12 monthly IT injections of idursulfase-IT 10 mg, once every 28 days.

Patients who are enrolled in the separate substudy will undergo surgical implantation of the IDDD. Patients in the substudy will receive 12 monthly IT injections of idursulfase-IT, once every 28 days. The IT dose of idursulfase-IT to be administered to patients below 3 years of age will be adjusted as follows based on reference brain weight:

- Up to 8 months of age at dosing, idursulfase-IT 5 mg
- >8 months to 30 months of age at dosing, idursulfase-IT 7.5 mg
- >30 months to 3 years of age at dosing, idursulfase-IT 10 mg
Please refer to the Pharmacy Manual for complete details.

For treated patients in the pivotal study and patients in the substudy, on IT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

6.4 Method of Assigning Patients to Treatment Groups

The pivotal trial is randomized and open label. Patients who have met the eligibility criteria will be randomized (open-label, assessor-blinded) in a 2:1 randomization scheme to either IT treatment or no IT treatment. The randomization will be stratified according to baseline (Screening Visit) GCA score (≤70 or >70). The randomization schedule will be generated and administered by a third-party (e.g., interactive voice response (IVR) vendor) independent of the project team.

In a separate substudy, additional patients may be enrolled who are below the age of 3 years at the time of informed consent and have early cognitive impairment. Such patients are ineligible for the pivotal study and will not be randomized, but will receive idursulfase-IT treatment. The separate substudy is an open-label, single arm study. Data from patients participating in this separate substudy will be analyzed separately.

6.5 Blinding

Single and double blinding of patients, their families, and the Principal Investigator is not possible due to the absence of a sham device, sham injections, or placebo. The Sponsor will work with each site to clarify the process for assessor blinding and each site will document the manner in which blinding will be maintained at the site.

Every effort will be made to blind the assessors of the primary and secondary endpoints obtained from the DAS-II and VABS-II. The assessors responsible for these evaluations will not be informed of patients’ randomization assignments. The families will be instructed not to share this information with the assessors. Different assessors will be responsible for administration of the DAS-II and VABS-II. The assessors will not be part of the study team or participate in study team meetings.

6.6 Concomitant Medications, Therapies, and Medical/Surgical Interventions

Treatment with any other investigational therapies at any time during this study is prohibited.

All patients are to receive Elaprase therapy throughout this study. Elaprase will be prescribed by the patient’s physician and will be administered in accordance with local prescribing information. Elaprase will not be provided by the study Sponsor.

Concomitant therapies such as speech therapy, ergotherapy, music therapy, and physical therapy are permitted, and will be captured during the study.
6.6.1 Infusion Reactions and Management

Infusions of proteins can be associated with reactions to the infusion that may or may not be immune mediated. Thus, potential reactions to the infusion of an investigational product are unpredictable.

Infusion-related reactions have been observed in patients receiving IV enzyme replacement therapy (ERT) with Elaprase, with symptoms including cutaneous reactions (rash, pruritus, and urticaria), pyrexia, headache, hypertension, and flushing. Previous experience with Elaprase is fully described in the Elaprase United States (US) Package Insert and the EU Summary of Product Characteristics (SmPC). Pretreatment with antihistamines and/or corticosteroids may prevent subsequent reactions in those cases where symptomatic treatment was required. The safety information reported from administration of Elaprase may be relevant to management of adverse events in relation to idursulfase-IT.

Successful management of Elaprase infusion-related adverse events included slowing or interrupting the infusion at the time of the event or pre-treatment with low-dose corticosteroids and/or antihistamines. Most adverse events of this type were treated with antihistamines such as chlorpheniramine (IV administration preferred if available), oxygen, or mild glucocorticoids such as hydrocortisone and prednisolone. All were monitored closely until symptoms of the reactions had subsided. In clinical trials of Elaprase, an apparent decrease in the overall rates of adverse events, and specifically infusion-related adverse events, was observed over time, suggesting that patients may better tolerate infusions during long-term therapy.

Because idursulfase-IT is administered intrathecally, it is not expected that systemic blood levels will be high enough to cause an infusion-related reaction. Clinical studies with idursulfase-IT have not revealed adverse events consistent with infusion-related reactions sometimes observed with IV Elaprase infusion. There have been no significant concerns regarding infusion-related immune reactions following IT administration in studies HGT-HIT-045 and HGT-HIT-046.

Note that any patient with prior experience of infusion-related anaphylactoid event(s) or evidence of consistent severe adverse events related to treatment with Elaprase is excluded from participating in this study.

6.7 Restrictions

6.7.1 Prior Therapies

All patients must have received and tolerated 4 months of therapy with idursulfase IV (Elaprase) therapy prior to participation in this study.

Prior therapies that are exclusion criteria for the study include the following: treatment with another investigational product (drug or [intrathecal/spinal] device) within the 30 days prior to study enrollment (or at any time during the study, see Section 6.6), receipt of blood product transfusions within 90 days prior to Screening, receipt of a cord blood or bone marrow transplant at any time.
6.7.2 Fluid and Food Intake

Not applicable.

6.7.3 Patient Activity Restrictions

Please refer to the SOPH-A-PORT Mini S IFU for details regarding patient activity restrictions for patients to be implanted with this device.

6.8 Treatment Compliance

Treatment with the investigational product will be administered via an IDDD (or lumbar puncture) under the supervision of the Investigator and in the controlled environment of a clinical center; therefore, full patient compliance with treatment is anticipated in this study.

The initial implantation and revision and/or explantation of the SOPH-A-PORT Mini S will be performed by pediatric or general neurosurgeons or anesthesiologists who have experience in port and catheter implant procedures and intrathecal access procedures. Please refer to the IFU for further details.

Investigational product administration will be performed in a clinical setting by appropriately trained and skilled healthcare providers (nurses or physicians) with knowledge of the patient’s drug regimen and experienced in accessing vascular or CNS ports or CNS infusion pumps. Patients and patients’ families will not be directly using the device to administer drugs and will have limited direct interaction with the device as there is minimal care required both during the immediate postoperative period as the implant site heals, and at times of drug administration.

6.9 Packaging and Labeling

All packaging and labeling will be in accordance with applicable regulatory requirements.

6.9.1 Investigational Product

Idursulfase-IT drug product is a sterile liquid formulation for IT administration that is packaged in 3-mL type-I borosilicate glass vials. The drug product is filled to deliver a minimum dose volume of 1 mL per vial with minimal waste and for handling convenience in the clinical setting.

6.9.2 Intrathecal Drug Delivery Device

The SOPH-A-PORT Mini S Access Port is available in one size, individually packaged, with other SOPH-A-PORT Mini S components in double peel-off, sterile, pyrogen-free packaging, sterilized with Ethylene Oxide. Instructions for use are also included in the packaging. A guidewire is provided in separate double pouch, sterile, pyrogen-free packaging.

Labels are provided on the outer carton and on both the SOPH-A-PORT Mini S box and guidewire/cannula package inside.
6.10 Storage and Accountability

6.10.1 Investigational Product

Idursulfase-IT will be shipped by Shire or a qualified distributor to the clinical study site(s) at 2 to 8 °C (36 to 46 °F). The investigational product should be handled as follows:

- idursulfase-IT vials should be stored at 2 to 8°C (36 to 46°F).
- idursulfase-IT is intended for IT use only.
- It is recommended that idursulfase-IT be filtered prior to use through a standard 0.22 µm filter.
- Perform a visual inspection of each vial. Idursulfase-IT is a clear to slightly opalescent, colorless solution. Do not use if the solution in the vials is discolored or particulate matter is present.
- DO NOT SHAKE. Idursulfase-IT should not be agitated vigorously at any time.
- Withdraw the volume of idursulfase-IT from the vial.
- Do not mix with, or administer in conjunction with other drug solutions.
- Because it does not contain preservatives, idursulfase-IT should be used as soon as possible after it is prepared.
- Idursulfase-IT is supplied in single-use vials. Only 1 dose of idursulfase-IT is to be withdrawn from a vial.

See the Pharmacy Manual for additional details.

The disposition of all investigational product delivered to a Principal Investigator must be recorded on a patient-by-patient basis by completing the Accountability Log. The date and time of administration of the investigational product and use of the device must be documented on the patient’s appropriate CRF.

The Principal Investigator, Clinical Research Coordinator, or designee (eg, Pharmacist) must ensure that all documentation regarding investigational product receipt, storage, dispensing, loss/damaged and return of used/unused product is complete, accurate, and ready for review at each monitoring visit and/or audit. The sites must ensure that the investigational product is available for the monitor to inventory and prepare for return shipment to the Sponsor or designee, if required.

6.10.2 Intrathecal Drug Delivery Device

The disposition of all SOPH-A-PORT Mini S devices delivered to a Principal Investigator must be recorded on a patient-by-patient basis by completing the Accountability Log. The date and time of administration of the investigational product and use of the SOPH-A-PORT Mini S device must be documented on the patient’s appropriate CRF.

The Principal Investigator, Clinical Research Coordinator, or designee (eg, Pharmacist) must ensure that all documentation regarding receipt, storage, dispensing, loss/damaged SOPH-A-PORT Mini S devices and return of used/unused SOPH-A-PORT Mini S device(s) is
complete, accurate, and ready for review at each monitoring visit and/or audit. The sites must ensure that the SOPH-A-PORT Mini S devices are available for the monitor to inventory and prepare for return shipment to the Sponsor or designee, if required.


Please refer to the IDDD Manual for device return instructions.

**6.10.3 Comparator Product**

Not applicable to this study.
7 STUDY PROCEDURES

The pivotal study will consist of a Screening period of up to 28 days (during which re-testing of patients who were initially unwilling or unable to comply with all scheduled screening assessments is permitted) prior to randomization (Day 0).

Those patients randomized to the IT treatment arm will undergo surgical implantation of the SOPH-A-PORT Mini S IDDD followed by a post-operative recovery period of at least 14 days prior to the first IT administration of idursulfase-IT. Treated patients will then receive 12 monthly IT injections of idursulfase-IT corresponding to a treatment and assessment interval of 13 (28-day) months from randomization to the EOS evaluations. Likewise, patients randomized to the no IT treatment arm will be assessed over 13 (28-day) months after randomization.

Patients in the IT treatment arm of the pivotal study will be assessed according to the following schedule:

- Screening (Weeks -4 to -1 [Day -28 to Day -1])
- Randomization (Week 0 [Day 0])
- Pre-surgery, Surgery, Follow-up, and Post-operative Recovery (Week 2 [+7 days])
- Treatment and Assessments (Week 4 through Week 48 [+7 days])
- End of Study (EOS, Week 52 [+7 days])
- Follow-up (telephone contact) 7 (±2) days from the Week 52 (or EOS)

Patients in the no IT treatment arm of the pivotal study will be assessed according to the following schedule:

- Screening (Weeks -4 to -1 [Day -28 to Day -1])
- Randomization (Week 0 [Day 0])
- Telephone Contact (Week 2 [+7 days])
- Assessments (Week 4 through Week 48 [+7 days])
- End of Study (EOS, Week 52 [+7 days])
- Follow-up (telephone contact) 7 (±2) days from the Week 52 (or EOS)

The separate substudy is open label and single arm. Patients who meet all entry criteria for participation in the substudy will be considered enrolled on Day 0. Thereafter, patients in the separate substudy will follow the same schedule of study visits as idursulfase-IT-treated patients in the pivotal study.

Patients in the substudy will be assessed according to the following schedule:

- Screening (Weeks -4 to -1 [Day -28 to Day -1])
- Enrollment (Week 0 [Day 0])
- Pre-surgery, Surgery, Follow-up, and Post-operative Recovery (Week 2 [+7 days])
- Treatments and Assessments (Week 4 through Week 48 [+7 days])
- End of Study (EOS, Week 52 [+7 days])
Follow-up (telephone contact) 7 (+2) days from the Week 52 (or EOS)

All patients will complete EOS assessments at Week 52 (Visit Month 13) and will participate in a follow-up contact (by telephone) approximately 7 days after the EOS visit.

A patient who discontinues or is withdrawn prior to study completion will be asked to participate in an EOS visit within approximately 30 days after withdrawal or discontinuation (EOS assessments for such patients will be the same as Week 52 assessments), and also to complete a follow-up contact approximately 7 days after the patient’s EOS visit. There is no replacement of patients who do not complete the study.

All patients will receive weekly IV Elaprase infusions as prescribed throughout the study.

For treated patients in the pivotal study and patients in the substudy, on IT Dosing Weeks the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

See Section 13 for the Schedules of Events for the pivotal study (Appendix 1 and Appendix 2) and separate substudy (Appendix 3).

All data collected are to be recorded on the appropriate CRF.

Details for study procedures including sample collection are described in the Study Operations Manual.

7.1 Informed Consent

Prior to conducting any study-related procedures, written informed consent (signed and dated) must be obtained from the patient’s parent(s) or legally authorized representative(s) (and assent from the patient, if applicable). The nature, scope, and possible consequences, including risks and benefits, of the study will be explained by the Investigator or designee in accordance with the guidelines described in Section 11.4. Documentation and filing of informed consent documents should be completed according to Section 11.4.

7.2 Study Entrance Criteria

Each patient will be reviewed for eligibility against the study entrance criteria. Patients who do not meet the study entrance criteria will not be allowed to participate in the study. The reason(s) for the patient’s ineligibility for the study will be documented. No protocol exemptions will be permitted.

7.3 Medical History

A standard medical history of each patient will be obtained at Screening and will include age at onset of Hunter syndrome symptoms, age of Hunter syndrome diagnosis, evidence of iduronate-2-sulfatase deficiency, genotype, family history of Hunter syndrome, Hunter syndrome signs and symptoms in the following domains: head/neck, eyes, mouth, ear, nose, throat,
chest/lung, cardiovascular system, abdomen, gastrointestinal system, genitourinary system, skin, skeletal system, neurological system, psychiatric disorders and surgical history.

Patients who do not have a documented diagnosis of Hunter syndrome in their medical history will provide a blood sample at Screening to assay for iduronate-2-sulfatase enzyme activity in plasma, fibroblasts, or leukocytes (patients must exhibit ≤10% of the reference laboratory’s lower limit of the normal range to confirm diagnosis). These samples will also be assayed for normal enzyme activity level of one other sulfatase in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).

7.3.1 Genotype

Patients who have not had a previous iduronate-2-sulfatase gene (IDS) genotype analysis performed at Greenwood Genetic Center’s Diagnostic Laboratory (Greenwood, South Carolina, USA), referred to here as “Greenwood Labs,” will provide a blood sample for genotyping to document the diagnosis of Hunter syndrome. Even patients for whom prior genotyping was performed at Greenwood Labs may need to have a repeat analysis performed if the original information was insufficient for an unambiguous classification of genotype (eg, to document the integrity of the FMR1 and FMR2 genes in patients with large deletion/rearrangement mutations).

Specific instructions concerning genotyping and the timing of enrollment are provided below:

- A Greenwood Labs IDS genotype will be obtained for all patients in the study. If the patient has no Greenwood Labs IDS genotype in his file at the time of informed consent, a blood sample will be drawn at Screening. If the patient has a prior Greenwood Labs genotype in his file, and it indicates the presence of a mutation(s) that is within the IDS locus (eg, small deletion or point mutation), the test will not have to be redone. If the patient has a prior Greenwood Labs genotype in his file, and it indicates the presence of a large deletion/rearrangement mutation but does not confirm the integrity of the FMR1 and FMR2 genes, a new sample may have to be drawn.
- If the patient has no documented IDS genotype at Screening, then enrollment/randomization will have to await the arrival of the Greenwood Labs genotype results.
- If the patient has a locally determined IDS genotype indicating the presence of a small deletion or point mutation, the site may proceed and enroll/randomize him while awaiting the confirmatory results from Greenwood Labs.
- If the patient has a locally determined IDS genotype indicating the presence of a large deletion/rearrangement mutation, then enrollment/randomization will have to await the results of the Greenwood Labs genotype analysis to confirm the integrity of the FMR1 and FMR2 genes.
- If the patient has a Greenwood Labs IDS genotype indicating the presence of a small deletion or point mutation, he can be enrolled/randomized at once.
- If the patient has a Greenwood Labs IDS genotype indicating the presence of a large deletion/rearrangement mutation, he may only be enrolled/randomized if and when a Greenwood Labs genotype confirming the integrity of the FMR1 and FMR2 genes is available, either in his original genotype documentation, or by analysis of a new sample.
7.4  Echocardiogram

An echocardiogram will be performed as part of the study screening assessments. This procedure will not be necessary if the patient has had an echocardiogram performed within 3 months of study entry, the data are available, and deemed satisfactory for evaluation of anesthesia risk.

7.5  Device Related Procedures

7.5.1  IDDD Implantation and Revision

The IDDD will be surgically implanted or revised at the clinical site. Procedures for implantation and revision are detailed in the device’s IFU. Standard hospital procedures for surgery will be followed; the patient will be under general anesthesia for this procedure.

An additional medical device, the catheter passer, is necessary for the implantation procedure. The catheter passer is a sterile, single use device that will be used in the subcutaneous placement of the catheter. The Phoenix Neuro Disposable Catheter Passer, manufactured by Sophysa is CE marked in the EU and cleared under K853370 in the US.

Details of the implantation/revision and malfunctions/failure will be documented on the patient’s CRF.

7.5.2  X-ray Verification of Intrathecal Drug Delivery Device Placement

A postoperative X-ray check of the IDDD will be performed following surgery to verify proper installation and confirmation of IDDD placement at the mid-thoracic level. The X-rays may be performed to check placement of the device, as needed, throughout the study, and will be performed at the end of the study (to verify that the IDDD is in the correct position). At a minimum, the date of the X-ray verifying correct IDDD placement will be documented on the patient’s CRF. If the device requires revision or replacement during the study, additional X-rays will be taken to document the proper positioning of the device. If the IDDD malfunctions, an X-ray will be performed to assess the potential cause of malfunction.

7.5.3  CSF Sampling Procedure

Cerebrospinal fluid will be sampled via the device. If this is not possible, and if CSF sampling is necessary, either for adherence to the protocol, or to investigate clinical concerns, a lumbar puncture may be performed to sample CSF, either with or without administration of drug afterwards (See Section 4.1.1).

7.5.4  Device Removal

If at the time of a scheduled dosing it is not possible to administer a full medication dosage as per the standard administration steps detailed in the device’s IFU due to a device related issue, the IDDD will be declared a device malfunction. If the device malfunction is irreversible and
cannot be corrected without a device surgical intervention, the IDDD will be declared a device failure, starting from the date of the initial malfunction.

The IDDD will then be surgically removed or revised and a new device and/or device components will be re-implanted at the earliest possible opportunity, preferably at the same time.

Details of the device removal will be recorded in the patient’s CRF. For further details, please refer to the SOPH-A-PORT Mini S IFU.

Patients will have the IDDD removed when they discontinue from the study, unless the patient is continuing to receive treatment through another mechanism (eg, extension study, expanded access program).

7.6 Investigational Product Administration

It is planned that idursulfase-IT will be administered every 28 days by means of the IDDD. A visual examination of both the port and catheter track will be performed before each IT injection.

A 22-gauge Huber non-coring needle is to be used for access to the implanted port; standard hypodermic needles would damage the septum and may cause leakage. If no needle free connector is present, either a stopcock of the Huber needle infusion set’s clamp is to be used to prevent CSF backflow and to mitigate the risk of air entering the system. It is possible to use other brands of Huber non-coring needles, provided that their specifications are identical to that of the Huber needle (22G) supplied by Sophysa in a SOPH-A-PORT Mini S.

If the intrathecal space is not accessible via the IDDD, idursulfase-IT may be administered by lumbar puncture (See Section 4.1.1).

The injection date, injection start/stop time, planned dose, injection volume, and flush volume will be recorded on the patient’s CRF.

Intrathecal administration of investigational product will be preceded by CSF sampling for laboratory analysis, pharmacodynamic analysis (GAG concentration), and analyses of idursulfase enzyme concentration and anti-idursulfase antibodies. The total volume of investigational product and flush administered is targeted towards replenishing the volume of CSF withdrawn. Therefore, while the total volume of idursulfase-IT administered will be less than the total volume of CSF withdrawn, additional saline will be administered to ensure a balance between the amount administered and the amount withdrawn.

Specifically, the investigational product will be administered in a volume of 1 mL (1 mL of a 10 mg/mL solution) (See Section 6.1.1). The minimal proposed flush volume is 2 mL, so the minimal volume administered will be 3 mL. Additional volume of preservative-free saline will be administered to add up to a total volume that is equal to that which was withdrawn.

This design was intended to mitigate any risk of overfilling or underfilling the IT compartment as well as the risk of inducing acute intracranial hypertension or brain herniation.
Patients will remain under the observation of study personnel in the hospital setting (may include lounge, infusion center, or waiting room) for 4 hours post administration of investigational product for safety assessments. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of study visit weeks at which serial blood sampling for pharmacokinetic evaluation is planned). For the first 6 months of treatment with idursulfase-IT, patients must return to the clinic the day after each IT administration for a safety follow-up visit. Note that, under these circumstances, there is no requirement for an overnight hospital stay; if a decision is made to keep the patient overnight for convenience, this hospitalization should not initiate a serious adverse event report. For the latter 6 months of treatment with idursulfase-IT (ie, from Week 28 onward) and in the absence of any safety concerns, patients may complete the safety follow-up visit on the same day as IT administration prior to discharge.

7.7 Pharmacokinetic Assessments

Blood samples will be collected for determination of idursulfase serum concentration-time profiles and serum pharmacokinetic parameters after IT administration.

Idursulfase concentrations will be measured in CSF samples obtained immediately prior to each IT administration (and at the EOS Visit) to determine the degree of accumulation of monthly idursulfase-IT administrations in the CSF.

The blood and CSF sampling schedules for pharmacokinetic assessments are provided in the SOE for patients in the treated arm of the pivotal study (Appendix 1) and in the separate substudy (Appendix 3).

7.8 Pharmacodynamic/Biomarker Assessments

7.8.1 CSF Glycosaminoglycan

Cerebrospinal fluid will be collected for measurement of the concentration of GAG (refer to the SOE for the pivotal study [Appendix 1 and Appendix 2] and separate substudy [Appendix 3]).

7.8.2 CSF and Serum Albumin

Albumin levels will be measured in samples of CSF and serum (refer to the SOE for the pivotal study ([Appendix 1 and Appendix 2] and separate substudy [Appendix 3]) to monitor the permeability of the blood-brain barrier.

7.9 Efficacy Assessments

The efficacy endpoints are specified in Section 3.
7.9.1 Neurodevelopmental Assessment Tools

The study methodology will include standardized neurodevelopmental assessments to provide a quantifiable measure of patient neurodevelopmental status. Neurodevelopmental status will be assessed over time by measuring cognitive and adaptive functions as follows.

Cognition: the Differential Ability Scales, Second Edition (DAS-II) \(^{17}\) will be used to assess all randomized patients. The DAS-II comprises 2 overlapping batteries. The Early Years battery is designed for children ages 2 years 6 months through 6 years 11 months. The School Age Battery is designed for children ages 7 years 0 months through 17 years 11 months. These batteries are fully co-normed for ages 5 years 0 months through 8 years 11 months. Spanish-speaking patients will be assessed using the Spanish version of the DAS-II Early Years only.

For patients participating in the separate substudy only (ie, patients who are below the age of 3 years and who have early cognitive impairment) cognition will be assessed initially using the BSID-III. \(^{20}\) When these patients reach at least 42 months of age, if considered evaluable using the DAS-II instrument, they will transition to use of the DAS-II for continued assessment of cognition.

Adaptive Behaviors: the Vineland Adaptive Behavioral Scales, Second Edition (VABS-II) \(^{19}\) will be used to assess all patients. The Expanded Interview Form will be utilized.

It is intended that full neurodevelopmental assessments be conducted for all patients; however, it is recognized that the feasibility of conducting these assessments may be dependent on the patient’s ability to cooperate and/or level of cognitive impairment.

All assessments will be administered by qualified study personnel. The DAS-II will be administered by a trained practitioner.

7.10 Health Status Assessment

The health status of patients will be assessed using the EQ-5D questionnaire, a standardized instrument for use as a measure of health status which is applicable to a wide range of health conditions and treatments. \(^{22, 23}\) The EQ-5D provides a descriptive profile and index value for health status.

7.11 Safety Assessments

Safety will be assessed by adverse events (by type, severity, and relationship to treatment [idursulfase-IT, the IDDD, device surgical procedure, or IT administration process] and IV Elaprase infusion), changes in clinical laboratory testing (serum chemistry, hematology, urinalysis), physical and neurological examination, vital signs, 12-lead ECG recordings, CSF laboratory parameters (chemistries, cell counts), anti-idursulfase antibodies in CSF and serum, and determination of antibodies having enzyme neutralizing activity.

SOPH-A-PORT Mini S assessments will include measures of device implantation, device function, device longevity, record of revisions, removals, and replacements of the implanted...
IDDD, and adverse events associated with the device. This data will be collected on the patient’s CRF from the time of implantation and continue throughout the study as long as the SOPH-A-PORT Mini S remains implanted.

### 7.11.1 Physical and Neurological Examination

A physical examination will be performed with a thorough review of body systems on specified study days.

Physical examinations will include a review of the patient’s general appearance, neurological examination, as well as evaluation of the body systems listed in Table 7-1 and the device port and catheter track. Any abnormal change in findings will be recorded as an adverse event on the appropriate CRF.

#### Table 7-1 Assessments for Physical and Neurological Examinations

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>General appearance</td>
<td>Endocrine</td>
</tr>
<tr>
<td>Head and neck</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td>Eyes</td>
<td>Abdomen</td>
</tr>
<tr>
<td>Ears</td>
<td>Genitourinary</td>
</tr>
<tr>
<td>Nose</td>
<td>Skin</td>
</tr>
<tr>
<td>Throat</td>
<td>Musculoskeletal</td>
</tr>
<tr>
<td>Chest and lungs</td>
<td>Neurological</td>
</tr>
<tr>
<td>Port and catheter</td>
<td></td>
</tr>
</tbody>
</table>

### 7.11.2 Height and Weight

Height (cm) and weight (kg) will be recorded for all patients at Screening and during the study at time points specified in the SOE. The clinical site staff will be instructed to use a calibrated scale for weight measurement.

### 7.11.3 Head Circumference

Head circumference (cm) will be measured in a uniform manner for all patients.

### 7.11.4 Hearing Assessment

Each patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator’s judgment, to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days.

The Investigator will confirm that, with hearing aids in place if needed, each patient has sufficient understanding to participate in study assessments.
7.11.5 Vital Signs

Vital signs are to be recorded for all patients and will include pulse, blood pressure, respiration rate, oxygen saturation, and temperature.

7.11.6 Electrocardiogram

An electrocardiogram (12-lead) will be performed in accordance with the clinical site’s standard practice(s). Electrocardiogram recordings will be read locally at the clinical site by a qualified cardiologist. The ECG will include assessment of heart rate, sinus rhythm, atrial or ventricular hypertrophy, and assessment of PR, RR, QRS, and QT intervals. Identification of any clinically significant findings and/or conduction abnormalities will be recorded on the CRF.

7.11.7 Intracranial Pressure Measurement

Intracranial pressure (ICP) measurement (cm of H$_2$O) will be assessed for all patients. The ICP measurement will be conducted by lumbar puncture and while the patient is under anesthesia.

Patients with a surgically implanted IDDD should undergo X-ray prior to lumbar puncture to verify the position of the catheter.

7.11.8 Brain Magnetic Resonance Imaging

Patients will undergo magnetic resonance imaging (MRI) of the brain. Brain structure volumes will be measured. Refer to the Study Operations Manual and/or MRI Manual for specific procedures and precautions.

7.11.9 Clinical and Other Laboratory Tests

Blood and urine samples will be collected as described in this section for clinical laboratory testing. All blood samples will be collected by venipuncture or via central line.

Clinical laboratory tests will include the following (See Table 7-2):

**Table 7-2 List of Laboratory Tests**

<table>
<thead>
<tr>
<th>Hematology:</th>
<th>Serum Chemistry:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit (Hct)</td>
<td>Albumin (ALB)</td>
</tr>
<tr>
<td>Hemoglobin (Hgb)</td>
<td>Alkaline phosphatase (ALK-P)</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin (MCH)</td>
<td>Alanine aminotransferase (ALT; SGPT)</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin</td>
<td>Aspartate aminotransferase (AST; SGOT)</td>
</tr>
<tr>
<td>concentration (MCHC)</td>
<td>Blood urea nitrogen (BUN)</td>
</tr>
<tr>
<td>Mean corpuscular volume (MCV)</td>
<td>Calcium (Ca)</td>
</tr>
<tr>
<td>Platelet count</td>
<td>Carbon dioxide (CO$_2$)</td>
</tr>
<tr>
<td>Red blood cell (RBC) count</td>
<td>Chloride (Cl)</td>
</tr>
<tr>
<td>White blood cell (WBC) count with</td>
<td>Creatinine</td>
</tr>
<tr>
<td>differential</td>
<td>Creatine phosphokinase</td>
</tr>
<tr>
<td>Urinalysis:</td>
<td>Gamma-glutamyl transferase (GGT)</td>
</tr>
</tbody>
</table>
Table 7-2  List of Laboratory Tests

- Appearance (clarity and color)  - Glucose
- Bilirubin  - Lactate dehydrogenase (LDH)
- Blood  - Magnesium (Mg)
- Glucose  - Phosphorus (P)
- Ketones  - Potassium (K)
- Leukocyte esterase  - Sodium (Na)
- Microscopic examination of sediment  - Total and direct bilirubin
- Nitrite  - Total cholesterol
- pH  - Total protein
- Protein  - Total thyroxine (T4)
- Specific gravity  - Thyroid-stimulating hormone (TSH)
- Urobilinogen  - Triglycerides
- Protein  - Uric acid

Coagulation:
  - Prothrombin time (PT)
  - Partial thromboplastin time (PTT)

Urine samples will be collected for determination of GAG concentration. Urine GAG will be analyzed and reported by a Sponsor-designated laboratory. Urine creatinine will be analyzed in the collected samples. Urine GAG concentration will be normalized to urine creatinine and reported as mg GAG/mmol creatinine.

7.11.10  Cerebrospinal Fluid Assessments

Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard safety laboratory parameters (chemistries [including protein, glucose, cell counts], albumin, GAG, and concentration of idursulfase enzyme. The CSF samples will also be analyzed for idursulfase-specific antibodies and antibodies with enzyme neutralizing activity (See Section 7.11.11).

Cerebrospinal fluid will be obtained from patients in the treated arm of the pivotal study and in the substudy at Screening (by lumbar puncture and under general anesthesia), during surgical implantation of the IDDD, prior to each intrathecal injection of investigational product, and at the EOS visit. Should the IDDD become clogged, undergo mechanical complications or otherwise not be accessible, the CSF sample may be obtained by lumbar puncture up to 12 times during the treatment phase of the study.

Patients in the no-treatment arm of the pivotal study will undergo lumbar puncture (under general anesthesia) to obtain CSF samples at the Screening and EOS Visits.

7.11.11  Antibody Assessments

Blood and CSF samples will be collected and evaluated by a Shire-designated laboratory for the presence of anti-idursulfase antibodies and antibodies with enzyme neutralizing activity.
7.11.12 Device Assessments

SOPH-A-PORT Mini S assessments will include measures of device implantation, device function, device longevity, record of revisions, removals, and replacements of the implanted IDDD, and adverse events associated with the device. These data will be collected on the patient’s CRF from the time of implantation and continue throughout the study as long as the SOPH-A-PORT Mini S remains implanted.

As part of the assessment of the SOPH-A-PORT Mini S, it may be necessary to determine the levels of leachables from the device into the CSF and blood. Samples of stored CSF and serum may be used to determine the levels of leachable materials related to the IDDD.

7.11.13 Pregnancy Testing

Not applicable.

7.12 Sample Collection, Storage, and Shipping

Details for study procedures, including sample collection, are provided in the Study Operations Manual and/or Laboratory Manual for this study.

7.13 Concomitant Medications, Therapies/Interventions, and Medical/Surgical Procedures Assessments

All medications, therapies/interventions administered to and medical/surgical procedures performed on patients from the time of informed consent through the follow-up contact are regarded as concomitant and will be documented on the CRF.

Non-permitted (per the exclusion criteria) medications, therapies, or surgical interventions will lead to exclusion from the study or a possible protocol violation depending on when the non-permitted event occurs.

7.14 Adverse Events Assessments

7.14.1 Definitions of Adverse Events and Serious Adverse Events

7.14.1.1 Adverse Events

An adverse event is any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. This includes an exacerbation of a pre-existing condition.

Adverse events include:

- Worsening (change in nature, severity, or frequency) of conditions present at the onset of the study
• Intercurrent illnesses
• Drug interactions
• Events related to or possibly related to concomitant medications
• Clinically significant abnormal laboratory values (includes shifts from baseline within the range of normal that the Investigator considers to be clinically important)
• Clinically significant abnormalities in physical and neurological examination, vital signs, ECG

Throughout the study, the Investigator must record all adverse events on the AE CRF, regardless of the severity or relationship to investigational product. The Investigator should treat patients with adverse events appropriately and observe them at suitable intervals until the events stabilize or resolve. Adverse events may be discovered through observation or examination of the patient, questioning of the patient or his parent(s)/legally authorized guardian(s), complaint by the patient or his parent(s)/legally authorized guardian(s), or by abnormal clinical laboratory values or physical findings.

In addition, adverse events may also include laboratory values that become significantly out of range. In the event of an out-of-range value, the laboratory test should be repeated until it returns to normal or can be explained and the patient’s safety is not at risk.

Additional illnesses present at the time when informed consent is given are regarded as concomitant illnesses and will be documented on the appropriate pages of the CRF. Illnesses first occurring or detected during the study, and worsening of a concomitant illness during the study, are to be regarded as adverse events and must be documented as such in the CRF.

7.14.1.2 Elaprase-related Adverse Events

All patients will receive concomitant IV therapy with Elaprase throughout their participation in this study. Adverse events that are potentially related to IV Elaprase infusion will be captured. The most commonly reported adverse events that have been assessed as related to Elaprase in patients with Hunter syndrome are listed in Section 6.6.1. Note that, during weeks of IT dose administration, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT dosing in order to help distinguish adverse events related to IV compared to IT administration.

7.14.1.3 IDDD-related Adverse Events

Examples of adverse events related to use of the IDDD include, but are not limited to, the following: device failure (such as may occur with migration of the portal/catheter, occlusion of the portal/catheter, incorrect connection of IDDD components, fibrin sheath formation around the catheter tip), erosion of the portal/catheter through the skin, hematoma, implant rejection, or subcutaneous tract infection. A malfunction of the device (defined in Section 7.14.2.2) should not be entered as an adverse event unless this has physiopathological consequences such as those listed above. In the event of device failure (defined in Section 7.14.2.3), the device may need to be replaced or repaired as needed. Hospitalization for such a procedure will be reported as a serious adverse event. Details of the cause of IDDD malfunction or failure will be recorded on
the device Malfunction/Failure CRF. A list of the most common IDDD adverse events is included in Appendix 4.

7.14.1.4 Device Surgical Procedure-related Adverse Events

Examples of adverse events related to device surgical procedures include, but are not limited to, the following: events that occur during or following IDDD implant/explant, IDDD adjustment, full revision, partial revision, IDDD removal, and delayed re-implantation after previous IDDD removal (such as complications of anesthesia, excessive bleeding, wound hematoma), and post-operative complications (such as post-operative infection).

7.14.1.5 Intrathecal Administration Process Adverse Events

Intrathecal administration process adverse events may include those caused by anesthesia during drug administration and other drug administration issues (e.g., extravasation during infusion or hematoma due to the Huber needle), or complications of lumbar puncture.

7.14.1.6 Serious Adverse Events

A serious adverse event (SAE) is any adverse event occurring at any dose that results in any of the following outcomes:

- Death
- Is life-threatening
- Requires hospitalization (Note, however, for the purpose of this study, overnight hospitalizations post intrathecal administration of idursulfase-IT that are based on practical or logistical considerations, rather than safety will not be deemed serious adverse events [See Section 7.6])
- Requires prolongation of existing hospitalization
- A persistent or significant disability or incapacity
- A congenital anomaly or birth defect

Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. A life-threatening adverse event is defined as an adverse event that placed the patient, in the view of the initial reporter, at immediate risk of death from the adverse event as it occurred (i.e., this definition does not include an adverse event that, had it occurred in a more severe form, might have caused death).

Hospitalization, which is the result of elective or previously scheduled surgery for pre-existing condition, which has not worsened after initiation of treatment, should not be classified as a serious adverse event. For example, an admission for a previously scheduled ventral hernia repair would not be classified as a serious adverse event; however, complication(s) resulting from a hospitalization for an elective or previously scheduled surgery that meet(s) serious criteria
must be reported as serious adverse event(s). Furthermore, this does not apply to device failures resulting in scheduled surgical revisions, which should be reported as serious adverse events.

7.14.1.7 Unanticipated Adverse Device Effect

An unanticipated adverse device effect (UADE) is any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of patients (21CFR812.3[s] or other regulatory requirements, as applicable).

7.14.2 Device-associated Definitions

7.14.2.1 Device Revision (Partial and Full)

Partial device revision: surgical revision/replacement of one or more component(s) of the device; other component(s) of the original device remain implanted and are not affected (eg, port revision).

Full device revision: the device is removed (explanted) in its entirety and a completely new device is implanted.

7.14.2.2 Device Malfunction

The device does not perform as intended, based on the description in the device’s IFU, but does not require either a partial or full device revision.

7.14.2.3 Device Failure

The device irreversibly fails to perform as intended and requires either a partial or full device revision or removal.

7.14.3 Classification of Adverse Events and Serious Adverse Events

The severity of adverse events will be assessed by the Investigator based on the definitions shown in Table 7-3. The severity of all adverse events and serious adverse events should be recorded on the appropriate CRF page as mild, moderate, or severe.

<table>
<thead>
<tr>
<th>Table 7-3 Adverse Event Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Severity</strong></td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Severe</td>
</tr>
</tbody>
</table>
7.14.3.1 Clarification between Serious and Severe

The term “severe” is often used to describe the intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This is not the same as “serious,” which is based on the outcome or action criteria usually associated with events that pose a threat to life or functioning. Seriousness (not severity) and causality serve as a guide for defining regulatory reporting obligations.

7.14.4 Relatedness of Adverse Events and Serious Adverse Events

The relationship of an adverse event or serious adverse event to study treatment (study drug, the IDDD, device surgical procedure, or IT administration process) will be assessed by the Investigator as follows. The relationship to treatment will be categorized based on the definitions provided in Table 7-4.

- Relationship to idursulfase-IT
- Relationship to the IDDD (examples of IDDD-related adverse events are listed in Section 7.14.1.3)
- Relationship to a device surgical procedure (surgical implantation of the IDDD, partial or full device revision as described in Section 7.14.1.4)
- Relationship to the IT administration process (examples of IT administration process-related adverse events are listed in Section 7.14.1.5)

<table>
<thead>
<tr>
<th>Relationship to Treatment</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Related</td>
<td>Unrelated to investigational product, device, device surgical procedure, or IT administration process.</td>
</tr>
<tr>
<td>Possibly Related</td>
<td>A clinical event or laboratory abnormality with a reasonable time sequence to administration of investigational product, device, device surgical procedure, or IT administration process, but which could also be explained by concurrent disease or other drugs or chemicals.</td>
</tr>
<tr>
<td>Probably Related</td>
<td>A clinical event or laboratory abnormality with a reasonable time sequence to administration of investigational product, device, device surgical procedure, or IT administration process unlikely to be attributable to concurrent disease or other drugs and chemicals and which follows a clinically reasonable response on de-challenge. The association of the clinical event or laboratory abnormality must also have some biologic plausibility, at least on theoretical grounds.</td>
</tr>
<tr>
<td>Definitely related</td>
<td>The event follows a reasonable temporal sequence from administration of the investigational product, device, device surgical procedure, or IT administration process, follows a known or suspected response pattern to the investigational product, is confirmed by improvement upon stopping the investigational product (de-challenge), and reappears upon repeated exposure (re-challenge). Note that this is not to be construed as requiring re-exposure of the patient to investigational product; however, the determination of definitely related can only be used when recurrence of event is observed.</td>
</tr>
</tbody>
</table>
The relationship of an adverse event or serious adverse event to IV Elaprase infusion will be assessed by the Investigator as described in Section 7.14.1.2.

7.14.5 Procedures for Recording and Reporting Adverse Events

7.14.5.1 Adverse Event Monitoring and Period of Observation

Adverse events will be monitored continuously throughout the study.

For the purposes of this study, the period of observation extends from the time at which informed consent is obtained until the patient’s final evaluation of the study. For safety purposes, the final evaluation for patients who complete this study will be defined as the follow-up evaluation performed 7 (±2) days after the EOS visit.

If the Investigator considers it necessary to report an adverse event in a study patient occurring after the end of the safety observation period, he or she should contact the Sponsor to determine how the adverse event should be documented and reported.

7.14.5.2 Reporting Serious Adverse Events

Any serious adverse event, regardless of relationship to investigational product, device, device surgical procedure, IT administration process, or IV Elaprase infusion, which occurs in a patient after informed consent will be recorded by the clinical site on the SAE form. The serious adverse event must be completely described on the patient’s CRF, including the judgment of the Investigator as to the relationship of the serious adverse event to the investigational product and/or device. The Investigator will promptly supply all information identified and requested by the Sponsor (or contract research organization [CRO]) regarding the serious adverse event.

The Investigator must report the serious adverse event to the Shire Pharmacovigilance and Risk Management Department AND to the Shire HGT Medical Monitor on the SAE form. This form must be completed and FAXED or EMAILED within 24 hours of the Investigator’s learning of the event to:

Shire Pharmacovigilance and Risk Management Department:

International FAX: (UK) OR United States FAX:  AND

Email:  AND

AND

Shire HGT Medical Monitor: , MD, PhD

Email:  FAX: (USA)
Any follow-up information must also be completed on the SAE form and faxed or emailed to the same numbers or emails listed above.

In the event of a severe and unexpected, fatal, or life-threatening serious adverse event, the clinical site must contact the Shire HGT Medical Monitor by telephone; this is in addition to completing and transmitting the SAE form as stated above.

The following provides contact information for the Shire HGT Medical Monitor.

<table>
<thead>
<tr>
<th>If an SAE is assessed as severe and unexpected, fatal, or life-threatening, contact:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Shire Human Genetic Therapies, Inc.</strong></td>
</tr>
<tr>
<td><strong>300 Shire Way</strong></td>
</tr>
<tr>
<td><strong>Lexington, MA 02421 USA</strong></td>
</tr>
<tr>
<td><strong>Telephone:</strong> PPD</td>
</tr>
<tr>
<td><strong>Mobile:</strong> PPD</td>
</tr>
<tr>
<td><strong>Email:</strong> PPD</td>
</tr>
<tr>
<td><strong>Fax:</strong> PPD</td>
</tr>
</tbody>
</table>

The Investigator must promptly report all required information to the Institutional Review Board (IRB)/Independent Ethics Committee (IEC). It is the responsibility of the Sponsor to ensure that each Investigator receives a copy of any CIOMS I/MDR report that has been submitted to the appropriate regulatory agencies notifying them of an unexpected drug-related serious adverse event or unanticipated adverse device effect. The Investigator or Sponsor must ensure that the IRB/IEC receives a copy of the report and that a copy is also filed within their study files. The Investigator or Sponsor must also ensure that the IRB/IEC receives copies of UADE reports that have been submitted by Sophysa (or its designated agent) to the relevant regulatory agencies.

### 7.15 Pregnancy

Not applicable.

### 7.16 Abuse, Misuse, Overdose, and Medication Error

**Abuse** – Persistent or sporadic intentional intake of investigational product at a dose higher than prescribed per protocol (but below the dose defined for overdose) or when used for non-medical purpose (eg, altering one’s state of consciousness).

**Misuse** – Intentional or unintentional use of investigational product other than as directed or indicated at any dose, which is at or below the dose defined for overdose (Note: This includes a situation where the investigational product is not used as directed at the dose prescribed by the protocol).

**Overdose** – Intentional or unintentional intake of a dose of investigational product higher than the protocol-mandated dose. No clinical information on overdose is available. Idursulfase-IT
has been well tolerated at the highest once monthly dose (30 mg) administered intrathecally to pediatric patients in clinical trials.

**Medication Error** – A mistake made in prescribing, dispensing, administration and/or use of the investigational product.

The Investigator must report abuse, misuse, overdose, and medication error to the Shire Pharmacovigilance and Risk Management Department AND to the Shire HGT Medical Monitor on the SAE form. This form must be completed and FAXED or EMAILED within 24 hours of the Investigator’s learning of the event (refer to the contact information for reporting of SAEs provided in Section 7.14.5.2).

### 7.17 Removal of Patients from the Trial or Investigational Product

A patient’s participation in the study may be discontinued at the discretion of the Investigator. The following may be justifiable reasons for the Investigator to remove a patient from the study:

- The patient exhibits non-compliance with the study protocol that is considered disruptive to study conduct.
- The patient was erroneously included in the study.
- The patient develops an exclusion criterion.
- The patient suffers an intolerable adverse event.
- The study is terminated by the Sponsor.

The patient’s parent(s) or legally authorized guardian(s) acting on behalf of the patient is free to withdraw consent and discontinue participation in the study at any time without prejudice to further treatment.

If the patient’s parent(s) or legally authorized guardian(s) acting on behalf of the patient discontinues participation in the study, or the patient is discontinued by the Investigator, reasonable efforts will be made to follow the patient through the end of study assessments. The reason for refusal will be documented on the CRF. Any adverse events experienced up to the point of discontinuation must be documented on the AE CRF. If adverse events are present when the patient withdraws from the study, the patient will be re-evaluated within approximately 30 days of withdrawal. All ongoing serious adverse events at the time of withdrawal will be followed until resolution.

### 7.18 Other Study Procedures

#### 7.18.1 Safety-related Study Stopping Rules

This study will be stopped and the safety data reviewed if any patient experiences a life-threatening serious adverse event or a death occurs, if either is considered possibly or probably related to the study treatment (investigational product, the IDDD, device surgical procedure, or the IT administration process). After review of the safety data, the status of the study will be one of the following:
Patient safety in this study will be monitored by an independent DMC until the last patient completes his last scheduled study visit/assessment. The DMC will be an external group overseeing the safety of the study treatment, including both the investigational product and the IDDD, and will operate according to a charter determining the scope of its activities and frequency of meetings (See Section 11.8 for additional details).

7.19 Appropriateness of Measurements

The measures of safety to be used in the study are appropriate for an interventional study in MPS II patients. These include monitoring of adverse events and medication use, both standard parameters for the assessment of safety, as well as measurement of ICP and imaging.

Cognitive impairment is a key symptom of MPS II; however, clinical research in this area has been broadly lacking, instead focusing on the biological and physical aspects of the disease, and remains an unmet medical need. This highlights the need for a treatment that targets the cognitive involvement of MPS II, and an endpoint strategy that specifically targets the cognitive and behavioral symptoms associated with MPS II. The neurodevelopment measures planned for this study will assess cognitive and adaptive functions in children with MPS II. These assessment tools (DAS-II, VABS-II) will provide a quantifiable measure of CNS neurodevelopment status and are appropriate for use in the target population.

The DAS-II has been found to be valid and reliable. Evidence from published studies and previous Shire HGT clinical trials demonstrates that the DAS-II is able to detect both changes in a child’s ability and stabilization of functioning over time following treatment.

The rating of the child by the parent format of the VABS-II via the Expanded Interview Form is consistent with the Food and Drug Administration (FDA) Patient-reported Outcome (PRO) Guidance, which states that caregiver reports must be based on observable behaviors only.

The concepts measured by the DAS-II were mapped onto an MPS II conceptual model. The concept mapping exercise indicated adequate concept coverage across the three assessment tools, collectively. Following feedback from experts in the field of neurodevelopmental functioning, the concept mapping exercise was repeated for the VABS-II. The VABS-II was found to have strong concept coverage when combined with the DAS-II. Based on this evidence, the DAS-II and VABS-II will be utilized as the primary and secondary assessment tools for efficacy.

A model illustrating the efficacy endpoints in this study is presented in Table 7-5. The endpoints have been classified as primary, key secondary, and secondary based on their clinical importance. Secondary efficacy endpoints have been included for the purposes of providing additional data to support both the primary and key secondary endpoints. The change from baseline in GCA, as assessed by the DAS-II, will be the primary endpoint. The DAS-II will be used to measure secondary endpoints, including standard scores in cluster areas and
developmental quotients. Key secondary and other secondary endpoints are derived from the VABS-II to assess adaptive behaviors.

Table 7-5 Endpoint Model

<table>
<thead>
<tr>
<th>Concept</th>
<th>Subconcept</th>
<th>Assessment Tool</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive Function</td>
<td>General Conceptual Ability (GCA)</td>
<td>DAS II</td>
</tr>
<tr>
<td><strong>Key Secondary Endpoint</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adaptive Behavior</td>
<td>Adaptive Behavior Composite (ABC)</td>
<td>VABS-II</td>
</tr>
<tr>
<td><strong>Secondary Endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognitive Function</td>
<td>Standard score in DAS-II cluster areas: Verbal, Nonverbal, Spatial, GCA, and Special Nonverbal Composite (SNC)</td>
<td>DAS II - Early Years</td>
</tr>
<tr>
<td>Developmental quotient for the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 1 a</td>
<td>Verbal Comprehension</td>
<td>DAS II - Early Years</td>
</tr>
<tr>
<td>Picture Similarities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naming Vocabulary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pattern Construction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matrices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copying</td>
<td></td>
<td></td>
</tr>
<tr>
<td>or:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 2 a</td>
<td>Recall of Designs</td>
<td>DAS-II - School Age</td>
</tr>
<tr>
<td>Word Definition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pattern Construction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matrices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verbal Similarities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sequential Reasoning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantitative Reasoning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adaptive Behavior</td>
<td>Standard scores and developmental quotients (based on age equivalents) in VABS-II domains:</td>
<td>VABS-II</td>
</tr>
<tr>
<td>Communication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily Living Skills</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socialization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motor Skills</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maladaptive Behavior</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a The concepts assessed will be dependent on the chronological age of the child. The child will be given the relevant version of the DAS-II (Early Years or School Age) per their age and ability.
8 STUDY ACTIVITIES

Each activity will be performed as specified in the Schedule of Events (SOE). See Section 13 for the SOE for the pivotal study (Appendix 1 and Appendix 2) and separate substudy (Appendix 3).

8.1 Screening (Month -1, Week -4 to -1)

8.1.1 All Patients in the Pivotal Study and Substudy

The following procedures will be performed up to 28 days prior to randomization/enrollment (ie, Day -28 to Day -1):

- Written informed consent (assent if applicable) by patient’s parent(s) or legally authorized guardian(s) prior to any study-related procedures
- Assessment of eligibility according to review of study entry criteria
- Medical history
- Hunter syndrome diagnosis (blood sample collection for testing of iduronate-2-sulfatase activity and genotyping, as appropriate based on the patient’s medical history). Note that analysis of genotype will be required for all patients who have not had a previous genotyping performed at Greenwood Genetic Center’s Diagnostic Laboratory (Greenwood, South Carolina, USA). Even patients for whom prior genotyping was performed at Greenwood Genetic Center’s Diagnostic Laboratory may need have a repeat analysis performed if the original information was insufficient for an unambiguous classification of genotype (eg, to document the integrity of the FMR1 and FMR2 genes in patients with large deletion/rearrangement mutations). Please refer to Section 7.3.1 for specific instructions.
- Echocardiogram (note: this assessment will not need to be performed if an echocardiogram taken within 3 months of study start is available and deemed satisfactory for evaluation of anesthesia risk.)
- Physical and neurological examination
- Height and weight
- Head circumference
- Hearing assessment
- Neurodevelopmental assessments:
  - Differential Ability Scales, Second Edition (DAS-II)
  - Bayley Scales of Infant Development, Third Edition (BSID-III) for patients in the substudy only who are too young (<3 years of age) or unable to complete the DAS-II
• 12-lead ECG
• Vital signs
• Clinical laboratory tests (hematology, serum chemistry, urinalysis)
• Urine GAG and creatinine
• Anti-idursulfase antibody testing (serum and CSF)
• General anesthesia
• Brain MRI
• ICP measurement (by lumbar puncture)
• CSF sample collection (by lumbar puncture)
• Albumin (serum and CSF)
• Health status assessment (EQ-5D questionnaire)
• Concomitant medications, therapies/interventions, and medical/surgical procedures
• Adverse events

8.2 Randomization/Enrollment: Clinic Admission (Month 0, Week 0, Day 0)

8.2.1 All Patients (IT Treatment and No IT Treatment Groups) in the Pivotal Study

• Randomization
• Concomitant medications, therapies/interventions, and medical/surgical procedures*
• Adverse events*

*These assessments may occur by telephone.

8.2.2 All Patients in the Substudy

• Documentation of entry criteria for enrollment
• Concomitant medications, therapies/interventions, and medical/surgical procedures*
• Adverse events*

*These assessments may occur by telephone.

8.3 Treatment Period (Months 1 to 12)

During this period, several phases of activity will occur. These are designated in the SOE as:
Pre-surgery, Surgery, Follow-up, and Post-op Recovery at Week 2 (+7 days) and IT Dosing at
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 [±7 days] (Pre-treatment, IT Injection, Follow-
up).

8.3.1 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the
Substudy: Pre-surgery, Surgery, Follow-up, and Post-op Recovery
(Week 2 [±7 days])

IDDD placement will require surgical implantation under general anesthesia and post-surgical
assessment.
8.3.1.1 Pre-surgery

- Physical and neurological examination*
- Height and weight*
- 12-lead ECG‡
- Vital signs*
- Clinical laboratory tests (hematology, serum chemistry, urinalysis)*
- Coagulation tests ([PT, PTT] to be performed by the local laboratory)
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

*The assessments indicated do not need to be repeated if completed as part of Screening assessments within 7 days prior to surgery.

8.3.1.2 Surgery

- Vital signs
- General anesthesia
- CSF sample collection
- IDDD implantation
- X-ray (to verify IDDD is at the mid-thoracic level in the spinal canal and correctly installed)
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

8.3.1.3 Follow-up

The following assessments will be performed after surgery and prior to discharge. It is expected that, for most patients, post-surgical follow-up will occur within Week 2 (ie, within 1 to 2 days of surgery).

- Physical and neurological examination
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

8.3.1.4 Post-op Recovery

Surgical implantation of the IDDD will be followed by a post-operative recovery period of at least 14 days prior to the first IT administration of idursulfase-IT.
8.3.2 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the Substudy: IT Dosing (Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 [+7 days])

8.3.2.1 Pre-treatment

- Physical and neurological examination
- Height and weight (performed at Weeks 4, 16, 28, 40)
- Head circumference (performed at Weeks 4, 16, 28, 40)
- Hearing assessment (performed at Weeks 16, 28, 40)
- Neurodevelopmental assessments (performed at Weeks 16, 28, and 40)
  - Differential Ability Scales, Second Edition (DAS-II)
  - Bayley Scales of Infant Development, Third Edition (BSID-III) for patients in the substudy only who are too young (<3 years of age) or unable to complete the DAS-II
- 12-lead ECG
- Vital signs
- Clinical laboratory tests (hematology, serum chemistry, urinalysis, performed at Weeks 4, 16, 28 and 40)
- Albumin (serum [and CSF, see Section 8.3.2.2], performed at Weeks 4, 16, 28 and 40)
- Urine GAG and creatinine (performed at Weeks 4, 16, 28, 40)
- Anti-idursulfase antibody testing (serum [and CSF, see Section 8.3.2.2], performed at Weeks 4, 16, 28, and 40)
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

From Week 28 onward, pre-treatment assessments may be performed on the same day as IT administration of idursulfase-IT, if the patient can arrive at the study site early in the day and if the Investigator deems this clinically appropriate.

8.3.2.2 IT Injection

Patients will remain under observation in the hospital setting (may include lounge, infusion center, or waiting room) for 4 hours post IT injection for vital signs and other safety assessments. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of Visit Weeks 4, 24, and 48 at which serial blood sampling for PK evaluation is planned). The patient may need to be examined the following day (See Follow-up, Section 8.3.2.3) by the Investigator; however, there is no requirement for an overnight hospital stay. Note that, on IT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

- 12-lead ECG (performed within 4 hours of IT injection at Weeks 4, 16, 28, 40)
- Vital signs (collected at the following time points (+10 minutes) in association with IT administration of idursulfase-IT: within 15 minutes prior to IT administration, 30 minutes
post end of IT administration, 60 minutes post end of IT administration, 120 minutes post end of IT administration, and 4 hours post end of IT administration)

- CSF sample collection (performed at each IT Dosing Week prior to idursulfase-IT injection). Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard laboratory parameters (chemistries, cell counts), GAG, albumin, concentration of idursulfase enzyme, and presence of idursulfase-specific antibodies. Analyses of CSF samples for antibodies and albumin will be performed at IT Dosing Weeks 4, 16, 28, and 40.

- idursulfase-IT injection

- Serum sampling for PK analysis (performed at Weeks 4, 24, and 48). Samples will be collected within 15 minutes (±5 minutes) prior to intrathecal administration of idursulfase-IT and at 30 minutes (±5 minutes), 60 minutes (±5 minutes), 120 minutes (±5 minutes), 4 hours (±5 minutes), 6 hours (±5 minutes), 8 hours (±15 minutes), 12 hours (±15 minutes), 24 hours (±15 minutes), 30 hours (±15 minutes), 36 hours (±15 minutes) after the start of intrathecal administration.

- Concomitant medications, therapies/interventions, and medical/surgical procedures

- Adverse events

8.3.2.3 Follow-up (Post IT Injection)

For the first 6 months of treatment with idursulfase-IT (ie, Weeks 4, 8, 12, 16, 20, 24), patients must return to the clinic the day after each IT administration for a safety follow-up visit. Note that, under these circumstances, there is no requirement for an overnight hospital stay; if a decision is made to keep the patient overnight for convenience, this hospitalization should not initiate a serious adverse event report. For the latter 6 months of treatment with idursulfase-IT (ie, from Week 28 onward) and in the absence of any safety concerns, patients may complete the safety follow-up visit on the same day as IT administration prior to discharge.

- Physical and neurological examination
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

8.3.3 Patients in the No IT Treatment Group of the Pivotal Study (Months 1 to 12)

8.3.3.1 Week 2 (+7 days)

The following will be assessed by telephone contact:

- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events
8.3.3.2   Weeks 4, 16, 28, 40 (± 7 days)

- Physical and neurological examination
- Height and weight
- Head circumference
- Hearing assessment (performed at Weeks 16, 28, and 40)
- Neurodevelopmental assessments (performed at Weeks 16, 28, and 40)
  - Differential Ability Scales, Second Edition (DAS-II)
- 12-lead ECG
- Vital signs
- Clinical laboratory tests (hematology, serum chemistry, urinalysis)
- Urine GAG and creatinine
- Anti-idursulfase antibody testing (serum)
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

8.3.3.3   Weeks 8, 12, 20, 24, 32, 36, 44, 48 (± 7 days)

The following will be assessed by telephone contact:

- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

8.4   End of Study: Month 13 (Week 52 [± 7 days])

8.4.1   Patients in the IT Treatment Group of the Pivotal Study and All Patients in the Substudy

- Physical and neurological examination
- Height and weight
- Head circumference
- Hearing assessment
- Neurodevelopmental assessments
  - Differential Ability Scales, Second Edition (DAS-II)
  - Bayley Scales of Infant Development, Third Edition (BSID-III) for patients in the substudy only who are too young (<3 years of age) or unable to complete the DAS-II
• 12-lead ECG
• Vital signs
• Clinical laboratory tests (hematology, serum chemistry, urinalysis)
• Urine GAG and creatinine
• Anti-idursulfase antibody testing (serum and CSF)
• General anesthesia
• Brain MRI
• ICP measurement (by lumbar puncture)
• CSF sample collection
• Albumin (serum and CSF)
• X-ray
• Health status assessment (EQ-5D questionnaire)
• Concomitant medications, therapies/interventions, and medical/surgical procedures
• Adverse events

8.4.2 Patients in the No IT Treatment Group of the Pivotal Study

• Physical and neurological examination
• Height and weight
• Head circumference
• Hearing assessment
• Neurodevelopmental assessments:
  o Differential Ability Scales, Second Edition (DAS-II)
  o Vineland Adaptive Behavior Scales, Second Edition (VABS-II)
• 12-lead ECG
• Vital signs
• Clinical laboratory tests (hematology, serum chemistry, urinalysis)
• Urine GAG and creatinine
• Anti-idursulfase antibody testing (serum and CSF)
• General anesthesia
• Brain MRI
• ICP Measurement (by lumbar puncture)
• CSF sample collection (by lumbar puncture)
• Albumin (serum and CSF)
• Health status assessment (EQ-5D questionnaire)
• Concomitant medications, therapies/interventions, and medical/surgical procedures
• Adverse events
8.5 Follow-up (Day 7 [±2 Days] Post EOS)

8.5.1 All Patients in the Pivotal Study and Substudy

The following will be assessed by telephone contact:

- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events
9 QUALITY CONTROL AND ASSURANCE

Training on the study protocol, device usage, and investigational product administration will occur at an Investigator meeting, at the site initiation visit, or both. Instructions will be provided to aid consistency in data collection and reporting across sites.

Clinical sites will be monitored by the Sponsor or its designee to ensure the accuracy of data against source documents. The required data will be captured in a validated clinical data management system that is compliant with the FDA 21 CFR Part 11 Guidance. The clinical trial database will include an audit trail to document any evidence of data processing or activity on each data field by each user. Users will be trained and given restricted access, based on their role(s) in the study, through a password-protected environment.

Data entered in the system will be reviewed manually for validity and completeness against the source documents by a clinical monitor from the Sponsor or its designee. If necessary, the study site will be contacted for corrections or clarifications; all missing data will be accounted for.

Serious adverse event information captured in the clinical trial database will be reconciled with the information captured in the Pharmacovigilance and Risk Management database.
10 STATISTICAL ANALYSIS

10.1 General Methodology

All statistical analysis will be performed by Shire Biometrics Department using SAS software version 9.3 or higher (SAS Institute, Cary, NC, USA) unless otherwise specified.

Continuous variables will be summarized using descriptive statistics (N, mean, standard deviation, minimum, median, and maximum). Categorical variables will be summarized using the number and percentage of patients in each category. Data will be summarized with respect to patient disposition, demographic and baseline characteristics and concomitant medication use. The efficacy endpoints, safety assessments and other outcome results for each treatment group will be summarized descriptively unless otherwise indicated. Statistical model estimates of least squares means, treatment differences, p-values and 95% CIs for least squares mean treatment differences will also be provided where relevant for efficacy endpoints. The fit of linear models will be assessed using residual plots and/or other diagnostic plots as appropriate. All statistical tests will be 2-sided and will be performed at the 0.05 level of significance unless stated otherwise.

The separate substudy is an open-label, single arm study. Data from patients participating in this separate substudy will be analyzed separately. The safety and efficacy data from the substudy will be summarized descriptively or listed, as appropriate, in a manner similar to that of the pivotal study.

There are no formal hypotheses associated with the evaluation of the safety and performance of the IDDD (SOPH-A-PORT Mini S). All analyses of device safety and performance will be descriptive and no statistical testing will be performed. Device related analyses will be based on patients for whom the device implant procedure was performed and are described below.

10.2 Determination of Sample Size

Based on study HGT-HIT-050/045 Phase I/II data, the observed decline in mean GCA score in untreated patients was estimated to be 13.7 points with a standard deviation of 9.4 after 12 months. For the sample size calculation, we conservatively assumed an approximately 1 point per month rate of decline in the untreated control arm, so that the theoretical decline would be 13 points from baseline (screening) to Visit Week 52. As up to 2 months may elapse between the screening assessment and the start of idursulfase-IT treatment, a mean decline of 2 points at end of study would be expected if idursulfase was effective in stabilizing the decline. Therefore, in such a case, the mean projected treatment difference at Visit Week 52 would be 11 points, which is considered a clinically meaningful treatment difference.

Using a 2:1 allocation ratio, a sample size of 42 randomized patients (28 IT treated patients, 14 No IT control patients) will yield 80% power to detect a clinically meaningful mean treatment difference of 11 points in the primary endpoint, GCA change from baseline to Visit Week 52. This calculation further assumes a common standard deviation for the change from baseline of 10 points, a type-I error rate of 0.05 for a two-sided two-sample t-test, with approximately up to
20% missing an assessment at Visit Week 52. Given this sample size, and conditional on rejection of the null hypothesis for the primary endpoint, the power would be 80% to detect a clinically meaningful mean difference of 14.5 points in the key secondary endpoint, assuming a common standard deviation for the change from baseline of 13.5 points for a two-sided two-sample t-test with a significance level of 5% and 20% missing.

After approximately one-half of the planned number of patients (ie, 21 patients) have completed the Week 52 visit and their data has been entered in the clinical database, and prior to enrollment closure, a blinded assessment of overall variability for the primary and key secondary endpoints will be made by estimating the pooled standard deviation (SD) for each endpoint. The blinded variability assessment will be performed by an external, independent statistician who is not involved in the final analysis of this study. If it does not appear that the variability is consistent with the assumptions used in the sample size calculation, the Sponsor may consider increasing the sample size by amending the protocol. The sample size re-calculation in this case would be identical to the original calculation except that the estimate of the common standard deviation used for the primary and/or key secondary endpoint would be revised upward based on the pooled SD assessment. As there is no treatment comparison involved, no inflation of the type-I error results from this procedure, and no adjustment to the significance levels for the final analysis is necessary.

For the separate substudy, there is no target sample size. All patients meeting eligibility criteria for the substudy will be enrolled until enrollment for the pivotal trial is completed.

10.3 Method of Assigning Study Patients to Treatment Groups

Patients will be randomized (open-label, assessor-blinded) in a 2:1 allocation ratio between the active (idursulfase-IT treatment regimen) and control groups. Although this is a multi-center study, the randomization will not be stratified by center. The baseline GCA score (at Screening Visit) is expected to be a key prognostic factor. Therefore, the randomization will be stratified according to baseline GCA score: less than or equal to 70 versus greater than 70. The randomization schedule will be generated and administered centrally by Pharmaceutical Product Development, LLC (PPD), independent of the Sponsor’s project team. There is no replacement of patients who do not complete the study.

In a separate substudy, additional patients with cognitive impairment may be enrolled who are below the age of 3 years at the time of informed consent. Such patients are ineligible for the pivotal trial and will not be randomized, but will receive idursulfase-IT treatment monthly.

10.4 Population Description and Exposure

10.4.1 Analysis Populations

For the pivotal trial, all efficacy data analyses will be performed using the Intent-to-Treat (ITT) Population, which is defined as all randomized patients.

All safety data analyses will be performed according to treatment received using the Safety Population, which is defined as all randomized patients with any post-randomization safety
assessments. IDDD and procedure related analyses will be conducted in the set of patients in the Safety Population who had the device implant procedure performed.

All pharmacokinetic data analyses will be performed using the PK population. The PK population will be defined as all patients who received study drug and had sufficient serum samples collected to derive pharmacokinetic parameters.

For the substudy, all analyses will be performed on the Substudy Population, defined as all patients enrolled and treated with study drug in the substudy.

The planned analyses described below pertain to the pivotal study data. Similar descriptive summaries or listings as appropriate will be provided for the substudy data.

10.4.2 Patient Disposition

The total number of patients screened (ie, signed informed consent) will be presented. The number and percentage of patients screened (ie, signed informed consent), randomized, completed, and discontinued prematurely by reason for withdrawal will be summarized by treatment group. The number of patients included in the ITT and Safety populations will be summarized.

10.4.3 Protocol Deviations

An incident involving noncompliance with the protocol, but one which typically does not have significant effects on the patient’s rights, safety, or welfare, or the integrity of the resultant data will be considered a protocol deviation. An incident involving noncompliance with the protocol which may affect the patient’s rights, safety, or welfare, or the integrity of the resultant data will be known as a protocol violation. In particular, any serious deviation that affects the collection of data for the primary endpoint will be considered a protocol violation.

Examples of potential protocol violations may include violation of important admission (inclusion/exclusion) criteria, occurrence of a treatment dispensing error, treatment noncompliance or substantial use of a prohibited medication during the study. Reported protocol deviations and patient data will be examined prior to database lock to determine if conditions set forth in the study protocol have been violated and a more comprehensive list will be constructed at that time. The list of protocol deviations will not be presented; however, identified protocol violations will be summarized.

10.4.4 Demographics and Baseline Characteristics

Demographic and baseline characteristics (eg, age [years], race, ethnicity, genotype, weight [kg], height [cm], body mass index [BMI, kg/m²], country, age at onset of Hunter syndrome symptoms, age of Hunter syndrome diagnosis, family history of Hunter syndrome) will be summarized by treatment group and overall in the pivotal study.
10.4.5 Treatment Compliance

Treatment compliance will be summarized in terms of the percent of scheduled doses received in the idursulfase-IT arm. Percent compliance is defined as:

\[
\left(\frac{\text{No. of Complete IT injections Received}}{\text{Expected No. of IT injections at EOS}}\right) \times 100.
\]

10.4.6 Extent of Exposure

The number of IT injections received overall and by lumbar puncture, average dose, the duration of idursulfase-IT treatment and IT administration duration will be summarized descriptively in the idursulfase-IT arm. The duration of idursulfase-IT treatment, summarized in months, is defined as the time from first to last IT administration during the study. The duration for each idursulfase-IT administration (in minutes) is calculated by subtracting the administration start time from the administration end time.

10.5 Analysis of Efficacy

All efficacy analyses described below refer to the pivotal trial; all efficacy data from patients treated in the separate substudy will be listed, including any measurements from the BSID-III and VABS-II.

10.5.1 Primary Efficacy Endpoint Analysis

For the pivotal trial, the primary efficacy endpoint is the change from study baseline (screening visit) to Visit Week 52 in the GCA score as measured by the DAS-II. The primary analysis will compare the treatment groups using a linear mixed model repeated measures (MMRM) analysis. The repeated measures are the change from baseline GCA scores obtained at the scheduled Visit Weeks 16, 28, 40, and 52, respectively. The model will include fixed categorical effects for treatment, visit week, treatment by visit week interaction, baseline GCA classification factor (either \(\leq 70\) or \(> 70\)), and the baseline GCA score as a continuous covariate. SAS Proc Mixed with restricted maximum likelihood estimation (REML) and an unstructured within-patient covariance structure will be used. If this model fails to converge, a first order autoregressive (AR[1]) covariance structure will be used for the primary analysis. The Kenward-Roger approximation will be used to estimate denominator degrees of freedom for tests of fixed effects.

From this model, least squares means, standard errors, treatment differences in least squares means, and 95% CIs will be estimated for each time point. Primary inference is based on the treatment comparison of least squares means at Visit Week 52 from this model, and a p-value will be presented for this time point only. The null hypothesis is that the mean difference in the primary endpoint between the two treatment groups is zero, versus the alternative hypothesis that this difference is not zero. The hypotheses can be expressed as follows:

\[
H_0: \mu_{\text{IT}} - \mu_{\text{control}} = 0 \quad \text{versus} \quad H_1: \mu_{\text{IT}} - \mu_{\text{control}} \neq 0
\]

Where \(\mu_{\text{IT}}\) refers to the mean change from baseline to Visit Week 52 in GCA score in the idursulfase-IT treated group and \(\mu_{\text{control}}\) refers to the mean change from baseline to Visit Week 52 in the control group.
in GCA score in the untreated control group. The test will be performed using the final, MMRM model-based t-test with a two-sided significance level of 5%. Estimated least squares means (±SE) by treatment group will be plotted over time.

10.5.2 Key Secondary Efficacy Endpoint Analysis

The key secondary efficacy endpoint is the change from study baseline (Screening Visit) to Visit Week 52 in the Adaptive Behavior Composite (ABC) score as measured by the VABS-II. The key secondary analysis will compare the treatment groups using a linear mixed model repeated measures (MMRM) analysis. The repeated measures are the change from baseline ABC scores obtained at the scheduled Visit Weeks 16, 28, 40, and 52, respectively. The model will include effects of treatment, visit week, treatment by visit week interaction, baseline GCA classification factor (either ≤70 or >70) and the baseline ABC score as a continuous covariate. SAS Proc Mixed with REML and an unstructured within-patient covariance structure will be used. If this model fails to converge, a first order AR(1) covariance structure will be used instead. The Kenward-Roger approximation will be used to estimate denominator degrees of freedom for tests of fixed effects. From this model, least squares means, standard errors, treatment differences in least squares means, and 95% CIs will be estimated for each time point. The significance test will be based on the difference in least squares means at Visit Week 52 and a p-value will be presented for this time point only. Estimated least squares means (±SE) by treatment group will be plotted over time.

10.5.3 Other Secondary Efficacy Endpoints Analyses

The following secondary efficacy endpoints will be analyzed using an MMRM analysis in the same manner as described above for the key secondary endpoint with the continuous covariate corresponding to the baseline score for each measure:

- The change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores in cluster areas of the DAS-II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC)
- The change from baseline to Visit Weeks 16, 28, 40, and 52 in standard scores of the VABS-II domains: Communication, Daily Living Skills, Socialization, and Motor Skills

All other secondary efficacy endpoints will be summarized descriptively by treatment group. Mean values by treatment group will be plotted over time. This includes the following endpoints:

- The change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents, developmental quotients, and T-scores for the subtests of the DAS-II: Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices and Copying for the DAS-II/Early Years; and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities and Sequential and Quantitative Reasoning for the DAS-II/School Years
- The change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents, developmental quotients, and V-scale scores of the VABS-II subdomains:
Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine)

- The change from baseline to Visit Weeks 16, 28, 40, and 52 in V-scale scores and observed maladaptive levels of the VABS-II Maladaptive Behavior Index and its subscales (Internalizing, Externalizing)

### 10.5.4 Exploratory Analyses

As exploratory analyses, the primary and key secondary MMRM models will be refit including the continuous baseline covariate by treatment interaction term in the model. Estimated least square means and 95% CIs for each treatment at the 25th, 50th, and 75th percentiles of the pooled baseline covariate distribution will be evaluated.

Additional subgroup analyses are planned for exploratory purposes for the change from baseline in GCA and ABC scores. An MMRM model will be used to test for subgroup interactions at the 10% significance level. In general, the model will include effects for treatment, visit week, treatment by visit week interaction, subgroup, treatment by subgroup interaction, subgroup by visit interaction and the 3-way interaction between treatment, visit and subgroup. The p-values from interaction tests will be presented, as well as the least square means and 95% CIs by treatment and visit within each subgroup. Descriptive statistics of observed values and change from baseline will also be presented by treatment and visit week within each subgroup.

A subgroup analysis will be performed for baseline GCA groups. For this analysis, patients with a baseline GCA score of greater than 70 will be classified as having “Moderate” cognitive impairment, while patients with a baseline GCA score equal to or below 70 will be classified as having “Severe” cognitive impairment. The randomization is stratified by this classification variable to ensure treatment group balance within these subgroups. Similar exploratory subgroup analyses may be performed for age group (either ≤6 years or >6 years), native language (Spanish versus English speaking region) or other baseline factors using MMRM.

To explore the relationship between composite scores and their components, correlations between the GCA and ABC scores (absolute value and change from baseline) and their respective domain scores will be estimated. Scatter plots will also be presented.

### 10.6 Pharmacokinetic, Pharmacodynamic and Health Status Outcomes

#### 10.6.1 Pharmacokinetic Measurements and Parameters

The pharmacokinetic concentrations and derived pharmacokinetic parameters will be summarized descriptively for the PK population. All analyses will be by the Sponsor staff in the Clinical Pharmacology and Pharmacokinetics group or designee and reported separately in a pharmacokinetic report to be appended to the Clinical Study Report. Accordingly, further details of the planned PK analyses will be described in a separate PK analysis plan.
10.6.2 Pharmacodynamic Outcome

Glycosaminoglycan levels in CSF and urine and the change from baseline (Screening Visit) will be summarized by visit and treatment group. Mean (±SE) values will be plotted over time. A Wilcoxon Rank Sum test will be used to compare treatment groups on the CSF GAG change and percent change from baseline to the Week 52/EOS visit.

10.6.3 Health Status Outcome

The EQ-5D measures 5 dimensions of health status: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, there are 5 levels of response. The number and percent of patients with each response will be presented by dimension at each visit. The visual analog scale (VAS) records the patient’s parent/caregiver-rated health on a 0 (worst health) to 100 (best health) scale. The VAS score, as well as the change from baseline (screening visit to Week 52/EOS) will be summarized. A Wilcoxon Rank Sum test will be used to compare treatment groups on the change from baseline to Week 52/EOS visit in VAS score. Pharmacoeconomic analyses may be performed by the Sponsor staff in the Health Economics and Outcomes Research group or designee and reported separately in a pharmacoeconomic report to be appended to the Clinical Study Report. Accordingly, any planned pharmacoeconomic analyses related to this data may be described elsewhere.

10.7 Safety Assessments

All safety analyses will be descriptive, no statistical testing will be performed. All analyses described below refer to the pivotal trial; safety data from the separate substudy will be similarly summarized or listed as relevant.

10.7.1 Adverse Events

Adverse events will be recorded throughout the study and at early termination. Adverse events and medical conditions will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 16.0 or later. Adverse events occurring on or after randomization and on or before the follow-up visit (scheduled 7 days after EOS Visit) will be summarized by treatment group, both overall and within system organ class (SOC) by preferred term. A summary of adverse events related to study drug will be presented. An adverse event will be considered related if indicated to be “possibly,” “probably,” or “definitely” related. A separate tabulation of IV Elaprase infusion-related adverse events will also be presented by treatment group. Adverse events will be tabulated by severity (mild, moderate, severe) and treatment group. In addition, those events which resulted in death or were otherwise classified as serious will be summarized and presented in a separate listing.

10.7.2 IDDD and Procedure Related Adverse Events

IDDD and procedure related adverse events will be summarized within SOC by preferred term. Separate tabulations will be provided for adverse events related to the IDDD, device surgical procedure, and IT-administration process. An overall summary of adverse events related to the IT treatment regimen (ie, related to one or more of the following: study drug, IDDD, device
surgical procedure, and IT-administration process) will also be presented. IDDD and procedure related events will be analyzed in the set of treated patients in the Safety Population with the device implanted.

10.7.3 Clinical Laboratory Evaluations

Laboratory values (eg, chemistries, hematology, etc) including CSF components will be summarized in terms of the absolute value and change from baseline at each time point by treatment group. The number and percentage of patients with any clinically significant post-baseline laboratory result will be presented by treatment group.

10.7.4 Electrocardiogram Evaluations

The 12-lead ECG parameters (heart rate [bpm], PR interval [msec], RR interval [msec], QRS interval [msec], QT interval [msec], and QTc [msec] interval) will be summarized in terms of absolute value and change from baseline. The corrected QT interval (QTc) will be calculated using Bazett's formula as QT divided by the square root of RR interval. The number and percentage of patients with ECG abnormalities by treatment group will be presented.

10.7.5 Vital Signs and Physical Measurements

Vital signs (temperature [°C], pulse [bpm], blood pressure [systolic and diastolic, mmHg], respiration [per min], and oxygen saturation [%]) will be summarized graphically by study time point and treatment group.

Height (cm), weight (kg), and head circumference (cm) and the change from baseline (Screening Visit) will be summarized by study time point and treatment group. Intracranial pressure measurements (cm of H2O) and brain MRI volumes will be similarly summarized.

10.7.6 Physical Findings

Clinically significant physical and neurological examination findings will be recorded and summarized as part of the medical history or adverse event data.

10.7.7 Other Observations Related to Safety

10.7.7.1 Hearing Assessments

Any hearing assessment data will be summarized by treatment group or listed as appropriate.

10.7.7.2 Immunogenicity

Anti-idursulfase antibody formation will be monitored throughout the study for both serum and CSF. The number and percentage of patients testing anti-idursulfase antibody positive and negative at each time point will be summarized by treatment group. Titer values will be summarized using box plots over time in patients with positive antibodies at or prior to each
scheduled visit. The percent inhibition and titer will be plotted similarly for patients who developed positive neutralizing antibodies at or prior to each scheduled visit.

### 10.7.7.3 Device Performance

SOPH-A-PORT safety and performance will be summarized for implanted patients. The proportion of patients with at least one IDDD failure and the proportion with malfunction only, as well as the number of and reasons for IDDD failures and malfunctions will be summarized. The annual event rate of IDDD failures and malfunctions will be calculated for each patient and summarized descriptively. The time from initial implant surgery to first IDDD failure and the time to first resolved malfunction will be analyzed using the Kaplan Meier (KM) method. Patients without an IDDD failure or resolved malfunction will be censored at their last study drug injection date. The IDDD longevity (time to failure in weeks) and time to first resolved malfunction for all implanted IDDDs will also be plotted using the KM method. A by-patient listing of the device failure and resolved malfunction data will be displayed.

The number and proportion of patients for whom a successful first injection of study drug occurred will be summarized among those for whom a first injection was attempted (ie, those who had an apparently successful implantation and did not suffer a device removal or revision prior to first scheduled injection). The number and proportion of patients who had no failed injection attempts during the study and the total number of successful injections will also be summarized. Injections not given for patient reasons (eg, patient uncooperative, competing medical issue, etc) will not be included in the determination of these estimates.

### 10.7.8 Concomitant Medications/Therapies

Concomitant medications are defined as all medications taken on or after the time of the randomization and on or before the last follow-up date (scheduled 7 days after EOS Visit). Concomitant medications will be mapped using the WHO Drug Dictionary (WHO-DD) and summarized by the therapeutic class and preferred term for each treatment group. Concomitant therapies will be mapped using the MedDRA Version 16.0 or higher and summarized by the SOC and preferred term for each treatment group.

### 10.8 Statistical/Analytical Issues

#### 10.8.1 Handling of Drop-outs and Missing Data

For randomized patients who discontinue early from the study, their early EOS efficacy evaluations will be used for the next scheduled time point only if the EOS evaluation is performed within 45 days of the next scheduled visit. In general, no further imputation will be used for descriptive analyses, or for primary and secondary efficacy analyses utilizing MMRM methodology. However, in the unlikely event that a patient has no post-baseline efficacy assessments, the first post-baseline assessment (Visit Week 16) will be imputed so that all randomized patients are included in MMRM analyses. The median value estimated from the pooled data at Week 16 across all randomized patients with available data will be used for this purpose. Imputation of missing primary and key secondary endpoint values at the Visit Week 52
time point will be performed in sensitivity analyses only. The planned imputation methods for sensitivity analyses are described below in Section 10.8.6.

10.8.2 Adjustment for Covariates

Analyses of the change from baseline in efficacy endpoints utilizing MMRM methodology will adjust for the baseline score of the parameter of interest as a continuous covariate in the model. As the randomization of the study is stratified by the baseline GCA classification factor (either ≤70 or >70), MMRM analyses will also take into account the GCA strata as a classification factor.

10.8.3 Interim Analysis

No interim analysis for treatment comparison is planned during the course of the study. The DMC will monitor safety data periodically. Following the completion of the study and collection and verification of all final data, the database will be locked and the results of the planned statistical analysis will be described in a final study report.

10.8.4 Multicenter Studies

This is a multicenter study utilizing a central randomization. The randomization is not stratified by center. It is planned that the data from all centers that participate in this protocol will be combined so that an adequate number of patients will be available for analysis. Because of the potential for a relatively large number of centers, and small numbers of patients at some centers, no subset analyses by center are planned. No adjustment for center effect will be utilized in the statistical analyses.

10.8.5 Multiple Comparisons/Multiplicity

The familywise type-I error rate (FWER) for the statistical tests of the primary, key secondary and other selected secondary efficacy endpoints from the MMRM analyses specified above will be controlled at 0.05. To strongly control the FWER at this level, a Gatekeeping approach will be utilized in which each family of statistical tests will be conducted in a sequential manner. The test for the primary endpoint will be conducted first at the 5% significance level and, if significant, the key secondary endpoint will be similarly tested at the 5% significance level. If these two tests are both significant, tests of the additional secondary efficacy endpoints specified below will be conducted using the Hommel closed testing procedure to control the FWER.

The hypotheses for the primary, key secondary and other selected secondary efficacy endpoints will therefore be grouped into 3 ordered Gatekeeper families defined as follows:
• Family 1 (F1): Hypothesis test for primary endpoint
• Family 2 (F2): Hypothesis test for key secondary endpoint
• Family 3 (F3): Hypothesis tests for the change from baseline to Visit Week 52 for the following 6 endpoints:
  o Verbal, Nonverbal, and Spatial standard scores in cluster areas of the DAS-II
  o Communication, Daily Living Skills, and Socialization standard domain scores of the VABS-II.

The 3 sets of hypotheses in F1, F2 and F3 will be tested sequentially, with F1 and F2 serving as serial gatekeepers. The null hypothesis of no treatment difference for the primary endpoint will be tested first in F1. The statistical test for the key secondary endpoint in F2 may only be declared statistically significant if a significant result is also achieved for the primary efficacy endpoint. Since F1 and F2 each contain a single null hypothesis to be tested, each of the two tests will be conducted at the 5% significance level.

Further, only if the null hypotheses for both the primary and key secondary endpoints are rejected in F1 and F2, can any of the tests for the endpoints specified in F3 be declared statistically significant. If statistical significance is obtained for F1 and F2, the Hommel closed testing procedure\(^1\) will be used to control the FWER within F3, with each hypothesis test in F3 equally weighted. In this case, SAS Proc MULTTEST will be used to calculate and report adjusted p-values for each endpoint in F3.

All other endpoints not included in F1, F2 or F3 above are considered supportive and any statistical tests comparing treatments will be made without adjustment for multiplicity. The resulting unadjusted p-values from these supportive analyses will be interpreted descriptively as summarizing the weight of evidence for a treatment difference and may suggest avenues for further exploratory analyses or generate formal hypotheses to be tested in future trials.

### 10.8.6 Sensitivity Analyses

Sensitivity analyses for the primary and key secondary endpoints will be conducted to assess missing data assumptions in the MMRM analyses. The sensitivity analyses below will use worst-observation-carried forward (WOCF) to impute missing data at the Visit Week 52 time point. Within a given patient, the worst (lowest) observed score prior to Visit Week 52 (including the baseline value) will be used for the imputation of their missing Visit Week 52 value.

The first sensitivity analysis will compare the treatment groups at the Visit Week 52 time point using an analysis of covariance model with WOCF (ANCOVA-WOCF). The ANCOVA-WOCF model will include fixed categorical effects for treatment and baseline GCA classification factor (either ≤70 or >70), and the corresponding baseline score as a continuous covariate. The treatment difference in least squares means, 95% CI and p-value from this model will be compared to the corresponding inferential statistics at Visit Week 52 from the primary or key secondary MMRM model.
As a second sensitivity analysis, the Wilcoxon Rank-Sum test with WOCF (WRS-WOCF) will be used to compare treatment groups at Visit Week 52. This test is based on the ranked changes from baseline after imputation of the Visit Week 52 value using WOCF.

Additional sensitivity analyses and imputation methods may be specified in the statistical analysis plan.
11 ADMINISTRATIVE CONSIDERATIONS

11.1 Investigators and Study Administrative Structure

Before initiation of the study, the Investigator must provide the Sponsor with a completed Form FDA 1572 or Investigator Agreement. Investigational product may be administered only under the supervision of the Investigators and Sub-investigators listed on these forms. Curriculum vitae must be provided for the Investigators and Sub-investigators listed on Form FDA 1572 or the Investigator Agreement. If the study involves use of an investigational device and the study is being conducted in compliance with 21 CFR 812, the Sponsor will obtain a signed agreement from each participating Investigator per the requirements of 21 CFR 812.43 (c).

The Investigator should ensure that all persons assisting with the study are adequately informed about the protocol, any amendments to the protocol, the study treatments, and their study related duties and functions. The Investigator must maintain a list of Sub-investigators and other appropriately qualified persons to whom he or she has delegated significant study related duties.

The Lead Investigator for this study is Joseph Muenzer, MD, PhD, Professor at the Departments of Pediatrics and Genetics, School of Medicine, University of North Carolina at Chapel Hill (North Carolina, USA).

11.2 Institutional Review Board or Independent Ethics Committee Approval

Before initiation of the study, the Investigator must provide the Sponsor with a copy of the written IRB/IEC approval of the protocol and the informed consent form. This approval must refer to the informed consent form and to the study title, study number, and version and date of issue of the study protocol, as given by the Sponsor on the cover page of the protocol.

Status reports must be submitted to the IRB/IEC at least once per year. The IRB/IEC must be notified of completion of the study; a final status report must be provided to the IRB/IEC within 3 months of study completion or termination (or as required). Copies of the status reports will be sent to the study clinical monitor. The Investigators must maintain an accurate and complete record of all submissions made to the IRB/IEC, including a list of all reports and documents submitted. Drug-related adverse events which are reported to the US FDA or other regulatory agencies (Investigational New Drug (IND) Safety Reports) and UADEs reported to regulatory agencies must be submitted promptly to the IRB/IEC. Unanticipated adverse device effects will be reported to regulatory agencies consistent with relevant regulations. Copies of UADE reports will be submitted to the IRB/IEC in a timely fashion.

11.3 Ethical Conduct of the Study

The procedures set out in this study protocol, pertaining to the conduct, evaluation, and documentation of this study, are designed to ensure that the Sponsor and Investigators abide by Good Clinical Practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the International Conference on Harmonisation (ICH) GCP Guidelines Compliance with these
regulations and guidelines also constitutes compliance with the ethical principles described in the Declaration of Helsinki.

11.4 Patient Information and Consent

Before enrolling in the clinical study, the patient or the patient’s parent(s) or legally authorized representative(s), as appropriate, must consent to participate after the nature, scope, and possible consequences of the clinical study have been explained in a form understandable to him or her.

An informed consent form (assent form if applicable) that includes information about the study will be prepared and given to the patient or the patient’s parent(s) or legally authorized representative(s). This document will contain all FDA and ICH-required elements. The informed consent (or assent, if applicable) form must be in a language understandable to the patient or the patient’s parent(s) or legally authorized representative(s) and must specify who informed the patient, the patient’s parent(s), or the patient’s legally authorized representative(s).

After reading the informed consent document, the patient or the patient’s parent(s) or legally authorized representative(s) must give consent in writing. Consent (or assent, if applicable) must be confirmed at the time of consent by the personally dated signature of the patient, the patient’s parent(s) or the patient’s legally authorized representative(s) and by the personally dated signature of the person conducting the informed consent discussions.

If the patient or the patient’s parent(s) or legally authorized representative(s) is unable to read, oral presentation and explanation of the written informed consent form and information to be supplied must take place in the presence of an impartial witness. Consent (or assent, if applicable) must be confirmed at the time of consent orally and by the personally dated signature of the patient or by a local legally recognized alternative (e.g., the patient’s thumbprint or mark) or by the personally dated signature of the patient’s parent(s) or the patient’s legally authorized representative(s). The witness and the person conducting the informed consent discussions must also sign and personally date the informed consent document. It should also be recorded and dated in the source document that consent (or assent, if applicable) was given.

A copy of the signed and dated consent document(s) must be given to the patient or the patient’s parent(s) or legal representative(s). The original signed and dated consent document will be retained by the Investigator.

The Investigator will not undertake any measures specifically required solely for the clinical study until valid consent (or assent, if applicable) has been obtained.

A model of the informed consent form to be used in this study will be provided to the sites separately from this protocol.

11.5 Patient Confidentiality

Patient names will not be supplied to the Sponsor. The patient number (and in some regions, patient initials) will be recorded in the CRF, and if the patient name appears on any other document, it must be obliterated before a copy of the document is supplied to the Sponsor.
Study findings stored on a computer will be stored in accordance with local data protection laws. The patients will be told that representatives of the Sponsor, a designated CRO, the IRB/IEC, or regulatory authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence and in accordance with local data protection laws. The Investigator will maintain a personal patient identification list (patient numbers with the corresponding patient names) to enable records to be identified.

11.6 Study Monitoring

Monitoring procedures that comply with current GCP guidelines will be followed. Review of the CRFs for completeness and clarity, cross-checking with source documents, and clarification of administrative matters will be performed.

The study will be monitored by the Sponsor or its designee. Monitoring will be performed by a representative of the Sponsor (Clinical Study Monitor) who will review the CRFs and source documents. The site monitor will ensure that the investigation is conducted according to protocol design and regulatory requirements by frequent site visits and communications (letter, telephone, and facsimile).

11.7 Case Report Forms and Study Records

Case report forms (paper or electronic) are provided for each patient. All forms must be filled out by authorized study personnel. All corrections to the original CRF entry must indicate the reason for change. The Investigator is required to sign the CRF after all data have been captured for each patient. If corrections are made after review and signature by the Investigator, he or she must be made aware of the changes, and his or her awareness documented by resigning the CRF.

11.7.1 Critical Documents

Before the Sponsor initiates the trial (ie, obtains informed consent [and assent, if applicable] from the first patient’s parent[s] and/or legally authorized guardian(s), it is the responsibility of the Investigator to ensure that the following documents are available to the Sponsor or its designee:

- Applicable local regulatory documentation (eg, FDA 1572 Form); signed, dated, and accurate
- Curricula vitae of Investigator and Sub-investigator(s) (current, dated and signed within 24 months of study initiation)
- Copy of Investigator and Sub-investigator(s) current medical license (indicating license number and expiration date)
- Signed and dated agreement of the final protocol
- Signed and dated agreement of any amendment(s), if applicable
- Approval/favorable opinion from the IRB/IEC clearly identifying the documents reviewed by name, number and date of approval or re approval: protocol, any
amendments, Subject Information/Informed Consent Form, and any other written information to be provided to subjects regarding recruitment procedures

- Copy of IRB/IEC approved Subject Information/Informed Consent Form/any other written information/advertisement (with IRB approval stamp and date of approval, if applicable)
- Current list of IRB/IEC Committee members/constitution (dated within 12 months prior to study initiation)
- Financial Disclosure Form signed by Investigator and Sub-investigator(s)
- Current laboratory reference ranges (if applicable)
- Certification/QA scheme/other documentation (if applicable)

Regulatory approval and notification as required must also be available. The protocol will not be initiated until regulatory approval and notification are obtained; these are the responsibility of the Sponsor.

11.8 Data Monitoring Committee

An independent, external DMC will be established to provide an ongoing, independent review and assessment of the safety data, and to safeguard the interests and safety of the participating patients in the study.

The DMC will be notified of all IDDD failures and IDDD-related complications at times defined in the DMC charter.

The DMC will consist of a biostatistician and two clinical experts. The DMC will adhere to a prospectively determined charter, which will be written by Shire or its designee and approved by the DMC. The charter will define the responsibilities of the DMC and Shire, describe the conduct of the meetings, and define the data sets to be reviewed. Serious adverse events and other data will be distributed to the members of the DMC periodically for review.

The first meeting of the DMC will be an orientation meeting and will be held prior to the start of the study. Thereafter, it is anticipated that the DMC will meet at least annually. The DMC will keep detailed minutes of their discussions during the meetings, which will be kept in strict confidence.

11.9 Device Failure Adjudication Process

The final cause for device failures will be adjudicated by a Shire team by examining the clinical database, safety database, and manufacturer investigation of returned devices.

11.10 Protocol Violations/Deviations

Any violation of the protocol as described can be considered a protocol violation including not meeting inclusion/exclusion criteria during the study, not adhering to the study treatment and other issues of noncompliance.
The Investigator will conduct the study in compliance with the protocol. The protocol will not be initiated until the IRB/IEC and the appropriate regulatory authorities have given approval/favorable opinion. Modifications to the protocol will not be made without agreement of the Sponsor. Changes to the protocol will require written IRB/IEC approval/favorable opinion prior to implementation, except when the modification is needed to eliminate an immediate hazard(s) to patients. The IRB/IEC may provide, if applicable regulatory authorities permit, expedited review and approval/favorable opinion for minor change(s) in ongoing studies that have the approval/favorable opinion of the IRB/IEC. The Sponsor will submit all protocol modifications to the regulatory authorities in accordance with the governing regulations.

A record of patients screened, but not entered into the study, is also to be maintained. No protocol exemption will be granted for this study.

When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to patients, the Investigator will contact the Sponsor or its designee, if circumstances permit, to discuss the planned course of action. Any departures from the protocol must be fully documented as a protocol deviation. Protocol deviations will need to be reviewed by the medical monitor and may also be required to be submitted to the IRB/IEC.

Protocol modifications will only be initiated by the Sponsor and must be approved by the IRB/IEC and submitted to the FDA or other applicable international regulatory authority before initiation.

11.11 Premature Closure of the Study

If the Sponsor, Investigator, DMC, or regulatory authorities discover conditions arising during the study which indicate that the clinical investigation should be halted due to an unacceptable patient risk, the study may be terminated after appropriate consultation between the Sponsor and the Investigator. In addition, a decision on the part of the Sponsor to suspend or discontinue development of the investigational product may be made at any time. Conditions that may warrant termination of the study or site include, but are not limited to:

- The discovery of an unexpected, significant, or unacceptable risk to the patients enrolled in the study
- Failure of the Investigator to comply with pertinent global regulations
- Submission of knowingly false information from the study site to the Sponsor or other pertinent regulatory authorities
- Insufficient adherence by the Investigator to protocol requirements

11.12 Access to Source Documentation

Regulatory authorities, the IRB/IEC, and the Sponsor (or its representatives) may request access to all source documents, CRFs, and other study documentation for onsite audit or inspection. Direct access to these documents must be guaranteed by the Investigator, who must provide support at all times for these activities. Monitoring and auditing procedures that comply with current GCP guidelines will be followed. On-site review of the CRFs for completeness and
clarity, crosschecking with source documents, and clarification of administrative matters may be performed.

11.13 Data Generation and Analysis

The clinical database will be developed and maintained by a contract research organization or an electronic data capture technology provider as designated by the Sponsor. Shire or its designee will be responsible for performing study data management activities.

Adverse events will be coded using MedDRA. Concomitant medication will be coded using the WHO-DD. Centralized laboratories will be employed as described in the study manual to aid in consistent measurement of efficacy and safety parameters.

11.14 Retention of Data

Essential documents should be retained until at least 2 years after the last approval of a marketing application and until there are no pending or contemplated marketing applications or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product. The Sponsor will notify the Investigator if these documents must be retained for a longer period of time. It is the responsibility of the Sponsor to inform the Investigator or institution as to when these documents no longer need to be retained.

11.15 Financial Disclosure

The Investigator should disclose any financial interests in the Sponsor as described in 21 CFR Part 54 prior to beginning this study. The appropriate form will be provided to the Investigator by the Sponsor, which will be signed and dated by the Investigator, prior to the start of the study. Changes in status concerning financial interests during the study and after its completion will be disclosed by the Investigator in accordance 21 CFR Part 54.

11.16 Publication and Disclosure Policy

All information concerning the study material, such as patent applications, manufacturing processes, basic scientific data, and formulation information supplied by the Sponsor and not previously published are considered confidential and will remain the sole property of the Sponsor. The Investigator agrees to use this information only in accomplishing this study and will not use it for other purposes.

It is understood by the Investigator that the information developed in the clinical study may be disclosed as required to the authorized regulatory authorities and governmental agencies. In order to allow for the use of the information derived from the clinical studies, it is understood that there is an obligation to provide the Sponsor with complete test results and all data developed in the study in a timely manner.

The Investigator and any other clinical personnel associated with this study will not publish the results of the study, in whole or in part, at any time, unless they have consulted with Shire, provided Shire HGT a copy of the draft document intended for publication, and obtained Shire’s
written consent for such publication. All information obtained during the conduct of this study will be regarded as confidential.
12 LIST OF REFERENCES


## 13 APPENDICES

**Appendix 1** Schedule of Events for Patients Randomized to Treatment in the Pivotal Study

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Month -1</th>
<th>Month 0</th>
<th>Months 1 to 12</th>
<th>Month 13</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed Consent</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Review of Study Entry Criteria</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Medical History</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hunter Syndrome Diagnosis and Genotype</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Physical and Neurological Examination</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Height and Weight</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Head Circumference</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hearing Assessment</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Neurodevelopmental Assessment</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Vital Signs</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Clinical Laboratory Tests</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>(Hematology, Serum Chemistry, Urinalysis)</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Coagulation Tests</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Urine GAG and creatinine</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Anti-I IDR suflase Antibody Testing</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>General Anesthesia</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>ICP Measurement (by lumbar)</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

*Note:● = Assessment; ○ = Event*
<table>
<thead>
<tr>
<th>Assessment</th>
<th>Day -28 to Day -1</th>
<th>Day 0</th>
<th>Pre-Surgery</th>
<th>Surgery</th>
<th>Follow-Up</th>
<th>Pre-Tx</th>
<th>IT Injection</th>
<th>Follow-Up</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puncture</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF Sample Collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum albumin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDDD Implantation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X-ray (Additional imaging may be required)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idursulfate-IT Injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Sample for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health status questionnaire</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications, Therapies/Interventions, Medical/Surgical Procedures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:**
- CSF = cerebrospinal fluid
- ECG = electrocardiogram
- GAG = glycosaminoglycan
- ICP = intracranial pressure
- IDDD = intrathecal drug delivery device
- MRI = magnetic resonance imaging
- PK = pharmacokinetics
- Tx = treatment

**Footnotes:**
- a Informed consent (and patient assent, if applicable) must be obtained from the patient’s parent(s)/legally authorized guardian(s) before beginning Screening assessments.
- b Patients will be randomized after they have completed Screening assessments and met all eligibility criteria. The day of randomization is Day 0.
- c X-rays may be performed to check placement of the device, and as needed, throughout the study.
- d The assessments indicated will be performed at 3-month intervals, i.e., at IT Dosing Weeks 4, 16, 28, and 40.
- e The CSF sample is to be obtained at each IT Dosing Week prior to the injection of idursulfate-IT.
- f The 12-lead ECG is to be performed within 4 hours after IT administration of study drug at Weeks 4, 16, 28, and 40.
- g Serum samples for PK analysis will be obtained at IT Dosing Weeks 4, 24, and 48. Samples will be collected within 15 minutes (±5 minutes) prior to intrathecal administration of idursulfate-IT and at 30 minutes (±5 minutes), 60 minutes (±5 minutes), 120 minutes (±5 minutes), 4 hours (±5 minutes), 6 hours (±5 minutes), 8 hours (±15 minutes), 12 hours (±15 minutes), 24 hours (±15 minutes), 30 hours (±15 minutes), 36 hours (±15 minutes) after the start
<table>
<thead>
<tr>
<th>Month -1</th>
<th>Month 0</th>
<th>Months 1 to 12</th>
<th>Month 13</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks -4 to -1 Screening Day -28 to -1</td>
<td>Week 0 Randomization</td>
<td>Week 2 (+7 days) Pre-surgery, Surgery, Follow-up, and Post-op Recovery</td>
<td>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 IT Dosing (+7 days)</td>
<td>Week 52 End of Study (EOS) (+7 days)</td>
</tr>
</tbody>
</table>

of intrathecal administration.

Patients will remain under observation in the hospital setting (may include lounge, infusion center, or waiting room) for 4 hours post IT injection for vital signs and other safety assessments. Vital signs will be collected at the following time points (±10 minutes) in association with IT administration of idursulfase-IT: within 15 minutes prior to IT administration, 30 minutes post end of IT administration, 60 minutes post end of IT administration, 120 minutes post end of IT administration, and 4 hours post end of IT administration. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of Visit Weeks 4, 24, and 48 at which serial blood sampling for pharmacokinetic evaluation is planned). The patient may need to be examined the following day (See Follow-up, Section 8.3.2.3).

From Week 28 onward, pre-treatment assessments may be performed on the same day as IT administration of idursulfase-IT, if the patient can arrive at the study site early in the day and if the Investigator deems this clinically appropriate.

The CSF sample will be obtained via lumbar puncture and while the patient is under general anesthesia.

This assessment will not need to be performed if an echocardiogram taken within 3 months of study start is available and deemed satisfactory for evaluation of anesthesia risk.

The assessments indicated will be performed prior to discharge. It is expected that, for most patients, post-surgical follow-up will occur within Week 2 (ie, within 1 to 2 days of surgery).

Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard laboratory parameters (chemistries, cell counts), albumin, GAG, concentration of idursulfase enzyme, and presence of idursulfase-specific antibodies. Analyses of CSF samples for antibodies and albumin will be performed at IT Dosing Weeks 4, 16, 28, and 40.

These neurodevelopmental and hearing assessments will be performed at IT Dosing Weeks 16, 28, 40 (±7 days).

At least 14 days will be allowed for recovery following the placement of the IDDD before the administration of the first IT dose.

Note that, on IT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

Pre-surgery coagulation tests will be performed by the local laboratory.

The follow-up visit is to occur on the day after IT administration during the first 6 months of IT treatment (ie, at Weeks 4, 8, 12, 16, 20, 24). For the latter 6 months of treatment with idursulfase-IT (ie, from Week 28 onward) and in the absence of any safety concerns, patients may complete the safety follow-up visit on the same day as IT administration prior to discharge.

The assessments indicated do not need to be repeated if completed as part of Screening assessments within 7 days prior to surgery.

The results of patients' genotype analyses must be known prior to randomization (see Section 7.3.1).
### Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Month -1</th>
<th>Month 0</th>
<th>Months 1 to 12</th>
<th>Month 13</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weeks -4 to -1 Screening Day -28 to -1</td>
<td>Week 0 Randomization, Week 2 (+7 days)</td>
<td>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 (-7 days)</td>
<td>Weeks 4, 16, 28 40</td>
<td>Week 52 End of Study (EOS) (-7 days)</td>
</tr>
<tr>
<td>Assessed</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>Telephone</td>
<td>7 (+2) Days Post EOS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Day -28 to Day -1</th>
<th>Day 0</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed Consent(a)</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Review of Study Entry Criteria</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Medical History</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Hunter Syndrome Diagnosis and Genotype (f)</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Echocardiogram(d)</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Physical and Neurological Examination</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Height and Weight</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Head Circumference</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hearing Assessment</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Neurodevelopment Assessment</td>
<td>●</td>
<td>●(c)</td>
<td>●</td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Vital Signs</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Clinical Laboratory Tests (Hematology, Serum Chemistry, Urinalysis)</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>General Anesthesia</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Urine GAG and creatinine</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Anti-idursulfase Antibody Testing (serum)</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Anti-idursulfase Antibody Testing</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>ICP measurement (by lumbar puncture)</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>CSF Sample Collection(c)</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Randomization</td>
<td>●(b)</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Health status Questionnaire</td>
<td>●</td>
<td></td>
<td>●</td>
</tr>
<tr>
<td>Concomitant Medications, Therapies/Interventions, Medical/Surgical</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

\(a\) Must be conducted within 4 weeks prior to randomization.  
\(b\) Conducted immediately prior to surgery.  
\(c\) Conducted at week 16.  
\(d\) Conducted at screening visit.  
\(f\) Conducted at randomization visit.
Month -1 | Month 0 | Months 1 to 12 | Month 13 | Follow-up
---|---|---|---|---
Weeks -4 to -1 Screening Day -28 to -1 | Week 0 Randomization | Week 2 (+7 days) | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 (+7 days) | Week 52 End of Study (EOS) (+7 days) | 7 (±2) Days Post EOS

Assessment: Day -28 to Day -1 | Day 0 | Telephone | Telephone | Telephone

Procedures

Adverse Events: ● ● ● ● ● ● ● ● ● ●

Abbreviations:
- CSF = cerebrospinal fluid; ECG = electrocardiogram; GAG = glycosaminoglycan; ICP = intracranial pressure; MRI = magnetic resonance imaging.
- a Informed consent (and patient assent, if applicable) must be obtained from the patient’s parent(s)/legally authorized guardian(s) before beginning Screening procedures.
- b Patients will be randomized after they have completed Screening assessments and met all eligibility criteria. The day of randomization is Day 0.
- c The CSF sample will be obtained via lumbar puncture and while the patient is under general anesthesia. The samples will be used to analyze standard laboratory parameters (chemistries, cell counts), GAG, albumin, concentration of idursulfase enzyme, and presence of idursulfase-specific antibodies.
- d This assessment will not need to be performed if an echocardiogram taken within 3 months of study start is available and deemed satisfactory for evaluation of anesthesia risk.
- e These neurodevelopmental and hearing assessments will be performed at Weeks 16, 28, 40 (±7 days).
- f The results of patients’ genotype analyses must be known prior to randomization (see Section 7.3.1).
Appendix 3  Schedule of Events for Patients Enrolled in the Substudy

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Month -1</th>
<th>Month 0</th>
<th>Month 1 to 12</th>
<th>Month 13</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weeks -4 to -1 Screening Day -28 to -1</td>
<td>Week 0 Enrollment</td>
<td>Week 2 (+7 days) Pre-surgery, Surgery, Follow-up, and Post-op Recovery*</td>
<td>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 IT Dosing (+7 days)</td>
<td>Week 52 End of Study (EOS) (+7 days)</td>
</tr>
<tr>
<td>Informed Consent*</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of Study Entry Criteria</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hunter Syndrome Diagnosis and Genotype</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Echocardiogram*</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical and Neurological Examination</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height and Weight</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head Circumference</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hearing Assessment</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurodevelopmental Assessment</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-lead ECG</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital Signs</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Laboratory Tests (Hematology, Serum Chemistry, Urinalysis)</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coagulation Tests§</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine GAG and creatinine</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Idursulfase Antibody Testing</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Anesthesia</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain MRI</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICP Measurement (by lumbar puncture)</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF Sample Collection*</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum albumin</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Shire  Confidential  102
<table>
<thead>
<tr>
<th>Assessment</th>
<th>Month -1</th>
<th>Month 0</th>
<th>Months 1 to 12</th>
<th>Month 13</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documentation of Entry Criteria</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDDD Implantation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X-ray (Additional imaging may be required)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>idursulfase-IT Injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum Sample for PK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health status questionnaire</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications, Therapies/Interventions, Medical/Surgical Procedures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:**
- CSF = cerebrospinal fluid; ECG = electrocardiogram; GAG = glycosaminoglycan; ICP = intracranial pressure; IDDD = intrathecal drug delivery device; MRI = magnetic resonance imaging; PK = pharmacokinetics; Tx = treatment.

**Footnotes:**
- a Patients will be enrolled into the study only after they have completed Screening assessments and met all eligibility criteria. For these patients, the day of enrollment is considered Day 0. Note that once a patient is enrolled in the study, he cannot later be randomized into the pivotal study.
- b X-rays may be performed to check placement of the device, and as needed, throughout the study.
- c The assessments indicated will be performed at 3-month intervals, i.e., at IT Dosing Weeks 4, 16, 28, and 40.
- d The CSF sample is to be obtained at each IT Dosing Week prior to the injection of idursulfase-IT.
- e The 12-lead ECG is to be performed within 4 hours after IT administration of study drug at Weeks 4, 16, 28, and 40.
- f Serum samples for PK analysis will be obtained at IT Dosing Weeks 4, 24, and 48. Samples will be collected within 15 minutes (±5 minutes) prior to intrathecal administration of idursulfase-IT and at 30 minutes (±5 minutes), 60 minutes (±5 minutes), 120 minutes (±5 minutes), 4 hours (±5 minutes), 6 hours (±5 minutes), 8 hours (±15 minutes), 12 hours (±15 minutes), 24 hours (±15 minutes), 30 hours (±15 minutes), 36 hours (±15 minutes) after the start of intrathecal administration.
- g Patients will remain under observation in the hospital setting (may include lounge, infusion center, or waiting room) for 4 hours post IT injection for vital signs and other safety assessments. Vital signs will be collected at the following time points (±10 minutes) in association with IT administration of
<table>
<thead>
<tr>
<th>Assessment</th>
<th>Month -1</th>
<th>Month 0</th>
<th>Months 1 to 12</th>
<th>Month 13</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Weeks -4 to -1 Screening Day -28 to -1</td>
<td>Week 0 Enrollment</td>
<td>Week 2 (+7 days Pre-surgery, Surgery, Follow-up, and Post-op Recovery)</td>
<td>Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 IT Dosing (+7 days)</td>
<td>Week 52 End of Study (EOS) (+7 days)</td>
</tr>
<tr>
<td>Day -28 to Day -1</td>
<td>Day 0</td>
<td>Pre-Surgery</td>
<td>Surgery</td>
<td>Follow-Up</td>
<td>Pre-Tx</td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

idursulfase-IT: within 15 minutes prior to IT administration, 30 minutes post end of IT administration, 60 minutes post end of IT administration, 120 minutes post end of IT administration, and 4 hours post end of IT administration. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of Visit Weeks 4, 24, and 48 at which serial blood sampling for pharmacokinetic evaluation is planned). The patient may need to be examined the following day (See Follow-up, Section 8.3.2.3).

From Week 28 onward, pre-treatment assessments may be performed on the same day as IT administration of idursulfase-IT, if the patient can arrive at the study site early in the day and if the Investigator deems this clinically appropriate.

The CSF sample will be obtained via lumbar puncture and while the patient is under general anesthesia.

This assessment will not need to be performed if an echocardiogram taken within 3 months of study start is available and deemed satisfactory for evaluation of anesthesia risk.

The assessments indicated will be performed prior to discharge. It is expected that, for most patients, post-surgical follow-up will occur within Week 2 (ie, within 1 to 2 days of surgery).

Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard laboratory parameters (chemistries, cell counts), GAG, albumin, concentration of idursulfase enzyme, and presence of idursulfase-specific antibodies. Analyses of CSF samples for antibodies and albumin will be performed at IT Dosing Weeks 4, 16, 28, and 40.

The neurodevelopmental and hearing assessments will be performed at IT Dosing Weeks 16, 28, 40 (+7 days). Note that, unlike patients in the pivotal study, the cognitive status of patients in the substudy will be assessed initially using the BSID-III. When these patients reach 42 months of age, if considered evaluable using the DAS-II instrument, they will transition to use of the DAS-II for continued assessments of cognition.

At least 14 days will be allowed for recovery following the placement of the IDDD before the administration of the first IT dose.

Note that, on IT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

Pre-surgery coagulation tests will be performed by the local laboratory.

The follow-up visit is to occur on the day after IT administration during the first 6 months of IT treatment (ie, at Weeks 4, 8, 12, 16, 20, 24). For the latter 6 months of treatment with idursulfase-IT (ie, from Week 28 onward) and in the absence of any safety concerns, patients may complete the safety follow-up visit on the same day as IT administration prior to discharge.

The assessments indicated do not need to be repeated as part of Screening assessments within 7 days prior to surgery.

The results of patients’ genotype analyses must be known prior to enrollment (see Section 7.3.1).
Appendix 4 Expected Adverse Device Effects

A list of the adverse effects expected with the SOPH-A-PORT Mini S is reproduced below from the device’s IFU.

Procedure-Related Complications

- Components handled improperly before, during, or after implantation
- Access port implanted incorrectly
- Catheter positioned improperly
- Injection through septum performed incorrectly
- Injection of incorrect medication through access port
- Injection outside the access port into pocket or subcutaneous tissue or extravasation
- Pocket seroma, hematoma, erosion, or infection

Intrathecal Access Complications

- Surgical complications such as hemorrhage or hematoma
- Infection of the implant site or catheter track
- Radiculitis or arachnoiditis
- Intrathecal space infection resulting in meningitis or encephalitis
- Bleeding
- Spinal cord damage or trauma to the spinal cord or nerve roots
- Post-lumbar puncture, cerebrospinal fluid (CSF) leak, leading to headache, or subcutaneous CSF collection
- Epidural instead of intrathecal placement of catheter
- Inflammatory mass resulting in neurological impairment, including paralysis
- Pain on injection
- Complications of anesthesia
- Pseudomeningocele

System-Related Complications

- Improperly positioned access port
- Erosion of the skin because of the underlying access port or the catheter
- Wound dehiscence
- Access port migration, fracture, breakage or occlusion
- Catheter damage, dislodgement, migration, disconnection, kinking or occlusion, fibrosis, or hygroma, resulting in tissue damage or a loss of or change in therapy, or other potentially serious adverse health consequences
- Catheter breakage and migration of residual catheter fragments, potentially resulting in serious adverse health consequences and the need for surgical removal
- Local immunological or fibrous reaction to the presence of a foreign body (the device)
- End of device service life or component failure, requiring surgical replacement
- Component failure, resulting in loss of therapy
- Access port inversion ("flipping"), rotation, or extrusion
- Access port or catheter rejection
- Fibrin sheath formation around catheter tip
Appendix 5  Protocol Amendment Summary of Changes

AMENDMENT SUMMARY AND RATIONALE

Clinical protocol HGT-HIT-094 has been amended from the original version to include the following:

- Several modifications to the study schedules of events, in particular: scheduling of serum antibody sampling every 3 months in both treatment groups of the pivotal study and in the separate substudy, instructions concerning patient genotyping requirements, clarification concerning safety follow-up post IT injection, and introduction of serum and CSF albumin testing to monitor permeability of the blood-brain barrier
- Specification that the Expanded Interview Form of the VABS-II be utilized
- Specification that the DAS-II Early Years (Spanish version) only will be used for assessment of eligible Spanish-speaking patients who, additionally, must be below 7 years 8 months of age at the time of informed consent
- Adjustment to dosing for patients below 3 years of age; the dose of idursulfase-IT dose will be adjusted based on reference brain weights, and introduction of cognitive eligibility criteria for this patient subgroup
- Increase in the required duration of prior Elaprase therapy from 3 to 4 months
- Modification of the planned statistical analysis

DETAILED SUMMARY OF CHANGES FOR THE AMENDMENT 1

This is a section that has been updated to describe significant changes from the original protocol version. Noteworthy changes and additions to the protocol text are captured below. **Bold** text indicates new text. **Strikethrough** text indicates deleted text.

Changes in grammar, spelling, punctuation, format, minor editorial changes (including changes for consistency and clarity), and refinements to the introductory text, list of abbreviations and cross references are not reflected in the change summary.

<table>
<thead>
<tr>
<th>Change: Clarification to lead investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: <strong>Cover page</strong></td>
</tr>
<tr>
<td>New Text: Principal Lead Investigator Joseph Muenzer, MD, PhD</td>
</tr>
<tr>
<td>Other sections impacted by this change: <strong>Section 11.1 Investigators and Study Administrative Structure</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to safety objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: <strong>Section 2.3 Safety Objectives</strong></td>
</tr>
<tr>
<td>New Text: • To determine the effect of the treatment regimen on safety as assessed by adverse events, clinical laboratory</td>
</tr>
</tbody>
</table>
testing, physical and neurological examination findings, vital signs, and electrocardiogram (ECG) results recordings.

Other sections impacted by this change: Synopsis

<table>
<thead>
<tr>
<th>Change: Clarification to pharmacokinetic objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 2.5 Pharmacokinetic and Pharmacodynamic Objectives</td>
</tr>
<tr>
<td>Previous Text:</td>
</tr>
<tr>
<td>• To evaluate the concentration of idursulfase in serum and cerebrospinal fluid (CSF) after IT administration and determine pharmacokinetic parameters</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>• To evaluate the concentration of idursulfase and determine PK parameters in serum after IT administration</td>
</tr>
<tr>
<td>• To evaluate the concentration of idursulfase in CSF prior to each monthly administration of idursulfase-IT</td>
</tr>
<tr>
<td>Other sections impacted by this change: Synopsis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to substudy objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 2.7 Substudy Objective</td>
</tr>
<tr>
<td>Previous Text:</td>
</tr>
<tr>
<td>• To examine the effect of the treatment regimen in pediatric patients with Hunter syndrome &lt;3 years old and having a complex rearrangement/genotype of the iduronate-2-sulfatase gene on safety and efficacy measures</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>• To examine the effect of the treatment regimen on safety and efficacy measures in pediatric patients with Hunter syndrome and early cognitive impairment who are below 3 years of age</td>
</tr>
<tr>
<td>Other sections impacted by this change: Synopsis, Section 5.1 Study Population , Section 5.2 Inclusion Criteria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to secondary endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 3.2 Secondary Efficacy Endpoints</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>• Change from baseline to Visit Weeks 16, 28, 40, and 52 in the standardized scores of the VABS-II domains: Communication, Daily Living Skills, Socialization, and Motor Skills, and Maladaptive Behavior</td>
</tr>
<tr>
<td>• Change from baseline to Visit Weeks 16, 28, 40, and 52 in age equivalents, developmental quotients, and T-scores for the subtests of the DAS-II: Verbal Comprehension, Picture Similarities, Naming Vocabulary, Pattern Construction, Matrices, and Copying for the DAS-II/Early Years and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal Similarities, and Sequential and Quantitative Reasoning for the DAS-II/School Years</td>
</tr>
<tr>
<td>• Change from baseline to Visit Weeks 16, 28, 40, and 52 in age equivalents, developmental quotients, and V-scale scores of the VABS-II subdomains: Communication (Receptive, Expressive, Written), Daily Living Skills (Personal, Domestic, Community), Socialization (Interpersonal Relationships, Play and Leisure Time, Coping Skills), Motor Skills (Gross, Fine) and Maladaptive Behavior</td>
</tr>
<tr>
<td>• Change from baseline to Visit Weeks 16, 28, 40, and 52 in the V-scale scores and observed maladaptive levels of the VABS-II Maladaptive Behavior Index and its subscales (Internalizing, Externalizing)</td>
</tr>
<tr>
<td>Other sections impacted by this change: Synopsis, Section 10.5.3 Other Secondary Efficacy Endpoint Analyses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to CSF laboratory tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 3.4 Safety Assessments</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>Safety will be assessed during the study by collection of adverse events (by type, severity, and relationship to</td>
</tr>
</tbody>
</table>
treatment [idursulfase-IT, the IDDD, device surgical procedure, or IT administration process] and IV Elaprase infusion), changes in clinical laboratory testing (serum chemistry, hematology, urinalysis), physical and neurological examination, vital signs, 12-lead ECG recordings, CSF chemistries laboratory parameters (including chemistries, cell counts, protein, and glucose), anti-idursulfase antibodies in CSF and serum, and determination of antibodies having enzyme neutralizing activity.

Other sections impacted by this change: Synopsis, Section 7.11 Safety Assessments, Section 7.11.10 Cerebrospinal Fluid Assessments

Change: Clarification to study design
Section impacted by this change: Section 4.1 Overall Study Design and Plan
New Text:
The separate substudy is open label and single arm. **Patients who are enrolled in the substudy will follow the same schedule of study visits as idursulfase-IT-treated patients in the pivotal study.**

Other sections impacted by this change: Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to study duration
Section impacted by this change: Section 4.3 Study Duration
New Text:
An extension study is planned during which patients who complete HGT-HIT-094 **and are eligible according to the inclusion/exclusion criteria for the extension study** may continue, or begin, to receive IT treatment with idursulfase-IT via the SOPH-A-PORT Mini S device.

Other sections impacted by this change: Synopsis

Change: Clarification to substudy population
Section impacted by this change: Section 5.1 Study Population
New Text:
A separate substudy will enroll patients who have a complex rearrangement of the iduronate 2 sulfatase gene **early cognitive impairment** and are below the age of 3 years at the time of informed consent.

Other sections impacted by this change: Synopsis, Section 6.4 Method of Assigning Patients to Treatment Groups

Change: Update the inclusion criteria for Spanish-speaking patients
Section impacted by this change: Section 5.2 Inclusion Criteria
Previous Text:
Patients must meet the following criteria to be considered eligible for randomization in the pivotal study:
1. The patient is male and is **≥3 and <18 years** of age at the time of informed consent.

*Note that patients who are younger than 3 years of age may be enrolled in a separate substudy provided that they have a documented complex rearrangement genotype of the iduronate-2-sulfatase gene and meet other inclusion criteria, provided below.*

New Text:
Patients must meet the following criteria to be considered eligible for randomization in the pivotal study:
1. The patient is male and is **≥3 and <18 years** of age at the time of informed consent.

**Spanish-speaking patients who are to be assessed using the Spanish version of the DAS-II Early Years must be <7 years 8 months of age at the time of informed consent.**

*Note that patients who are younger than 3 years of age may be enrolled in a separate substudy provided that they have a documented complex rearrangement/large deletion genotype of the iduronate-2-sulfatase gene and meet other inclusion criteria, provided below.*
Other sections impacted by this change: **Synopsis**

**Change**: Clarification to inclusion criteria 2 for the pivotal study  
**Section impacted by this change**: Section 5.2.1 Inclusion Criteria for the Pivotal Study  
**New Text**:  
2. The patient must have a documented diagnosis of MPS II. Of the three criteria below, the combinations (2a AND 2b) or (2a AND 2c) will be accepted as diagnostic of MPS II:  
   a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).  
   AND  
   b. The patient has a documented mutation in the iduronate-2-sulfatase gene that leaves the FMR1 and FMR2 genes intact. **In the case of a positive family history, the genotype of a brother or uncle (with appropriate informed consent, or assent if applicable) may be accepted as documentation at the discretion of the Medical Monitor.**

Other sections impacted by this change: **Synopsis**

**Change**: Clarification to inclusion criteria 4 for the pivotal and substudy  
**Section impacted by this change**: Section 5.2.1 Inclusion Criteria for the Pivotal Study  
**New Text**:  
4. The patient has received and tolerated a minimum of 34 months of therapy with Elaprase during the period immediately prior to Screening.  

Other sections impacted by this change: Section 5.2.2 Inclusion Criteria for the Substudy, Synopsis, 4.1 Overall Study Design and Plan, 6.7.1 Prior Therapy

**Change**: Clarification to inclusion criteria 5 for the pivotal and substudy  
**Section impacted by this change**: Section 5.2.1 Inclusion Criteria for the Pivotal Study  
**New Text**:  
Each patient must have sufficient auditory capacity, with or without a hearing aid(s), if needed, in the Investigator’s judgment, to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days.  

Other sections impacted by this change: Section 5.2.2 Inclusion Criteria for the Substudy, Synopsis, Section 7.11.4 Hearing Assessment

**Change**: Clarification to inclusion criteria 2 for the substudy  
**Section impacted by this change**: Section 5.2.2 Inclusion Criteria for the Substudy  
**New Text**:  
2. The patient must have a documented diagnosis of MPS II. The following two types of documentation will be accepted as diagnostic of MPS II:  
   a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity of ≤10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on the reference laboratory’s normal range).  
   AND  
   b. The patient has a documented complex chromosomal rearrangement/large deletion of mutation in the iduronate-2-sulfatase gene that leaves the FMR1 and FMR2 genes intact. **In the case of a positive family history, the genotype of a brother or uncle (with appropriate informed consent, or assent if applicable) may be accepted as documentation at the discretion of the Medical Monitor.**  
   OR  
   c. The patient has a normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on the normal range of measuring laboratory).  

Other sections impacted by this change: **Synopsis**
Change: Addition of inclusion criteria 3 for the substudy
Section impacted by this change: Section 5.2.2 Inclusion Criteria for the Pivotal Study
New Text:
3. The patient has evidence at Screening of Hunter syndrome-related cognitive impairment as assessed using the BSID-III and defined as a composite score on the cognitive scale ≥55 and ≤85.

Other sections impacted by this change: Synopsis

Change: Clarification to exclusion criteria
Section impacted by this change: Section 5.3 Exclusion Criteria
New Text:
2. The patient has a large chromosomal deletion or complex rearrangement genotype that includes a n-inactivation and/or deletion of the FMR1 and/or FMR2 genes.
6. The patient has an opening CSF pressure upon lumbar puncture that exceeds 30.0 cm H2O.

Other sections impacted by this change: Synopsis

Change: Clarification of dosing for patients <3 years of age in the separate substudy
Section impacted by this change: Section 6.3 Selection and Timing of Dose for Each Patient
New Text:
Patients who are enrolled in the separate substudy will undergo surgical implantation of the IDDD. Patients in the substudy will receive 12 monthly IT injections of idursulfase-IT, once every 28 days. The IT dose of idursulfase-IT to be administered to patients below 3 years of age will be adjusted as follows based on reference brain weight:

Up to 8 months of age at dosing, idursulfase-IT 5 mg; >8 months to 30 months of age at dosing, idursulfase-IT 7.5 mg; >30 months to 3 years of age at dosing, idursulfase-IT 10 mg.

Please refer to the Pharmacy Manual for complete details.

Other sections impacted by this change: Synopsis

Change: Clarification concerning assessors
Section impacted by this change: Section 6.5 Blinding
New Text:
Single and double blinding of patients, their families, and the Principal Investigator is not possible due to the absence of a sham device, sham injections, or placebo. The Sponsor will work with each site to clarify the process for assessor blinding and each site will document the manner in which blinding will be maintained at the site. Every effort will be made to blind the assessors of the primary and secondary endpoints obtained from the DAS-II and VABS-II. The assessors responsible for these evaluations will not be informed of patients’ randomization assignments. The families will be instructed not to share this information with the assessors. Different assessors will be responsible for administration of the DAS-II and VABS-II. The assessors will not be part of the study team or participate in study team meetings.

Other sections impacted by this change: None

Change: Clarification concerning concomitant therapies
Section impacted by this change: Section 6.6 Concomitant Medications, Therapies, and Medical/Surgical Interventions
New Text:
Treatment with any other investigational therapies at any time during this study is prohibited. All patients are to receive Elaprase therapy throughout this study. Elaprase will be prescribed by the patient’s physician and will be administered in accordance with local prescribing information. Elaprase will not be provided by the study Sponsor.
Concomitant therapies such as speech therapy, ergotherapy, music therapy, and physical therapy are permitted, and will be captured during the study.

Other sections impacted by this change: Section 6.6.1 Infusion Reactions and Management

<table>
<thead>
<tr>
<th>Change: Clarification concerning investigational product vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 6.9 Packaging and Labeling, Section 6.9.1 Investigational Product</td>
</tr>
<tr>
<td>New Text: Idursulfase-IT drug product is a sterile liquid formulation for IT administration that is packaged in 2–3-mL type-I borosilicate glass vials. The drug product is filled to deliver a minimum dose volume of 1 mL per vial with minimal waste and for handling convenience in the clinical setting.</td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification concerning investigational product storage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 6.10 Storage and Accountability, Section 6.10.1 Investigational Product</td>
</tr>
<tr>
<td>New Text: Idursulfase-IT will be shipped by Shire HGT or a qualified distributor to the clinical study site(s) at 5 ±3 °C (36 to 46 °F). The investigational product should be handled as follows:</td>
</tr>
<tr>
<td>• idursulfase-IT vials should be stored at 5 ±3 °C (36 to 46 °F).</td>
</tr>
</tbody>
</table>
| [...]
| • Because it does not contain preservatives, idursulfase-IT should be used as soon as possible after it is prepared, because it does not contain preservatives. |
| Other sections impacted by this change: None |

<table>
<thead>
<tr>
<th>Change: Clarification to diagnostic testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 7.3 Medical History, Section 7.3.1 Genotype</td>
</tr>
<tr>
<td>New Text: Patients who have not had a previous IDS genotype analysis performed at Greenwood Genetic Center’s Diagnostic Laboratory (Greenwood, South Carolina, USA), referred to here as “Greenwood Labs”, will provide a blood sample for genotyping at Screening to document the diagnosis of Hunter syndrome. Even patients for whom prior genotyping was performed at Greenwood Labs may need to have a repeat analysis performed if the original information was insufficient for an unambiguous classification of genotype (eg, to document the integrity of the FMR1 and FMR2 genes in patients with complex mutations/chromosomal rearrangements large deletion/rearrangement mutations). Specific instructions concerning genotyping and the timing of enrollment are provided below:</td>
</tr>
<tr>
<td>A Greenwood Labs IDS genotype will be obtained for all patients in the study. If the patient has no Greenwood Labs IDS genotype in his file at the time of informed consent, a blood sample will be drawn at Screening. If the patient has a prior Greenwood Labs genotype in his file, and it indicates the presence of a mutation(s) that is within the IDS locus (eg, small deletion or point mutation), the test will not have to be redone. If the patient has a prior Greenwood Labs genotype in his file, and it indicates the presence of a large deletion/rearrangement mutation but does not confirm the integrity of the FMR1 and FMR2 genes, a new sample may have to be drawn.</td>
</tr>
<tr>
<td>• If the patient has no documented IDS genotype at Screening, then enrollment/randomization will have to await the arrival of the Greenwood Labs genotype results.</td>
</tr>
<tr>
<td>• If the patient has a locally determined IDS genotype indicating the presence of a small deletion or point mutation, the site may proceed and enroll/randomize him while awaiting the confirmatory results from Greenwood Labs.</td>
</tr>
<tr>
<td>• If the patient has a locally determined IDS genotype indicating the presence of a large deletion/rearrangement mutation, then enrollment/randomization will have to await the results of the Greenwood Labs genotype analysis to confirm the integrity of the FMR1 and FMR2 genes.</td>
</tr>
<tr>
<td>• If the patient has a Greenwood Labs IDS genotype indicating the presence of a small deletion or point mutation, he can be enrolled/randomized at once.</td>
</tr>
</tbody>
</table>
• If the patient has a Greenwood Labs IDS genotype indicating the presence of a large deletion/rearrangement mutation, he may only be enrolled/randomized if and when a Greenwood Labs genotype confirming the integrity of the FMR1 and FMR2 genes is available, either in his original genotype documentation, or by analysis of a new sample.

Other sections impacted by this change: Section 8.1 Screening (Month -1, Week -4 to -1), 8.1.1 All Patients in the Pivotal Study and Substudy

Change: Clarification to investigational product administration
Section impacted by this change: Section 7.6 Investigational Product Administration
New Text:
Patients will remain under the observation of study personnel in the hospital setting (may include lounge, infusion center, or waiting room) for at least 4 hours post administration of investigational product for safety assessments, and will be discharged when deemed clinically stable by the Investigator. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of study visit weeks at which serial blood sampling for pharmacokinetic evaluation is planned). For the first 6 months of treatment with idursulfase-IT, patients must return to the clinic the day after each IT administration for a safety follow-up visit. Note that, under these circumstances, there is no requirement for an overnight hospital stay; if a decision is made to keep the patient overnight for convenience, this hospitalization should not initiate a serious adverse event report. For the latter 6 months of treatment with idursulfase-IT (ie, from Week 28 onward) and in the absence of any safety concerns, patients may complete the safety follow-up visit on the same day as IT administration prior to discharge.

Other sections impacted by this change: Section 8.3.2.2 IT Injection, Section 8.3.2.3 Follow-up (Day after IT Injection at Weeks 4, 8, 12, 16, 20, 24)

Change: Clarification to assessments
Section impacted by this change: Section 7.7 Pharmacokinetic Assessments and Section 7.8 Pharmacodynamic/Biomarker Assessments
New Text:
7.7 Pharmacokinetic Assessments
Blood samples will be collected for determination of idursulfase serum concentration-time profiles and serum pharmacokinetic parameters after IT administration. Idursulfase concentrations will be measured in CSF samples obtained immediately prior to each IT administration (and at the EOS Visit) to determine the degree of accumulation of monthly idursulfase-IT administrations in the CSF.
The blood and CSF sampling schedule for pharmacokinetic assessments is provided in the Schedule of Events for patients in the treated arm of the pivotal study (Appendix 1) and in the separate substudy (Appendix 3).
7.8 Pharmacodynamic/Biomarker Assessments
7.8.1 CSF Glycosaminoglycan
Cerebrospinal fluid and urine samples will be collected for measurement of the concentration of GAG (refer to the SOE for the pivotal study [Appendix 1 and Appendix 2] and separate substudy [Appendix 3]).
7.8.2 CSF and Serum Albumin
Albumin levels will be measured in samples of CSF and serum (refer to the SOE for the pivotal study ([Appendix 1 and Appendix 2] and separate substudy [Appendix 3]) to monitor the permeability of the blood-brain barrier during the study.

Other sections impacted by this change: Section 7.11.10 Cerebrospinal Fluid Assessments, Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Use of the DAS-II Early Years only for Spanish-speaking patients
Section impacted by this change: Section 7.9 Efficacy Assessments
Cognition: the Differential Ability Scales, Second Edition (DAS-II)\(^\text{17}\) will be used to assess all randomized patients. For patients participating in the separate substudy only (ie, patients with a complex rearrangement/large deletion genotype of the iduronate-2-sulfatase gene and who are below the age of 3 years) cognition will be assessed initially using the Bayley Scales of Infant Development, Third Edition (BSID-III).\(^\text{20}\) When these patients reach at least 42 months of age, if considered evaluable using the DAS-II instrument, they will transition to use of the DAS-II for continued assessment of cognition.

Adaptive Behaviors: the Vineland Adaptive Behavioral Scales, Second Edition (VABS-II)\(^\text{19}\) will be used to assess all patients.

New Text:
Cognition: the Differential Ability Scales, Second Edition (DAS-II)\(^\text{17}\) will be used to assess all randomized patients. The DAS-II comprises 2 overlapping batteries. The Early Years battery is designed for children ages 2 years 6 months through 6 years 11 months. The School Age Battery is designed for children ages 7 years 0 months through 17 years 11 months. These batteries are fully co-normed for ages 5 years 0 months through 8 years 11 months. Spanish-speaking patients will be assessed using the Spanish version of the DAS-II Early Years only. Spanish-speaking patients will be assessed using the Spanish version of the DAS-II Early Years only. For patients participating in the separate substudy only (ie, patients with a complex rearrangement/large deletion genotype of the iduronate-2-sulfatase gene and who are below the age of 3 years \textit{and have early cognitive impairment}) cognition will be assessed initially using the Bayley Scales of Infant Development, Third Edition (BSID-III).\(^\text{20}\) When these patients reach at least 42 months of age, if considered evaluable using the DAS-II instrument, they will transition to use of the DAS-II for continued assessment of cognition.

Adaptive Behaviors: the Vineland Adaptive Behavioral Scales, Second Edition (VABS-II)\(^\text{19}\) will be used to assess all patients. \textit{The Expanded Interview Form will be utilized.}

[...]
All assessments will be administered by qualified study personnel. The DAS-II will be administered by a trained practitioner.

Other sections impacted by this change: Synopsis

---

Change: Change to vital signs collection
Section impacted by this change: Section 7.11.12 Device Assessments

New Text:
As part of the assessment of the SOPH-A-PORT Mini S, it may be necessary to determine the levels of leachables from the device into the CSF and blood. Samples of stored CSF and serum may be used to determine the levels of leachable materials related to the IDDD.

Other sections impacted by this change: None

---

Change: Change to vital signs collection
Section impacted by this change: Section 7.11.4 Hearing Assessment

New Text:
Each patient must have sufficient auditory capacity, with a hearing aid(s), if needed, in the Investigator's judgment, to complete the required protocol testing and must be compliant with wearing the hearing aid(s), if needed, on scheduled testing days.

The Investigator will confirm that, with hearing aid(s) in place if needed, each patient has sufficient understanding to participate in study assessments.

Hearing assessment will be performed using age-appropriate testing methods based on the patient's age at the time of testing. It is recognized that the ability to conduct hearing assessment will depend on the patient's ability to cooperate and that it might not be possible to complete a hearing assessment for every patient. A reasonable effort should be made to perform a hearing assessment for each patient; however, inability to collect these data may not be
considered a protocol deviation.

Other sections impacted by this change: Section 5.2 Inclusion Criteria, Synopsis

Change: Change to vital signs collection
Section impacted by this change: Section 7.11.5 Vital Signs
New Text:
Vital signs are to be recorded for all patients and will include pulse, blood pressure, respiration rate, oxygen saturation, and temperature.

Other sections impacted by this change: Section 10.7.5 Vital Signs and Physical Measurements

Change: Change to ECG recording
Section impacted by this change: Section 7.11.6 Electrocardiogram
New Text:
The ECG will include assessment of heart rate, sinus rhythm, atrial or ventricular hypertrophy, and assessment of PR, RR, QRS, and QT, and corrected QT (QTc) intervals.

Other sections impacted by this change: Section 10.7.4 Electrocardiogram Evaluations

Change: Clarification to blood sample collection
Section impacted by this change: Section 7.11.9 Clinical and Other Laboratory Tests
New Text:
Blood and urine samples will be collected as described in this section for clinical laboratory testing. All blood samples will be collected by venipuncture or via central line. Patients will be in a seated or supine position during blood collection.

Clinical laboratory tests will include the following (See Table 7-2):

**Table 13-1 List of Laboratory Tests**

<table>
<thead>
<tr>
<th>Serum Chemistry:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Globulin</td>
</tr>
</tbody>
</table>

Other sections impacted by this change: None

Change: Clarification to CSF sample collection
Section impacted by this change: Section 7.11.10 Cerebrospinal Fluid Assessments
New Text:
Cerebrospinal fluid samples will be collected via the IDDD (or lumbar puncture) and used to analyze standard safety laboratory parameters (including chemistries, cell counts, protein, and glucose), GAG, and concentration of idursulfase enzyme. The CSF samples will also be analyzed for idursulfase-specific antibodies and antibodies with enzyme neutralizing activity (See Section 7.11.11).

[…] Should the IDDD become clogged, undergo mechanical complications or otherwise not be accessible, the CSF sample may be obtained by lumbar puncture up to 12 times during the treatment phase of the study. Patients in the no-treatment arm of the pivotal study will undergo lumbar puncture (under general anesthesia) to obtain CSF samples at the Screening and EOS visits.

Other sections impacted by this change: Section 4.1.1 Intrathecal Drug Delivery

Change: Clarification concerning adverse events
Section impacted by this change: Section 7.14.1.1 Adverse Events
New Text:
Adverse events include:

[…]

- **Clinically significant** abnormal laboratory values (this includes significant shifts from baseline within the range of normal that the Investigator considers to be clinically important)
- Clinically significant abnormalities in physical and neurological examination, vital signs, ECG, weight

Throughout the study, the Investigator must record all adverse events on the AE CRF, regardless of the severity or relationship to investigational product. The Investigator should treat patients with adverse events appropriately and observe them at suitable intervals until the events stabilize or resolve. Adverse events may be discovered through observation or examination of the patient, questioning of the patient or his parent(s)/legally authorized guardian(s), complaint by the patient or his parent(s)/legally authorized guardian(s), or by abnormal clinical laboratory values or physical findings.

Other sections impacted by this change: None

| Change: Clarification concerning AEs related to Elaprase |
| Section impacted by this change: Section 7.14.1.2 Elaprase-related Adverse Events |
| New Text: All patients will receive concomitant IV therapy with Elaprase throughout their participation in this study. Adverse events that are potentially related to IV Elaprase infusion will be captured. The most commonly reported adverse events that have been assessed as related to Elaprase in patients with Hunter syndrome are listed in Section 6.6. Note that, during weeks of IT dose administration, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT dosing in order to help distinguish adverse events related to IV compared to IT administration. |

Other sections impacted by this change: None

| Change: Clarification concerning AEs related to the IDDD |
| Section impacted by this change: Section 7.14.1.3 IDDD-related Adverse Events |
| New Text: Examples of adverse events related to use of the IDDD include, but are not limited to, the following: device failure (such as may occur with migration of the portal/catheter, occlusion of the portal/catheter, incorrect connection of IDDD components, fibrin sheath formation around the catheter tip), erosion of the portal/catheter through the skin, hematoma, implant rejection, or subcutaneous tract infection. A malfunction of the device (defined in Section 7.14.2.2) should not be entered as an adverse event unless this has physiopathological consequences such as those listed above. In the event of device failure (defined in Section 7.14.2.3), the device may need to be replaced or repaired as needed. Hospitalization for such a procedure will be reported as a serious adverse event. Details of the cause of IDDD malfunction or failure will be recorded on the device Malfunction/Failure CRF. A list of the most common IDDD adverse events is included in Appendix 4. |

Other sections impacted by this change: None

| Change: Clarification concerning AEs related to Surgery |
| Section impacted by this change: Section 7.14.1.4 Device Surgical Procedure-related Adverse Events |
| New Text: Examples of adverse events related to device surgical procedures include, but are not limited to, the following: events that occur during or following IDDD implant/explant, IDDD adjustment, full revision, partial revision, IDDD removal, and delayed re-implantation after previous IDDD removal (such as complications of anesthesia, excessive bleeding, wound hematoma), and post-operative complications (such as post-operative infection). |

Other sections impacted by this change: None

| Change: Clarification concerning SAEs |
### Section 7.14.1.6 Serious Adverse Events

**New Text:**
Hospitalization, which is the result of elective or previously scheduled surgery for pre-existing condition, which has not worsened after initiation of treatment, should not be classified as a serious adverse event. For example, an admission for a previously scheduled ventral hernia repair would not be classified as a serious adverse event; however, complication(s) resulting from a hospitalization for an elective or previously scheduled surgery that meet(s) serious criteria must be reported as serious adverse event(s). Furthermore, this does not apply to device failures resulting in scheduled surgical revisions, which should be reported as serious adverse events.

### Change: Correction of the meaning of the UADE acronym

**Section impacted by this change:** Section 7.14.1.7 Unanticipated Adverse Device Effect

**Previous Text:**
Unexpected Adverse Device Event

**New Text:**
Unanticipated Adverse Device Effect

### Change: Correction to the AE classification guide

**Section impacted by this change:** Section 7.14.3 Classification of Adverse Events and Serious Adverse Events

**Revised Text:**
The severity of adverse events will be assessed by the Investigator using the National Cancer Institute Common Toxicity Criteria (NCI CTC) grading scale (provided in the Study Operations Manual). If an adverse event is not described in the NCI CTC, the severity should be recorded based on the scale definitions shown in Table 7-3. The severity of all adverse events and serious adverse events should be recorded on the appropriate CRF page as mild, moderate, or severe.

### Change: Correction to the reporting of abuse, misuse, overdose, and medication error

**Section impacted by this change:** Section 7.16 Abuse, Misuse, Overdose, and Medication Error

**Revised Text:**
The Investigator must report abuse, misuse, overdose, and medication error to the Shire Pharmacovigilance and Risk Management Department AND to the Shire HGT Medical Monitor on the SAE form. This form must be completed and FAXED or EMAILED within 24 hours of the Investigator’s learning of the event (refer to the contact information for reporting of SAEs provided in Section 7.14.5.2).

### Change: Clarification to screening assessments

**Section impacted by this change:** Section 8.1 Screening (Month -1, Week -4 to -1), 8.1.1 All Patients in the Pivotal Study and Substudy

**New Text:**
- Hunter syndrome diagnosis (blood sample collection for testing of iduronate-2-sulfatase activity and genotyping, as appropriate based on the patient’s medical history). Note that analysis of iduronate-2-sulfatase genotype will be required for all patients who have not had a previous genotyping performed at Greenwood Genetic Center’s Diagnostic Laboratory (Greenwood, South Carolina, USA). Even patients for whom prior genotyping was performed at Greenwood Genetic Center’s Diagnostic Laboratory may need a repeat analysis performed if the original information was insufficient for an unambiguous classification of genotype (eg, to
document the integrity of the FMR1 and FMR2 genes in patients with large deletion/rearrangement mutations). Please refer to Section 7.3.1 for specific instructions.

- Clinical laboratory tests (hematology, serum chemistry, urinalysis)
- Urine GAG and creatinine
- ICP measurement (by lumbar puncture)
- CSF sample collection (by lumbar puncture)
- Albumin (serum and CSF)
- Anti-idursulfase antibody testing (serum and CSF)

Other sections impacted by this change: Section 7.3 Medical History, Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to randomization/enrollment assessments

Section impacted by this change: Section 8.2 Randomization/Enrollment: Clinic Admission (Month 0, Week 0, Day 0)

New Text:
8.2.1 All Patients (IT Treatment and No IT Treatment Groups) in the Pivotal Study
- Randomization
- Concomitant medications, therapies/interventions, and medical/surgical procedures*
- Adverse events*
*These assessments may occur by telephone.

8.2.2 All Patients in the Substudy
- Documentation of entry criteria for enrollment
- Concomitant medications, therapies/interventions, and medical/surgical procedures*
- Adverse events*
*These assessments may occur by telephone.

Other sections impacted by this change: Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to pre-surgery, surgery, and post-operative recovery assessments

Section impacted by this change: Section 8.3.1 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the Substudy: Pre-surgery, Surgery, Follow-up, and Post-op Recovery (Week 2 [+7 days])

New Text:
IDDD placement will require surgical implantation under general anesthesia and post-surgical assessment.

8.3.1.1 Pre-surgery
- Physical and neurological examination*
- Height and weight*
- 12-lead ECG*
- Vital signs*
- Clinical laboratory tests (hematology, serum chemistry, and urinalysis)*
- Coagulation tests ([PT, PTT] to be performed by the local laboratory)
- Concomitant medications, therapies/interventions, and medical/surgical procedures
- Adverse events

*The assessments indicated do not need to be repeated if completed as part of Screening assessments within 7 days prior to surgery.

Other sections impacted by this change: Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to schedule of assessments

Section impacted by this change: Section 8.3.1.3 Follow-up and Section 8.3.1.4 Post-op Recovery
The following assessments will be performed after surgery and prior to discharge. It is expected that, for most patients, post-surgical follow-up will occur within Week 2 (ie, within 1 to 2 days of surgery). 

8.3.1.4 Post-op Recovery
Surgical implantation of the IDDD will be followed by a post-operative recovery period of at least 14 days prior to the first IT administration of idursulfase-IT.

Other sections impacted by this change: Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to schedule of assessments
Section impacted by this change: Section 8.3.2.1 Pre-treatment

New Text:
• Physical and neurological examination
• Height and weight (performed at Weeks 4, 16, 28, 40)
• Head circumference (performed at Weeks 4, 16, 28, 40)
• Hearing assessment (performed at Weeks 4, 16, 28, 40)
• Neurodevelopmental assessments (performed at Weeks 16, 28, and 40)
• Differential Ability Scales, Second Edition (DAS-II)
• Bayley Scales of Infant Development, Third Edition (BSID-III) for patients in the substudy only who are too young (<3 years of age) or unable to complete the DAS-II
• Vineland Adaptive Behavior Scales, Second Edition (VABS-II)
• 12-lead ECG
• Vital signs
• Clinical laboratory tests (hematology, serum chemistry, urinalysis, performed at Weeks 4, 16, 28 and 40)
• Albumin (serum and CSF, see Section 8.3.2.2), performed at Weeks 4, 16, 28 and 40
• Urine GAG and creatinine (performed at Weeks 4, 16, 28, 40)
• Anti-idursulfase antibody testing (serum and CSF, see Section 8.3.2.2), performed at Weeks 4, 16, 28, and 40
• Concomitant medications, therapies/interventions, and medical/surgical procedures
• Adverse events

From Week 28 onward, pre-treatment assessments may be performed on the same day as IT administration of idursulfase-IT, if the patient can arrive at the study site early in the day and if the Investigator deems this clinically appropriate.

Other sections impacted by this change: Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to schedule of assessments
Sections impacted by this change: 8.3.2.2 IT Injection and 8.3.2.3 Follow-up

New Text:
8.3.2.2 IT Injection
Patients will remain under observation in the hospital setting (may include lounge, infusion center, or waiting room) for 4 hours post IT injection for vital signs and other safety assessments. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of Visit Weeks 4, 24, and 48 at which serial blood sampling for PK evaluation is planned). The patient may need to be examined the following day (See Follow-up, Section 8.3.2.3) by the Investigator; however, there is no requirement for an overnight hospital stay. Note that, on IT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

• 12-lead ECG (performed within 4 hours of IT injection at Weeks 4, 16, 28, 40)
• Vital signs (collected at the following time points (±10 minutes) in association with IT administration of idursulfase-IT: within 15 minutes prior to IT administration, 30 minutes post end of IT administration, 60 minutes post end of IT administration, 120 minutes post end of IT administration, and 4 hours post end of IT
administration. 6 hours post end of IT administration, 8 hours post end of IT administration, 12 hours post end of IT administration)

• CSF sample collection (performed at each IT Dosing Week prior to idursulfase-IT injection). Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard laboratory parameters (chemistries, cell counts), GAG, albumin, concentration of idursulfase enzyme, and presence of idursulfase-specific antibodies. Analyses of CSF samples for antibodies and albumin will be performed at IT Dosing Weeks 4, 16, 28, and 40.

• idursulfase-IT injection. Patients will remain under observation in the hospital setting (may include lounge, infusion center, or waiting room) for at least 4 hours post IT injection for safety assessments. Thereafter, if deemed clinically stable by the Investigator, patients may leave the hospital setting (with exception of Visit Weeks 4, 24, and 48 at which serial blood sampling for pharmacokinetic evaluation is planned). The patient may need to be examined the following day (See Follow-up, Section 8.3.2.3) by the Investigator; however, there is no requirement for an overnight hospital stay. Note that, on IT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a minimum of 48 hours after IT administration of idursulfase-IT.

8.3.2.3 Follow-up (Post IT Injection)

For the first 6 months of treatment with idursulfase-IT (ie, Weeks 4, 8, 12, 16, 20, 24), patients must return to the clinic the day after each IT administration for a safety follow-up visit. Note that, under these circumstances, there is no requirement for an overnight hospital stay; if a decision is made to keep the patient overnight for convenience, this hospitalization should not initiate a serious adverse event report. For the latter 6 months of treatment with idursulfase-IT (ie, from Week 28 onward) and in the absence of any safety concerns, patients may complete the safety follow-up visit on the same day as IT administration prior to discharge.

Physical and neurological examination
• Concomitant medications, therapies/interventions, and medical/surgical procedures
• Adverse events

Other sections impacted by this change: 7.6 Investigational Product Administration, Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study, Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

Change: Clarification to schedule of assessments
Section impacted by this change: Section 8.3.3.1 Week 2 (+7 days)
New Text:
The following will be assessed by telephone contact:
• Concomitant medications, therapies/interventions, and medical/surgical procedures
• Adverse events

Other sections impacted by this change: Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study

Change: Clarification to schedule of assessments
Section impacted by this change: Section 8.3.3 Patients in the No IT Treatment Group of the Pivotal Study (Months 1 to 12), Section 8.3.3.2 Weeks 4, 16, 28, 40 (+ 7 days)
New Text:
• Clinical laboratory tests (hematology, serum chemistry, urinalysis)
• Urine GAG and creatinine
• Anti-idursulfase antibody testing (serum)

Other sections impacted by this change: Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study

Change: Clarification to schedule of assessments
Section impacted by this change: Section 8.3.3.3 Weeks 8, 12, 20, 24, 32, 36, 44, 48 (+ 7 days)
New Text: 
The following will be assessed by telephone contact:

Other sections impacted by this change: Appendix 1 Schedule of Events for Patients Randomized to No Treatment in the Pivotal Study

<table>
<thead>
<tr>
<th>Change: Clarification to schedule of assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change:</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>Other sections impacted by this change:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change:</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>Statistical model estimates of least squares means, treatment differences, p-values and 95% confidence intervals for least squares mean treatment differences will also be provided where relevant for efficacy endpoints. The fit of linear models will be assessed using residual plots and/or other diagnostic plots as appropriate. All the hypothesis statistical tests will be 2-sided and will be performed at the 0.05 level of significance unless stated otherwise.</td>
</tr>
<tr>
<td>The separate substudy is an open-label, single arm study. Data from patients participating in this separate substudy will be analyzed separately. The safety and efficacy data from the substudy will be summarized descriptively or listed as appropriate, as appropriate, in a manner similar to that of the pivotal study.</td>
</tr>
<tr>
<td>Other sections impacted by this change:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change:</td>
</tr>
<tr>
<td>New Text:</td>
</tr>
<tr>
<td>Using a 2:1 allocation ratio, a sample size of 42 randomized patients (28 IT treated patients, 14 No IT control patients) will yield 80% power to detect a clinically meaningful mean treatment difference of 11 points in the primary endpoint, GCA change from baseline to Visit Week 52. This calculation further assumes a common standard deviation for the change from baseline of 10 points, a type-I error rate of 0.05 for a two-sided twosample t-test, with approximately up to 20% missing an assessment at Visit Week 52. Given this sample size, and conditional on rejection of the null hypothesis for the primary endpoint, the power would be 80% to detect a clinically meaningful mean difference of 14.5 points in the key secondary endpoint, assuming a common standard deviation for the change from baseline of 13.5 points for a two-sided two-sample t-test with a significance level of 5% and 20% missing. Using a 2:1 randomization, a sample size of 42 randomized patients (28 IT patients, 14 control patients) will yield 80% power to detect a clinically meaningful mean treatment difference in the primary endpoint, GCA change from baseline to Visit Week 52 of 11 points. This calculation further assumes a common standard deviation for the change from baseline of 10 points, a type I error rate of 0.05 for a two-sided two-sample t-test, with approximately up to 20% missing an assessment at Visit Week 52.</td>
</tr>
</tbody>
</table>
After approximately one-half of the planned number of patients (ie, 21 patients) have completed the Week 52 visit, and prior to enrollment closure, a blinded assessment of overall variability for the primary and key secondary endpoints will be made by estimating the pooled standard deviation (SD) for each endpoint. The blinded variability assessment will be performed by an external, independent statistician who is not involved in the final analysis of this study. If it does not appear that the variability is consistent with the assumptions used in the sample size calculation, the Sponsor may consider increasing the sample size by amending the protocol. The sample size re-calculation in this case would be identical to the original calculation except that the estimate of the common standard deviation used for the primary and/or key secondary endpoint would be revised upward based on the pooled SD assessment. As there is no treatment comparison involved, no inflation of the type-I error results from this procedure, and no adjustment to the significance levels for the final analysis is necessary. For the separate substudy, there is no target sample size. All patients meeting eligibility criteria for the substudy will be enrolled until enrollment for the pivotal trial is completed.

Other sections impacted by this change: None

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 10.3 Method of Assigning Study Patients to Treatment Groups</td>
</tr>
<tr>
<td>New Text: Therefore, the randomization will be stratified according to baseline GCA score: less than or equal to 70 versus greater than 70. The randomization schedule will be generated and administered centrally by a third party (eg, IVR vendor) Pharmaceutical Product Development, LLC (PPD), independent of the Sponsor’s project team.</td>
</tr>
</tbody>
</table>

Other sections impacted by this change: None

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 10.4.1 Analysis Population</td>
</tr>
<tr>
<td>New Text: For the pivotal trial, all efficacy data analyses will be performed using the Intent-to-Treat (ITT) Population, which is defined as all randomized patients. All safety data analyses will be performed according to treatment received using the Safety Population, which is defined as all randomized patients with any post-randomization safety assessments. IDDD and procedure related analyses will be conducted in the set of patients in the Safety Population who had the device implant procedure performed. All pharmacokinetic data analyses will be performed using the PK population. The PK population will be defined as all patients who received study drug and had at least one sufficient serum samples collected for to derive pharmacokinetic parameters. For the substudy, all analyses will be performed on the Substudy Population, defined as all patients enrolled and treated with study drug in the substudy. The planned analyses described below pertain to the pivotal study data. Similar descriptive summaries or listings as appropriate will be provided for the substudy data.</td>
</tr>
</tbody>
</table>

Other sections impacted by this change: Synopsis

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 10.4.2 Patient Disposition</td>
</tr>
<tr>
<td>New Text: The total number of patients screened (ie, signed informed consent) will be presented. The number and percentage of patients screened (ie, signed informed consent), randomized, completed, and discontinued prematurely by reason for withdrawal will be summarized by treatment group. The number of patients included in the ITT and Safety populations will be summarized.</td>
</tr>
</tbody>
</table>

Other sections impacted by this change: None
Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.4.4 Demographics and Baseline Characteristics
New Text:
Demographic and baseline characteristics (e.g., age [years], race, ethnicity, genotype, weight [kg], height [cm], body mass index [BMI, kg/m²], country, age at onset of Hunter syndrome symptoms, age of Hunter syndrome diagnosis, family history of Hunter syndrome) will be summarized by treatment group and overall in the pivotal study.

Other sections impacted by this change: None

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.5 Analysis of Efficacy
New Text:
All efficacy analyses described below refer to the pivotal trial; all efficacy data from patients treated in the separate substudy will be listed, including any measurements from the BSID-III and VABS-II.

Other sections impacted by this change: None

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.5.1 Primary Efficacy Endpoint Analysis
New Text:
For the pivotal trial, the primary efficacy endpoint is the change from study baseline (screening visit) to Visit Week 52 in the General Conceptual Ability (GCA) score as measured by the DAS-II. The primary analysis will compare the treatment groups using a linear mixed model repeated measures (MMRM) analysis. The repeated measures are the change from baseline GCA scores obtained at the scheduled Visit Weeks 16, 28, 40, and 52, respectively. The model will include fixed categorical effects for treatment, visit week, treatment by visit week interaction, baseline GCA classification factor (either ≤70 or >70), and the baseline GCA score as a continuous covariate. From this model, least squares means, standard errors, treatment differences in least squares means, and 95% confidence intervals and p-values will be estimated for each time point. Significance tests will be based on the difference in least squares means. Primary inference is based on the treatment comparison of least squares means at Visit Week 52 from this model, and a p-value will be presented for this time point only.

Other sections impacted by this change: Synopsis

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.5.2 Key Secondary Efficacy Endpoint Analysis
New Text:
As exploratory analyses, the primary and key secondary MMRM models will be refit including the
Continuous baseline covariate by treatment interaction term in the model. Estimated least square means and 95% CIs for each treatment at the 25th, 50th and 75th percentiles of the pooled baseline covariate distribution will be evaluated.

Additional subgroup analyses are planned for exploratory purposes for the change from baseline in GCA and ABC scores. An MMRM model will be used to test for subgroup interactions at the 10% significance level. In general, the model will include effects for treatment, visit week, treatment by visit week interaction, subgroup, treatment by subgroup interaction, subgroup by visit interaction and the 3-way interaction between treatment, visit and subgroup. The p-values from interaction tests will be presented, as well as the least square means and 95% confidence intervals by treatment and visit within each subgroup. Descriptive statistics of observed values and change from baseline will also be presented by treatment and visit week within each subgroup.

A subgroup analysis will be performed for baseline GCA groups. For this analysis, patients with a baseline GCA score of greater than 70 will be classified as having “Moderate” cognitive impairment, while patients with a baseline GCA score equal to or below 70 will be classified as having “Severe” cognitive impairment. The randomization is stratified by this classification variable to ensure treatment group balance within these subgroups.

The primary endpoint model (MMRM) also includes baseline GCA factor (≤70 or >70) as a factor. The treatment by baseline GCA factor interaction will be tested using this model at the 10% significance level. Descriptive statistics for the primary endpoint will be presented by treatment within each GCA subgroup (Moderate versus Severe cognitive impairment, as described above). The baseline GCA factor by Visit interaction and the three way interaction of treatment, baseline GCA factor and Visit will likewise be investigated for this model. Similar exploratory subgroup subset analyses of the primary endpoint may be performed for age group (either ≤6 years or >6 years), country, native language (Spanish versus English speaking region) or other baseline factors using MMRM.

To explore the relationship between composite scores and their components, correlations between the GCA and ABC scores (absolute value and change from baseline) and their respective subdomain scores will be estimated. Scatter plots will also be presented.

Other sections impacted by this change: None
Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.7 Safety Assessments
New Text:
All safety analyses will be descriptive, no statistical testing will be performed. All analyses described below refer to the pivotal trial; safety data from the separate substudy will be similarly summarized or listed as relevant.

10.7.1 Adverse Events

Adverse events will be recorded throughout the study and at early termination. Adverse events and medical conditions will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 12.1 or later. Adverse events occurring on or after randomization and on or before the follow-up visit (7 days after EOS Visit) will be summarized by treatment group, both overall and within system organ class by preferred term. A summary of adverse events related to study drug will be presented. An adverse event will be considered related if indicated to be “possibly”, “probably” or “definitely” related. A separate tabulation of IV Elaprase infusion-related adverse events will also be presented by treatment group. Adverse events will be tabulated by highest severity (mild, moderate, severe) and treatment group. In addition, those events which resulted in death or were otherwise classified as serious will be summarized and presented in a separate listing.

10.7.2 IDDD and Procedure Related Adverse Events

IDDD and procedure related adverse events will be summarized within system organ class by preferred term. Separate tabulations will be provided for adverse events related to the IDDD, device surgical procedure, and IT-administration process. An overall summary of AEs related to the IT treatment regimen (ie, related to one or more of the following: study drug, IDDD, device surgical procedure, and IT-administration process) will also be presented. IDDD and procedure related events will be analyzed in the set of treated patients in the Safety Population with the device implanted.

Other sections impacted by this change: Synopsis

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.7.3 Clinical Laboratory Evaluations
New Text:
Laboratory values (eg, chemistries, hematology, etc) including CSF components (standard chemistries, glucose, protein, cell counts) will be summarized in terms of the absolute value and change from baseline at each time point by treatment group. The number and percentage of patients with any clinically significant post-baseline laboratory result will be presented by treatment group.

Other sections impacted by this change: None

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.7.4 Electrocardiogram Evaluations
New Text:
The 12-lead ECG parameters (heart rate [bpm], PR interval [msec], RR interval [msec], QRS interval [msec], QT interval [msec] and QTc [msec] interval) will be summarized in terms of absolute value and change from baseline. The corrected QT interval (QTc) will be calculated using Bazett's formula as QT divided by the square root of RR interval. The number and percentage of patients with clinically significant post-baseline ECG results abnormalities by treatment group will be presented.

Other sections impacted by this change: None
<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Section impacted by this change: Section 10.7.5 Vital Signs and Physical Measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Text:</td>
<td>Vital signs (temperature [°C], pulse [bpm], blood pressure [systolic and diastolic, mmHg], respiration [per min], and oxygen saturation [%]) will be summarized graphically by study time point and treatment group.</td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Section impacted by this change: Section 10.7.6 Physical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Text:</td>
<td>Clinically significant physical and neurological examination findings will be recorded and summarized as part of the medical history or adverse event data.</td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Section impacted by this change: Section 10.7.7.1 Hearing Assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Text:</td>
<td>Any hearing assessment data will be summarized by treatment group or listed as appropriate.</td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Section impacted by this change: Section 10.7.7.2 Immunogenicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Text:</td>
<td>Titer values will be summarized using box plots over time in patients with positive antibodies at or prior to each scheduled visit. The percent inhibition and titer will be plotted similarly for patients who developed positive neutralizing antibodies at or prior to each scheduled visit.</td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Section impacted by this change: Section 10.7.7.3 Device Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Text:</td>
<td>SOPH-A-PORT safety and performance will be summarized for implanted patients. The proportion of patients with at least one IDDD failure and the proportion with malfunction only, as well as the number of and reasons for IDDD failures and malfunctions will be summarized. The annual event rate of IDDD failures and malfunctions will be calculated for each patient and summarized descriptively. The time from initial implant surgery to first IDDD failure and the time to first resolved malfunction will be analyzed using the Kaplan Meier (KM) method. Patients without an IDDD failure or resolved malfunction will be censored at their last study drug injection date. The IDDD longevity (time to failure in weeks) and time to first resolved malfunction for all implanted IDDDs will also be plotted using the KM method. A by-patient listing of the device failure and resolved malfunction data will be displayed. The number and proportion of patients for whom a successful first injection of study drug occurred will be summarized among those for whom a first injection was attempted (ie, those who had an apparently successful implantation and did not suffer a device removal or revision prior to first scheduled injection). The number and proportion of patients who had no failed injection attempts during the study and the total number of successful injections will also be summarized. Injections not given for patient reasons (eg, patient uncooperative, competing medical issue, etc) will not be included in the determination of these estimates.</td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Section impacted by this change: Section 10.7.8 Concomitant Medications/Therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Text:</td>
<td></td>
</tr>
<tr>
<td>Other sections impacted by this change: None</td>
<td></td>
</tr>
</tbody>
</table>

Shire Confidential 126
New Text:
Concomitant medications are defined as all medications taken on or after the time of the randomization and on or before the last follow-up date (scheduled 7 days after EOS Visit). Concomitant medications will be mapped using the WHO Drug Dictionary (WHO-DD) and summarized by the therapeutic class and preferred term for each treatment group. **Concomitant therapies will be mapped using MedDRA Version 16.0 or higher and summarized by the system organ class and preferred term for each treatment group.**

Other sections impacted by this change: None

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.8.1 Handling of Drop-outs and Missing Data

New Text:
For randomized patients who discontinue early from the study, their early EOS efficacy evaluations will be used for the next scheduled time point only if the EOS evaluation is performed within 45 days of the next scheduled visit. In general, no further imputation will be used for descriptive analyses, or for primary and secondary efficacy analyses utilizing MMRM methodology. **However, in the unlikely event that a patient has no post-baseline efficacy assessments, the first post-baseline assessment (Visit Week 16) will be imputed so that all randomized patients are included in MMRM analyses. The median value estimated from the pooled data at Week 16 across all randomized patients with available data will be used for this purpose. Imputation of missing primary and key secondary endpoint values at the Visit Week 52 time point will be performed in sensitivity analyses only. The planned imputation methods for sensitivity analyses are described below in Section 10.8.6. A possible exception is for randomized patients who discontinue early from the study. For these patients, their early EOS efficacy evaluations will be used for the next scheduled time point only if the EOS evaluation is performed within 45 days of the next scheduled visit. For sensitivity analyses using the Wilcoxon Rank Sum test at the Week 52 Visit, the most or lowest score will be imputed for missing data as a sensitivity analysis for the primary and key secondary endpoints. Imputation methods will be described in the prospective statistical analysis plan.**

Other sections impacted by this change: None

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.8.2 Adjustment for Covariates

New Text:
Analyses of the change from baseline in efficacy endpoints utilizing MMRM methodology will adjust for the baseline score of the parameter of interest as a continuous covariate in the model. As the randomization of the study is stratified by the baseline GCA classification factor (either ≤70 or >70), MMRM analyses will also take into account the GCA strata as a classification factor. **As the randomization of the study is stratified by the baseline GCA classification factor (≤70 or >70), the primary MMRM analysis of the change from study baseline to Visit Week 52 in GCA score will take into account the GCA score as a classification factor. In addition, for a supportive analysis, a similar MMRM analysis will be performed adjusting for the baseline GCA score as a continuous covariate. Key secondary and secondary analyses of the change from baseline in efficacy scores utilizing MMRM methodology will adjust for the baseline score of the parameter of interest as a continuous covariate in the model. Exploratory MMRM analyses to evaluate treatment interactions or other interactions and to identify potential predictors of efficacy outcome may also utilize covariate adjustment.**

Other sections impacted by this change: None

Change: Clarification to planned statistical analysis
Section impacted by this change: Section 10.8.3 Interim Analysis

New Text:
No formal interim analysis or interim statistical testing for treatment comparison is planned during the course of the study. The DMC DSMB will monitor safety data periodically during the trial. A pooled, blinded assessment of the overall variability of the primary endpoint will be conducted during the study in order to assess the appropriateness of the variability assumption used in the sample size calculation. Following the completion of the study and collection and verification of all final data, the database will be locked and the results of the planned
statistical analysis will be described in a final study report.

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Other sections impacted by this change: None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 10.8.4 Multicenter Studies</td>
<td>New Text: The randomization is not be stratified by center.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Other sections impacted by this change: None</th>
</tr>
</thead>
</table>
| Section impacted by this change: Section 10.8.5 Multiple Comparisons/Multiplicity | New Text: The familywise type-I error rate (FWER) for the statistical tests of the primary, key secondary and other selected secondary efficacy endpoints (specified below) from the MMRM analyses specified above will be controlled at 0.05. To strongly control the FWER at this level, a Gatekeeping approach will be utilized in which each family of statistical tests will be conducted in a sequential manner. The test for the primary endpoint will be conducted first at the 5% significance level and, if significant, the key secondary endpoint will be similarly tested at the 5% significance level. If these two tests are both significant, tests of the additional secondary efficacy endpoints specified below will be conducted using the Hommel closed testing procedure\(^1\) to control the FWER. The hypotheses for the primary, key secondary and other selected secondary efficacy endpoints will therefore be grouped into 3 ordered Gatekeeper families defined as follows:  
  • Family 1 (F1): Hypothesis test for primary endpoint  
  • Family 2 (F2): Hypothesis test for key secondary endpoint  
  • Family 3 (F3): Hypothesis tests for the change from baseline to Visit Week 52 for the following 6 endpoints:  
    - Verbal, Nonverbal, and Spatial standard scores in cluster areas of the DAS-II  
    - Communication, Daily Living Skills, and Socialization standard domain scores of the VABS-II  
  The 3 sets of hypotheses in F1, F2 and F3 will be tested sequentially, with F1 and F2 serving as serial gatekeepers. The null hypothesis of no treatment difference for the primary endpoint will be tested first in F1. The statistical test for the key secondary endpoint in F2 may only be declared statistically significant if a significant result is also achieved for the primary efficacy endpoint. Since F1 and F2 each contain a single null hypothesis to be tested, each of the two tests will be conducted at the 5% significance level. Further, only if the null hypothesis for both the primary and key secondary endpoints are rejected in F1 and F2, can any of the tests for the endpoints specified in F3 be declared statistically significant. If statistical significance is obtained for F1 and F2, the Hommel closed testing procedure\(^1\) will be used to control the FWER within F3, with each hypothesis test in F3 equally weighted. In this case, SAS Proc MULTTEST will be used to calculate and report adjusted p-values for each endpoint in F3. All other endpoints not included in F1, F2 or F3 above are considered supportive and any statistical tests comparing treatments will be made without adjustment for multiplicity. The resulting unadjusted p-values from these supportive analyses will be interpreted descriptively as summarizing the weight of evidence for a treatment difference and may suggest avenues for further exploratory analyses or generate formal hypotheses to be tested in future trials. |

<table>
<thead>
<tr>
<th>Change: Clarification to planned statistical analysis</th>
<th>Other sections impacted by this change: None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section impacted by this change: Section 10.8.6 Sensitivity Analyses</td>
<td>New Text: Sensitivity analyses for the primary and key secondary endpoints will be conducted to assess missing data assumptions in the MMRM analyses. The sensitivity analyses below will use worst-observation-carried forward (WOCF) to impute missing data at the Visit Week 52 time point. Within a given patient, the worst (lowest) observed score prior to Visit Week 52 (including the baseline value) will be used for the imputation of</td>
</tr>
</tbody>
</table>
their missing Visit Week 52 value.
The first sensitivity analysis will compare the treatment groups at the Week 52 time point using an analysis of covariance model with WOCF (ANCOVA-WOCF). The ANCOVA-WOCF model will include fixed categorical effects for treatment and baseline GCA classification factor (either ≤70 or >70), and the corresponding baseline score as a continuous covariate. The baseline covariate by treatment interaction will be included in the model if the interaction was included in the corresponding primary or key secondary MMRM model. The treatment difference in least squares means, 95% confidence interval and p-value from this model will be compared to the corresponding inferential statistics at Visit Week 52 from the primary or key secondary MMRM model.

As a second sensitivity analysis of the primary endpoint, the Wilcoxon Rank-Sum test with WOCF (WRS-WOCF) will be used to compare treatment groups at Visit Week 52. This test is based on the ranked changes from baseline. Patients who terminate the study early or who have a Visit Week 52 visit, but are not able to complete the GCA assessment for any reason, including either low cognitive ability or behavioral problems during the assessment, will have the rank of their change from baseline imputed to the lowest possible value, to represent the worst possible outcome. This imputation method was chosen because a missing score may be indicative of low cognitive function and/or behavioral issues. The same sensitivity analysis using the Wilcoxon Rank Sum test as described above for the primary endpoint will also be performed for the key secondary endpoint after imputation of the Visit Week 52 value using WOCF.

Additional sensitivity analyses and imputation methods may be specified in the statistical analysis plan.

Other sections impacted by this change: None

Change: Clarification concerning data monitoring
Section impacted by this change: Section 11.8 Data Monitoring Committee
New Text:
11.8 Data and Safety Monitoring Committee Board
An independent, external DSMB DMC will be established to provide an ongoing, independent review and assessment of the safety data, and to safeguard the interests and safety of the participating patients in the study. The DSMB DMC will be notified of all IDDD failures and IDDD-related complications at times defined in the DSMB DMC charter.

The DSMB DMC will consist of a biostatistician and two clinical experts. The DSMB DMC will adhere to a prospectively determined charter, which will be written by Shire HGT or its designee and approved by the DSMB DMC. The charter will define the responsibilities of the DSMB DMC and Shire HGT, describe the conduct of the meetings, and define the data sets to be reviewed. Serious adverse events and other data will be distributed to the members of the DSMB DMC periodically for review.

The first meeting of the DSMB DMC will be an orientation meeting and will be held prior to the start of the study. Thereafter, it is anticipated that the DMC will meet at least annually. The DSMB DMC will keep detailed minutes of their discussions during the meetings, which will be kept in strict confidence.

Other sections impacted by this change: Section 4.1.1 Intrathecal Drug Delivery, Section 7.18 Other Study Procedures, Section 10.8.3 Interim Analysis, Section 11.11 Premature Closure of the Study

Change: Addition of new reference
Section impacted by this change: Section 12 List of References
New Text:

Other sections impacted by this change: None

Change: Clarification to schedule of assessments
Section impacted by this change: Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study
New Text:
### Vital Signs Collection

Vital signs will be collected at the following time points (±10 minutes) in association with IT administration of idursulfase-IT: within 15 minutes prior to IT administration, 30 minutes post end of IT administration, 60 minutes post end of IT administration, 120 minutes post end of IT administration, 4 hours post end of IT administration, 6 hours post end of IT administration, and 8 hours post end of IT administration, and 12 hours post end of IT administration.

### From Week 24 onward

From Week 24 onward, pre-treatment assessments may be performed on the same day as IT administration of idursulfase-IT, if the patient can arrive at the study site early in the day and if the Investigator deems this clinically appropriate.

### Other Sections Impacted by This Change

- Section 8.3.2.1 Pre-treatment
- Appendix 3 Schedule of Events for Patients Enrolled in the Substudy

### Change: Analysis of Antibodies in CSF Samples

<table>
<thead>
<tr>
<th>Type</th>
<th>Section Impacted</th>
<th>Previous Text</th>
<th>New Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>Text</td>
<td>Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study</td>
<td>Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard laboratory parameters (chemistries, cell counts), concentrations of GAG and idursulfase enzyme, and presence of idursulfase-specific antibodies.</td>
<td>Cerebrospinal fluid samples will be collected via the IDDD or lumbar puncture and used to analyze standard laboratory parameters (chemistries, cell counts), albumin, GAG, concentrations of idursulfase enzyme, and presence of idursulfase-specific antibodies. <strong>Analyses of CSF samples for antibodies and albumin will be performed at IT Dosing Weeks 4, 16, 28, and 40.</strong></td>
</tr>
</tbody>
</table>

### Other Sections Impacted by This Change

- Appendix 1 Schedule of Events for Patients Randomized to Treatment in the Pivotal Study; Appendix 3 Schedule of Events for Patients Enrolled in the Substudy
Appendix 6 Protocol Signature Page

Study Title: A Controlled, Randomized, Two-arm, Open-label, Assessor-blind, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment

Study Number: HGT-HIT-094
Amendment 1
Final Date: 14 August 2013

I have read Protocol HGT-HIT-094, “A Controlled, Randomized, Two-arm, Open-label, Assessor-blind, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment”, and the idursulfase-IT Investigator's Brochure.

I agree to comply with all applicable regulations and to conduct the study as described in the protocol.

Signatory:

Investigator

<table>
<thead>
<tr>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
</table>

Printed Name

I have read and approve the protocol described above.

Signatory:

Shire HGT Medical Monitor

<table>
<thead>
<tr>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
</table>

PPD, MD, PhD

Printed Name